Redirecting the tropism of AAV capsids
By inserting targeted peptides into the AAV capsid and controlling mRNA expression using cell type-specific promoters, the problem of low efficiency of AAV capsids on CNS transduction is solved, and efficient targeted transduction in large animals is achieved, avoiding The limitations of traditional methods.
Patent Information
- Application Number
- CN201980078363.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-29
- Filing Date
- 2019-10-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-10-02
AI Technical Summary
The prior art is difficult to effectively improve the efficiency of transduction of adeno-associated virus (AAV) capsids to the central nervous system (CNS), and traditional methods are difficult to apply in large animals, especially due to cell type-specific challenges and neutralizing antibody problems.
The TRACER platform was developed to achieve targeted transduction by inserting targeted peptides into the AAV capsid gene to enhance tropism to specific cell types and to control AAV capsid mRNA expression using cell type-specific promoters, thereby achieving targeted transduction, avoiding assistance. Viral coinfection and demand for genetically modified animals.
It has achieved the improvement of the transduction efficiency of AAV capsid to specific cell types without co-infection of transgenic animals or auxiliary viruses, and enhanced the specificity of targeted transduction. It is suitable for large animal studies and improved the AAV capsid to CNS. trophicity reduces transduction of undesired cell types.
Smart Images

Figure CN113166208B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 740,310, filed on October 2, 2018, entitled AAV CAPSID LIBRARIES AND TISSUE TARGETING PEPTIDE INSERS; and U.S. Provisional Patent Application No. 62 / 839,883, filed on April 29, 2019, entitled REDIRECTION OF TROPISM AAV CAPSIDS; the contents of each of which are incorporated herein by reference in their entirety.
[0003] Reference to a sequence listing
[0004] This application is submitted with a sequence listing in electronic format. The sequence listing is provided in the form of a file entitled 20571060PCTSL.txt, which was created on October 2, 2019 and is 428,491 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
[0005] public domain
[0006] The present disclosure relates to compositions, methods, and processes for making, using, and / or formulating adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts that enhance tropism for target tissues.
[0007] background
[0008] Gene delivery to the adult central nervous system (CNS) remains a major challenge in gene therapy, and engineered AAV capsids with improved brain tropism represent an attractive solution.
[0009] Adeno-associated virus (AAV)-derived vectors are promising tools for clinical gene transfer due to their non-pathogenicity, low immunogenicity, low rate of integration into the host genome, and long-term transgene expression in non-dividing cells. However, the transduction efficiency of natural AAV variants in certain organs is too low for clinical application, and capsid neutralization by pre-existing neutralizing antibodies may prevent treatment of a large proportion of patients. For these reasons, great efforts have been made to obtain novel capsid variants with enhanced properties. To date, among the many approaches tested, the most significant progress has come from the directed evolution of AAV capsids, a process that is performed by in vitro or in vivo selection of capsid variants generated by randomization of the capsid sequence using error-prone PCR, shuffling of various parental serotypes, or insertion of fully randomized short peptides at specific positions.
[0010] In order to carry out the directed evolution of AAV capsids, the sequence encoding the viral capsid is itself flanked by inverted terminal repeats (ITRs) so that it can be packaged into its own capsid. After a mixed population of capsids infects cultured cells or animals, DNA encoding capsid variants that have successfully homed to the target tissue is recovered by PCR for further rounds of selection. In this approach, all viral DNA material present in a given tissue is recovered without distinguishing between specific cell types or vectors capable of complete transduction (cell surface binding, endocytosis, trafficking, nuclear import, uncoating, second chain synthesis, transcription). For example, in the case of highly complex tissues containing multiple cell types, such as the central nervous system (CNS), it is highly preferred to apply more stringent selective pressure to recover capsid variants that can transduce neurons and / or astrocytes rather than microglia or vascular endothelial cells.
[0011] Attempts to improve the CNS tropism of AAV capsids after systemic administration have met with limited success.
[0012] Two previous approaches have been used to address this problem. The first strategy used was to co-infect cultured cells (Grimm et al., 2008) or in situ animal tissue (Lisowski et al., 2014) with adenovirus to trigger exponential replication of infectious AAV DNA. Another successful approach involved the use of cell-specific CRE transgenic mice (Deverman et al., 2016), allowing viral DNA recombination specifically in astrocytes and then recovering CRE recombinant capsid variants. Both approaches proved successful, allowing the isolation of several capsid variants with enhanced transduction of target cell populations.
[0013] This finding suggests that cell type-specific library selection can improve the results of directed evolution. However, the transgenic CRE system used by Deverman et al. is not tractable in other animal species, and the AAV variants selected by directed evolution in mouse tissues did not show similar properties in large animals. Therefore, it is necessary to perform the entire directed evolution process directly in non-human primates to increase the possibility of translatability to human subjects. None of the previously described transduction-specific methods are suitable for large animal studies because: 1) many target tissues (e.g., CNS) are not easily co-infected by adenovirus, 2) specific Ad tropism itself will bias the library distribution, and 3) large animals are generally not suitable for transgenesis and cannot be genetically engineered to express CRE recombinase in a defined cell type.
[0014] To address this issue, we developed a broadly applicable platform for screening functional AAV capsid libraries for cell type-specific biopanning in non-transgenic animals. T ropism R edirection of A AV by C ell type-specific E Expression of R In the NA platform system, the capsid gene is placed under the control of a cell type-specific promoter to drive capsid mRNA expression in the absence of helper virus co-infection. This RNA-driven selection increases selective pressure, favoring capsid variants that transduce specific cell types.
[0015] The TRACER platform allows the generation of AAV capsid libraries, enabling specific recovery and subcloning of capsid mRNA expressed in transduced cells without the need for transgenic animals or helper virus co-infection. Since mRNA transcription is a hallmark of complete transduction, these methods will allow the identification of fully infected AAV capsid mutants. In addition to its high stringency, this method also allows the identification of highly tropic capsids for specific cell types using libraries designed to express CAP mRNA under the control of any cell-specific promoter (such as, but not limited to, the synapsin-1 promoter (neurons), the GFAP promoter (astroglia), the TBG promoter (liver), the CAMK promoter (skeletal muscle), the MYH6 promoter (cardiomyocytes)).
[0016] Public content
[0017] The present disclosure provides compositions and methods for engineering and / or redirecting the tropism of AAV capsids. Also provided herein are peptides that can be inserted into the AAV capsid sequence to increase the tropism of the capsid for specific tissues. In one aspect, the peptides can be used to target the capsid to the brain, or to regions of the brain or spinal cord.
[0018] The present disclosure provides a method for producing one or more variant AAV capsid polypeptides. In certain embodiments, the variant AAV capsid polypeptide exhibits at least one of improved transduction or increased cell or tissue specificity relative to the parent AAV capsid polypeptide. In certain embodiments, the method includes: (a) generating a library of variant AAV capsid polypeptides, wherein the library includes (i) a plurality of capsid polypeptides having a random sequence region of 2, 3, 4, 5, 6, 7, 8 or 9 consecutive amino acids, or (ii) a plurality of capsid polypeptides from more than one parent AAV capsid polypeptide; (b) generating an AAV vector library by cloning the capsid polypeptides of library (a) (i) or (a) (ii) into an AAV vector, wherein the AAV vector includes a first promoter and a second promoter, wherein the second promoter drives the expression of capsid mRNA in the absence of a helper virus co-infection.
[0019] In certain embodiments, the first promoter is AAV2 P40. In certain embodiments, the second promoter is a ubiquitous promoter. In certain embodiments, the first promoter is AAV2 P40 and the second promoter is a ubiquitous promoter.
[0020] In certain embodiments, the first promoter is AAV2 P40. In certain embodiments, the second promoter is a cell type specific promoter. In certain embodiments, the first promoter is AAV2 P40 and the second promoter is a cell type specific promoter.
[0021] In certain embodiments, the promoter is selected from any of the promoters listed in Table 3. In certain embodiments, a ubiquitous promoter or a cell-specific promoter allows for expression of RNA encoding the capsid polypeptide.
[0022] In certain embodiments, the method includes recovering RNA encoding capsid polypeptide. In certain embodiments, the method includes determining the sequence of capsid polypeptide. In certain embodiments, the capsid polypeptide recovered shows an increase in target cell transduction or target cell specificity (tropism) compared to the parent capsid polypeptide.
[0023] In certain embodiments, the target cell is a neuronal cell, a neural stem cell, an astrocyte, an oligodendrocyte, a microglia, a retinal cell, a tumor cell, a hematopoietic stem cell, an insulin-producing beta cell, a lung epithelial cell, an endothelial cell, a hepatocyte, a skeletal muscle cell, a muscle stem cell, a muscle satellite cell, or a cardiomyocyte.
[0024] In certain embodiments, the AAV vector comprises a first promoter and a second promoter, wherein the second promoter is located downstream of the capsid gene and drives the expression of its antisense RNA in the absence of helper virus co-infection.
[0025] In certain embodiments, the first promoter is AAV2 P40 and the second promoter is a ubiquitous promoter. In certain embodiments, the first promoter is AAV2 P40 and the second promoter is a cell-specific promoter. In certain embodiments, the ubiquitous or cell-specific promoter allows expression of a gene encoding a variant AAV capsid polypeptide in an antisense orientation, thereby producing antisense RNA. In certain embodiments, the method includes recovering the antisense RNA, which can be converted into RNA encoding a variant AAV capsid polypeptide for determining the sequence of the variant AAV capsid polypeptide.
[0026] In certain embodiments, the variant AAV capsid polypeptide exhibits increased target cell transduction or target cell specificity (tropism) compared to the parent capsid polypeptide.
[0027] Detailed Description of the Figures
[0028] The foregoing and other objects, features, and advantages will become apparent from the following description of certain embodiments of the present disclosure, as illustrated in the accompanying drawings, which are not necessarily drawn to scale, emphasis instead being placed upon illustrating the principles of the various embodiments of the present disclosure.
[0029] Figure 1A and Figure 1B A full map of wild-type AAV capsid gene transcription and CMV-CAP vector is shown. Figure 1A Transcription of VP1, VP2, and VP3 AAV transcripts from the wild-type AAV genome is shown. The transcription start site for each viral promoter is shown. SD, splice donor, SA, splice acceptor. The start codon sequence for each reading frame is shown. Translation of AAP and VP3 is performed by leaky scanning of the primary mRNA. Figure 1B The structure of the CMV-p40 dual promoter vector used to determine the minimal regulatory sequences necessary for efficient virus production is shown. The pREP2ΔCAP vector shown at the bottom was derived by deleting most of the CAP reading frame and is used to provide REP protein in trans.
[0030] Figure 2A and Figure 2B is a histogram representation of the data and shows the effect of CMV promoter position on virus yield and CAP mRNA splicing. Figure 2A Shows the use Figures 1A-1B Average yields of AAV9 produced in HEK-293T cells using the constructs described in [ 15 ] and co-transfected with an Ad helper vector. Wild-type AAV9 plasmid (pAV9) was used as a positive control. Y-axis values represent the number of AAV DNA copies / μl (~1000 ul total, left panel) or the percentage of wt AAV9 (right panel) from each 15 cm plate. Figure 2B Evidence of CAP transcript expression in transfected cells is shown. RT-PCR was performed on mRNA from transfected 293T cells using primers specific for the major spliced CAP transcript. Note the lack of p40-driven transcription in the absence of an Ad helper vector (lane 2).
[0031] Figure 3A 、 Figure 3B and Figure 3C The effect of REP helper plasmid optimization on virus yield is shown. Figure 3A The design of the improved pREP helper vector is shown. The deletion of the MscI fragment removes the C-terminal portion of the VP protein, which is essential for capsid formation. The asterisk indicates an early stop codon, which was introduced to disrupt the coding potential of the VP1, VP2, and VP3 reading frames. Figure 3B Figure 2. Synapsin-p40-CAP9 AAV yields generated using various REP plasmid constructs. Values on the Y axis represent the percentage of VG relative to wild-type AAV9. Figure 3C Quantification of recombination and / or aberrant packaging of full-length REP from the pREP plasmid is shown. qPCR was performed on the resulting viral stocks using a Taqman probe located in the N-terminal portion of REP lacking the ITR-containing vector.
[0032] Figure 4A 、 Figure 4B 、 Figure 4C and Figure 4D In vivo analysis of second generation vectors is described. Figure 4A The design of the Pro9 vector is shown. The structures of all three vectors are based on the BstEII construct. The AAV9 capsid RNA is placed under the control of P40 and CMV, hSyn1 or GFAP promoters, respectively. Figure 4B Silver staining of SDS-PAGE gels obtained by running 1e10 VG of each vector after two iodixanol purifications is shown. Figure 4C Figure 2 shows the biodistribution of viral DNA in the brain (cortex), liver, and heart of mice following tail vein injection of 1e12 VG per mouse. AAV9 VP3 DNA was quantified by Taqman PCR and normalized to the mouse transferrin receptor gene. Figure 4D Capsid RNA was recovered from mouse tissues. Total RNA was reverse transcribed and Taqman PCR was performed using capsid-specific Taqman primers and probes. Values represent the number of VP3 cDNA copies normalized to the TBP housekeeping gene.
[0033] Figure 5A 、 Figure 5B 、 Figure 5C 、 Figure 5D and Figure 5E In vitro analysis of intronic second-generation vectors is described. Figure 5A The design of the intronic Pro9 vector with a hybrid CMV / globin intron is shown. The AAV9 capsid RNA is placed under the control of the P40 and CBA, hSyn1, or GFAP promoters in a tandem configuration (top) or in a reverse configuration (bottom). In the reverse promoter vector, an additional SV40 polyadenylation site (orange) is added at the 3' end to allow polyadenylation of the antisense CAP9 transcript. Figure 5B AAV9 CAP cDNA amplification is shown. All vectors described were generated using triple transfection with pHelper (p-helper) and pREP-3stops (pREP-3stop), and the resulting viruses were used to infect HEK-293T cells at an MOI of 1e4 VG per cell. RNA was extracted 48 hours after infection and subjected to RT-PCR using primers that amplify the complete capsid (top) or the C-terminal fragment (bottom). Figure 5C Figure 2 Quantification of AAV9 VP3 cDNA by Taqman PCR from cells infected with intronless or intron-containing viruses with a tandem promoter in the forward orientation and normalized to the GAPDH housekeeping gene. Values represent the ratio of VP3 to GAPDH cDNA. Figure 5D Shown are maps of capsid RNA recovered from cells infected with either tandem or reverse constructs. Total RNA was reverse transcribed and PCR was performed using primers flanking the entire capsid gene. White arrows indicate VP3 size variants generated by aberrant splicing of the antisense CAP mRNA. Figure 5E Analysis of globin intron splicing is shown. PCR was performed on CAG9 plasmid (left) or cDNA from HEG-293T cells transduced with CAG9 virus using forward primers located before (Glo ex1) or within (GloSpliceF4 (SEQ ID NO: 26) and GloSpliceF6 (SEQ ID NO: 13)) the globin exon-exon junction. Primers spanning the linker between exon 1 (not underlined) and exon 2 (underlined) are depicted at the bottom.
[0034] Figure 6 In vitro evidence is provided that the presence of the P40 promoter downstream of either the synapsin or Gfabc1D promoter does not relieve repression of either promoter in HEK-293T cells.
[0035] Figure 7 The basic principle of the TRACER platform is shown.
[0036] Figure 8 Features of the TRACER platform, including the use of tissue-specific promoters and RNA recovery, are shown.
[0037] Figure 9 An implementation of the TRACER production architecture is provided.
[0038] Figure 10 A comparison between traditional vDNA recovery and second-generation vRNA recovery is provided.
[0039] Figure 11 An overview of the use of cell-specific RNA expression for targeted evolution is provided.
[0040] Figure 12A and Figure 12B Provided are representative natural AAV ( Figure 12A ) and TRACER libraries ( Figure 12B ) capsid gene transcription diagram.
[0041] Figure 13 Figure 2 is a diagram of AAV6, AAV5, and AAV-DJ capsid peptide display libraries used for in vivo evolution (SEQ ID NOs 27-32, respectively, in order of appearance).
[0042] Figure 14 is a diagram of the AAV9 capsid peptide display library used for in vivo evolution (SEQ ID NOs. 33-42, respectively, in order of appearance).
[0043] Figure 15A and Figure 15B The method used for library construction is shown. Figure 15A The sequences of the insertion sites used for introduction into the random library are shown (SEQ ID NOs 43-46, respectively, in order of appearance). Figure 15B A description of the assembly process is provided.
[0044] Figure 16 An exemplary diagram of the cloning-free rolling circle procedure for library amplification is provided (SEQ ID NO 47; NNK7).
[0045] Figure 17 Sequences of codon-mutated AAV9 library shuffles designed to minimize wild-type contamination are provided (SEQ ID NOs 33-34 and 48-52, respectively, in order of appearance).
[0046] Figure 18 A description of biopanning of an AAV9 peptide library is provided.
[0047] Figure 19 The recovery process from the initial pool is shown, with a recovery of 50%.
[0048] Figure 20Examples of cDNA recovery and amplification from GFAP-driven libraries (Panels B and F) are provided.
[0049] Figure 21A 、 Figure 21B and Figure 21C The progression of AAV9 peptide library diversity throughout the biopanning process is shown. Figure 21A RNA library evolution is described. Figure 21B and Figure 21C Amino acid distributions of NNK machine mix preparations for P0 and P1 viruses are shown.
[0050] Figure 22 A neuronal (SYN)-AAV9 peptide library composition at P2 is provided.
[0051] Figure 23 Astrocyte (GFAP)-AAV9 peptide library compositions at P2 are provided.
[0052] Figure 24 An assessment of brain / liver specificity among GFAP-AAV9 peptide library candidates is provided.
[0053] Figure 25 An assessment of brain / liver specificity among GFAP-AAV9 peptide library candidates is provided.
[0054] Figure 26 An example subset selection of variants is provided.
[0055] Figure 27 An exemplary design of the library generation and cloning process is provided.
[0056] Figure 28 Provided are the NNK / NNM codon distribution (covariance of codon mutants) of AAV generated using a synthetic library of 666 sequence variants (GFAP promoter).
[0057] Figure 29 Provided are the NNK / NNM codon distributions (covariance of codon mutants) of AAV generated using a synthetic library of 666 sequence variants (SYN9 promoter).
[0058] Figure 30 Data are presented on tissue recovery from brain and liver samples taken one month after injection.
[0059] Figure 31A 、 Figure 31B 、 Figure 31C and Figure 31D Results for control capsids from Syn-driven synthetic library NGS analysis are presented. Figure 31AEnrichment analysis of internal AAV9, PHP.B and PHP.eB controls is shown (SEQ ID NOs 53-58 and 53-58, respectively, in order of appearance). Figure 31B 、 Figure 31C and Figure 31D Shown is the NNK / NNM codon distribution in mRNA from mouse brain tissue.
[0060] Figure 32A and Figure 32B The results of NGS analysis of the neuronal synthetic library are provided (SEQ ID NOs 59-60, 59-61, 61-63, 62, 64, 64, 63, 65-67, 67, 65, 68, 66, 69, 70-71 and 70-74, respectively, in order of appearance).
[0061] Figure 33 The results of NGS analysis of astrocyte synthetic libraries are provided (SEQ ID NOs 53-58, 53-58, and 53-58, respectively, in order of appearance).
[0062] Figure 34A and Figure 34B Covariances of codon mutants from the astrocyte synthetic library are provided.
[0063] Figure 35The results of NGS analysis of astrocyte synthetic libraries are provided (SEQ ID NOs 75, 75-78, 76-77, 79-83, 65, 78, 84, 80, 85, 70, 86, 82, 81, 79, 87, 65, 85, 84, 70, 86, 88-90, 87, 91, 83, 88, 63, 89-90, 92-93, 91, 94-97, 93, 95, 98, 98, 97, 63, 92, 94, 99-101, 75, 75-78, 76-77, 79-83, 65, 78, 84, 80, 85 , 70, 86, 82, 81, 79, 87, 65, 85, 84, 70, 86, 88-90, 87, 91, 83, 88, 63, 89-90, 92-93, 91, 94-97, 93, 95, 98, 98, 97, 63, 92, 94, 99-102, 99, 103, 103-104, 96, 105-106, 101, 100, 102, 107, 104-105, 108-113, 106, 60, 66, 114-1 17, 109, 113, 72, 108, 110, 67, 118-119, 116, 120, 120, 107, 112, 121-123, 66, 124-125, 115, 118, 126, 121, 127-128, 60, 129, 119, 130-132, 72, 133, 123, 125, 69, 134-139, 62, 124, 67, 111, 114, 126, 140-141, 122, 142, 128-129, 143, 138, 144, 134, 62, 136, 145, 141, 146-153, 127, 154, 69, 144, 155, 71, 156, 133, 132, 137, 147, 157-158, 135, 159, 140, 117, 160, 139, 161-162, 130, 163, 143, 164, 152, 151, 165-167, 155, 168, 71, 169, and 146)
[0064] Figure 36 NGS analysis of GFAP synthetic libraries is provided.
[0065] Figure 37A and Figure 37B The top 38 variants from the synthetic library screen are presented. Figure 37APhylogenetic analysis of 9-mer peptide sequences is shown, along with sequences of peptide variants (SEQ ID NOs 67, 59, 64, 61, 77, 84, 96, 60, 80, 82, 66, 62, 83, 85, 106, 131, 94, 90, 76, 68-69, 79, 75, 81, 88, 139, 78, 155, 102, 63, 140, 87, 70, 105, 120, 89, 65, and 109, in order of appearance). Highlighted sequences represent peptides selected for individual transduction assays. Figure 37B A graphical representation of the neuronal and astroglial tropism of each peptide is shown, with both axes representing reverse sorting in the synaptophysin and GFAP screens.
[0066] Figure 38 The highest consensus sequences compared to PHP.N and PHP.B are provided (SEQ ID NOs 168 and 71 respectively in order of appearance).
[0067] Figure 39 Figure 1 is a diagram of the Gibson assembly library cloning process.
[0068] Figure 40 Examples of TRIM / NNK peptide prevalence are provided (SEQ ID NOs 170-171, respectively, in order of appearance).
[0069] Figure 41 Peptide diversity statistics are provided for a study using Illumina adapters with 42 million bacterial transformants, 81 million sequence reads, and 12 million sequence variants (SEQ ID NOs 172-173, 48-49, and 174-175, respectively, in order of appearance).
[0070] Figure 42 A schematic diagram of clone-free DNA amplification by rolling circle amplification is provided.
[0071] Figure 43 A diagram of telomerase monomer processing is provided (SEQ ID NOs 176-178, respectively, in order of appearance).
[0072] Figure 44 A graph comparing the traditional and clone-free methods is provided.
[0073] Figure 45A and Figure 45C Provides Syn-driven ( Figure 45A ) and GFAP-driven ( Figure 45B) Complete ranking of 333 variants. Capsid variants are ranked by their average brain RNA enrichment score (average of NNK and NNM codons). The rankings of the internal control capsids PHP.B, PHP.eB, and AAV9 are indicated ( Figure 45A and Figure 45B A comparison of the combined Syn-driven results and the GFAP-driven results is provided ( Figure 45C ). The GFAP-driven library represents only 4 animals, as 2 / 6 mice exhibited very different ranking profiles and were considered outliers.
[0074] Figure 46A and Figure 46B Comparison of NGS analysis of neuronal and astrocyte synthetic libraries is provided. Figure 46A Rankings of capsids using either the SYN or GFAP promoter are shown; Figure 46B Shown is a scatter plot showing the correlation of Syn- versus GFAP-driven libraries.
[0075] Figure 47 One embodiment of a multi-species (eg, rodent) study followed by next generation sequencing (NGS) is shown.
[0076] Figure 48A 、 Figure 48B and Figure 48C Results from a multi-strain / species comparison of 333 capsid variants are presented. Figure 48A Shown are the rankings of 333 capsids by brain RNA enrichment scores in C57BL / 6 mice, BALB / C mice, and rats. Capsids were ranked based on Syn-driven brain enrichment scores in C57BL / 6 mice. Figure 48B Shown are scatter plots showing the correlation between C57BL / 6 and BALB / C enrichment scores from Syn- and GFAP-driven libraries. Figure 48C A Venn diagram is shown showing the intersection and consensus of capsids with >10-fold enrichment scores in the brain compared to AAV9 (Syn- or GFAP-driven) in C57BL / 6 and BALB / C strains. In rat, no capsid showed >10-fold enrichment scores relative to AAV9.
[0077] Figure 49A 、 Figure 49B 、 Figure 49C and Figure 49D Provides Figure 49A Transduction (RNA) and biodistribution (DNA) analysis of the 10 capsid variants shown in (SEQ ID NOs 179-188, respectively, in order of appearance). Each capsid was used to package the self-complementary CBA-EGFP genome ( Figure 49B) and injected intravenously into C57BL / 6 mice. Figure 49C RNA expression in brain and spinal cord samples is shown. Figure 49D DNA distribution in brain and spinal cord samples is shown.
[0078] Figure 50A 、 Figure 50B and Figure 50C Results of testing individual capsids and their mRNA expression in brain, spinal cord, and liver are presented. Figure 50A ),spinal cord( Figure 50B ) and liver( Figure 50C ) EGFP mRNA expression results.
[0079] Figure 51 Results of NGS screening using the neuronal NeuN marker for GFAP screening and SYN screening are provided ( Figure 51 ).
[0080] Figure 52 Results of tests on individual capsids throughout the brain are presented.
[0081] Figure 53 Results from tests of other individual capsids throughout the brain are provided.
[0082] Figure 54 Results of testing of individual capsids in the cerebellum are presented.
[0083] Figure 55 Results of testing of individual capsids in the cortex are presented.
[0084] Figure 56 Results from testing individual capsids in the hippocampus are presented.
[0085] Figure 57A and Figure 57B Transduction data for 10 capsid variants in mouse liver are provided ( Figure 57B ), by EGFP RNA expression and whole tissue fluorescence analysis ( Figure 57A ).
[0086] Figure 58A and Figure 58B Provides 333 capsid variants for transduction of C57BL / 6 mouse BMVEC ( Figure 58A ) and human BMVEC ( Figure 58B ) compared with the results of a CNS efficacy study.
[0087] Figure 59A 、 Figure 59B and Figure 59C A diagram of NGS analysis of full-length capsid variants and the recovered external barcodes is provided. The universal barcode pair ( Figure 59C). Shown is a 5' ( Figure 59A ) and CAP sequence 3' barcode pair ( Figure 59B )'s complete ITR to ITR construct.
[0088] Figure 60A 、 Figure 60B and Figure 60C Detailed analysis of viral production and RNA splicing using an intron barcoding platform with various configurations is provided. Universal ITR to ITR constructs are shown in Figure 60A (SEQ ID NOs 189-193 in order of appearance), and intron barcode yield ( Figure 60B ), and the gel column shows the results of AAV intron splicing and globin intron splicing ( Figure 60C ).
[0089] Detailed public description
[0090] The details of one or more embodiments of the present disclosure are set forth in the following attached description. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, preferred materials and methods are now described. By description, other features, objects and advantages of the present disclosure will be apparent. In the specification, the singular also includes the plural, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs. In the event of conflict, this specification shall prevail.
[0091] According to the present disclosure, AAV particles with enhanced tropism for target tissues (e.g., CNS) are provided, as well as methods for their targeting, preparation, formulation, and use. Targeting peptides and nucleic acid sequences encoding the targeting peptides are provided. These targeting peptides can be inserted into AAV capsid protein sequences in vivo, ex vivo, or in vitro to alter tropism for specific cell types, tissues, organs, or organisms.
[0092] As used herein, an "AAV particle" or "AAV vector" comprises a capsid protein and a viral genome, wherein the viral genome comprises at least one payload region and at least one inverted terminal repeat (ITR). The AAV particle and / or its component capsids and viral genomes can be engineered to alter tropism for specific cell types, tissues, organs, or organisms.
[0093] As used herein, "viral genome" or "vector genome" refers to the nucleic acid sequence encapsulated in an AAV particle. The viral genome comprises a nucleic acid sequence having at least one payload region encoding a payload and at least one ITR.
[0094] As used herein, a "payload region" is any nucleic acid molecule encoding one or more "payloads" of the present disclosure. As a non-limiting example, a payload region can be a nucleic acid sequence encoding a payload comprising an RNAi agent or polypeptide.
[0095] As used herein, "targeting peptide" refers to a peptide of 3-20 amino acids in length. These targeting peptides can be inserted into or attached to a parent amino acid sequence to alter the properties (e.g., tropism) of the parent protein. As a non-limiting example, a targeting peptide can be inserted into an AAV capsid sequence to enhance targeting to a desired cell type, tissue, organ, or organism.
[0096] The AAV particles and payloads of the present disclosure can be delivered to one or more target cells, tissues, organs, or organisms. In a preferred embodiment, the AAV particles of the present disclosure exhibit enhanced tropism for target cell types, tissues, or organs. As a non-limiting example, the AAV particles can enhance tropism for cells and tissues of the central or peripheral nervous system (CNS and PNS, respectively). The AAV particles of the present disclosure can additionally or alternatively reduce tropism for undesirable target cell types, tissues, or organs.
[0097] Adeno-associated virus (AAV) is a small, non-enveloped, icosahedral capsid virus of the Parvoviridae family, characterized by a single-stranded DNA viral genome. The Parvoviridae family of viruses consists of two subfamilies: the Parvovirinae, which infect vertebrates, and the Denguevirinae, which infect invertebrates. The Parvoviridae family includes the Dependent virus genus, which includes AAV, and is capable of replicating in vertebrate hosts, including but not limited to humans, primates, bovine, canine, equine, and ovine species.
[0098] Parvoviruses and other members of the Parvoviridae family are generally described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication" (FIELDS VIROLOGY) (3rd ed. 1996), Chapter 69, the contents of which are incorporated by reference in their entirety.
[0099] AAV has proven useful as a biological tool due to its relatively simple structure, ability to infect a wide variety of cells (including quiescent and dividing cells) without integrating into the host genome and without the need for replication, and its relatively mild immunogenicity. The viral genome can be engineered to contain the minimum components for assembling a functional recombinant virus or viral particle loaded with a payload, or engineered to target specific tissues and express or deliver a desired payload.
[0100] The wild-type AAV vector genome is a linear, single-stranded DNA (ssDNA) molecule with a length of about 5,000 nucleotides (nt). Inverted terminal repeats (ITRs) typically cap the viral genome at the 5' and 3' ends, providing a replication origin for the viral genome. Although not wishing to be bound by theory, the AAV viral genome typically includes two ITR sequences. These ITRs have a characteristic T-shaped hairpin structure, which is limited by the self-complementary regions (145nt in wild-type AAV) at the 5' and 3' ends of ssDNA, forming an energy-stable double-stranded region. The double-stranded hairpin structure includes multiple functions, including but not limited to serving as a starting point for DNA replication by acting as a primer for the endogenous DNA polymerase complex of the host virus replication cell.
[0101] The wild-type AAV viral genome also includes the nucleotide sequences of two open reading frames, one for the four nonstructural Rep proteins (Rep78, Rep68, Rep52, Rep40, encoded by the Rep gene) and the other for the three capsid or structural proteins (VP1, VP2, VP3, encoded by the capsid gene or Cap gene). Rep proteins are important for replication and packaging, while capsid proteins assemble to form the protein shell of AAV or AAV capsid. Alternative splicing and alternate start codons and promoters result in the production of four different Rep proteins from a single open reading frame and the production of three capsid proteins from a single open reading frame. Although, as a non-limiting example, for AAV9 / hu.14 (SEQ ID NO: 123 of US 7,906,111, the contents of which are incorporated herein by reference in their entirety), which varies with AAV serotype, VP1 refers to amino acids 1-736, VP2 refers to amino acids 138-736, and VP3 refers to amino acids 203-736. In other words, VP1 is the full-length capsid sequence, while VP2 and VP3 are shorter components of the whole. As a result, changes in the sequence in the VP3 region are also changes in VP1 and VP2, but the percentage difference of VP3 compared to the parent sequence will be the largest because it is the shortest of the three sequences. Although described herein with respect to amino acid sequences, the nucleic acid sequences encoding these proteins can be similarly described. These three capsid proteins assemble together to form the AAV capsid proteins. Although not wishing to be bound by theory, the AAV capsid proteins typically include a 1:1:10 molar ratio of VP1:VP2:VP3. As used herein, "AAV serotype" is primarily defined by the AAV capsid. In some cases, the ITRs are also specifically described by the AAV serotype (e.g., AAV2 / 9).
[0102] The AAV vectors of the present disclosure can be recombinantly produced and can be based on an adeno-associated virus (AAV) parent or reference sequence. As used herein, a "vector" is any molecule or entity that transports, transduces, or otherwise acts as a vehicle for a heterologous molecule (e.g., a nucleic acid as described herein).
[0103] In addition to single-stranded AAV viral genomes (e.g., ssAAV), the present disclosure also provides self-complementary AAV (scAAV) viral genomes. The scAAV vector genome comprises DNA strands that anneal together to form double-stranded DNA. By skipping second-strand synthesis, scAAV can be rapidly expressed in transduced cells.
[0104] In one embodiment, the AAV particle of the present disclosure is a scAAV.
[0105] In one embodiment, the AAV particles of the present disclosure are ssAAV.
[0106] Methods for producing and / or modifying AAV particles, such as pseudotyped AAV vectors, are disclosed in the art (PCT Patent Publication Nos. WO200028004; WO200123001; WO2004112727; WO2005005610 and WO2005072364, the contents of each of which are herein incorporated by reference in their entirety).
[0107] In one embodiment, the AAV particles of the present disclosure comprising a capsid and a viral genome with an inserted targeting peptide can have increased tropism for cell types or tissues of the human CNS.
[0108] AAV capsid
[0109] The AAV particles of the present disclosure may comprise or be derived from any natural or recombinant AAV serotype. AAV serotypes may differ in characteristics such as, but not limited to, packaging, tropism, transduction, and immunogenicity. Without wishing to be bound by theory, the AAV capsid protein is generally considered to be a driver of the tropism of AAV particles for specific tissues.
[0110] In one embodiment, the AAV particles can have capsid proteins and ITR sequences derived from the same parental serotype (e.g., AAV2 capsid and AAV2 ITRs). In another embodiment, the AAV particles can be pseudotyped AAV particles in which the capsid proteins and ITR sequences are derived from different parental serotypes (e.g., AAV9 capsid and AAV2 ITRs; AAV2 / 9).
[0111] The AAV particles of the present disclosure can comprise an AAV capsid protein having a targeting peptide inserted into a parent sequence. The parent capsid or serotype can comprise or be derived from any natural or recombinant AAV serotype. As used herein, a "parent" sequence is a nucleotide or amino acid sequence into which a targeting sequence is inserted (i.e., a nucleotide sequence is inserted into a nucleic acid sequence or an amino acid sequence is inserted into an amino acid sequence).
[0112] In a preferred embodiment, the parent AAV capsid nucleotide sequence is shown in SEQ ID NO: 1.
[0113] In another embodiment, the parent AAV capsid nucleotide sequence is the K449R variant of SEQ ID NO: 1, wherein the codon encoding lysine (e.g., AAA or AAG) at position 449 (nucleotides 1345-1347) of the amino acid sequence is exchanged for a codon encoding arginine (CGT, CGC, CGA, CGG, AGA, AGG). The K449R variant has the same function as wild-type AAV9.
[0114] In one embodiment, the parent AAV capsid amino acid sequence is shown in SEQ ID NO:2.
[0115] In another embodiment, the parent AAV capsid amino acid sequence is shown in SEQ ID NO:3.
[0116] In one embodiment, the parent AAV capsid sequences are those shown in Table 1.
[0117] Table 1. AAV capsid sequences
[0118]
[0119] Each patent, application, and / or publication listed in Table 1 is incorporated herein by reference in its entirety.
[0120] The parent AAV serotype and the associated capsid sequence can be any of those known in the art. Non-limiting examples of such AAV serotypes include AAV9, AAV9 K449R (or K449RAAV9), AAV1, AAVrh10, AAV-DJ, AAV-DJ8, AAV5, AAVPHP.B (PHP.B), AAVPHP.A (PHP.A), AAVG2B-26, AAVG2B-13, AAVTH1.1-32, AAVTH1.1-35, AAVPHP.B2 (PHP.B2), AAVPHP.B3 (PHP.B3), AAVPHP.N / PHP.B-DGT, AAVPHP.B-EST, AAVPHP.B-GGT, AAVPHP.B-ATP, AAVPHP.B-ATT -T, AAVPHP.B-DGT-T, AAVPHP.B-GGT-T, AAVPHP.B-SGS, AAVPHP.B-AQP, AAVPHP.B-QQP, AAVPHP.B-SNP(3), AAVPHP.B-SNP, AAVPHP.B-QGT, AAV PHP.B-NQT, AAVPHP.B-EGS, AAVPHP.B-SGN, AAVPHP.B-EGT, AAVPHP.B-DST, AAVPHP.B-DST, AAVPHP.B-STP, AAVPHP.B-PQP, AAVPHP.B-SQP, AAV PHP.B-QLP, AAVPHP.B-TMP, AAVPHP.B-TTP, AAVPHP.S / G2A12, AAVG2A15 / G2A3(G2A3), AAVG2B4(G2B4), AAVG2B5(G2B5), PHP.S, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9 .45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-1b, AAV42-2, AAV42- 3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1,AAV43-12、AAV43-20、AAV43-21、AAV43-23、AAV43-25、AAV43-5、AAV44.1、AAV44.2、AAV44.5、AAV223.1、AAV223.2、AAV223.4、AAV223.5、AAV223.6、AA V223.7、AAV1-7 / rh.48、AAV1-8 / rh.49、AAV2-15 / rh.62、AAV2-3 / rh.61、AAV2-4 / rh.50、AAV2-5 / rh.51、AAV3.1 / hu.6、AAV3.1 / hu.9、AAV3-9 / rh.52、AAV3. AV3-11 / rh.53、AAV4-8 / r11.64、AAV4-9 / rh.54、AAV4-19 / rh.55、AAV5-3 / rh.57、AAV5-22 / rh.58、AAV7.3 / hu.7、AAV16.8 / hu.10、AAV16.12 / hu.11、AAV29.3 / bb.1、AAV29.5 / bb.2、AAV106.1 / hu.37、AAV114.3 / hu.40、AAV127.2 / hu.41、AAV127.5 / hu.42、AAV128.3 / hu.44、AAV130.4 / hu.48、AAV145.1 / h u.53、AAV145.5 / hu.54、AAV145.6 / hu.55、AAV161.10 / hu.60、AAV161.6 / hu.61、AAV33.12 / hu.17、AAV33.4 / hu.15、AAV33.8 / hu.16、AAV52 / hu.19、AAV52.1 / hu.20、AAV58.2 / hu.25、AAVA3.3、AAVA3.4、AAVA3.5、AAVA3.7、AAVC1、AAVC2、AAVC5、AAVF3、AAVF5、AAVH2、AAVrh.72、AAVhu.8、AAVrh.68、AAVrh .70、AAVpi.1、AAVpi.3、AAVpi.2、AAVrh.60、AAVrh.44、AAVrh.65、AAVrh.55、AAVrh.47、AAVrh.69、AAVrh.45、AAVrh.59、AAVhu.12、AAVh6、AAVh-1 / hu .1、AAVH-5 / hu.3、AAVLG-10 / rh.40、AAVLG-4 / rh.38、AAVLG-9 / hu.39、AAVN721-8 / rh.43、AAVCh.5、AAVCh.5R1、AAVcy.2、AAVcy.3、AAVcy.4、AAVcy.5.AAVCy.5R1、AAVCy.5R2、AAVCy.5R3、AAVCy.5R4、AAVcy.6、AAVhu.1、AAVhu.2、AAVhu.3、AAVhu.4、AAVhu.5、AAVhu.6、AAVhu.7、AAVhu.9、AAVhu.10、AAVhu.11、AAVhu.13、AAVhu.15、AAVhu.16、AAVhu.17、AAVhu.18、AAVhu.20、AAVhu.21、AAVhu.22、AAVhu.23.2、AAVhu.24、AAVhu.25、AAVhu.27、AAVhu.28、AAVhu.29、AAVhu.29R、AAVhu.31、AAVhu.32、AAVhu.34、AAVhu.35、AAVhu.37、AAVhu.39、AAVhu.40、AAVhu.41、AAVhu.42、AAVhu.43、AAVhu.44、AAVhu.44R1、AAVhu.44R2、AAVhu.44R3、AAVhu.45、AAVhu.46、AAVhu.47、AAVhu.48、AAVhu.48R1、AAVhu.48R2、AAVhu.48R3、AAVhu.49、AAVhu.51、AAVhu.52、AAVhu.54、AAVhu.55、AAVhu.56、AAVhu.57、AAVhu.58、AAVhu.60、AAVhu.61、AAVhu.63、AAVhu.64、AAVhu.66、AAVhu.67、AAVhu.14 / 9、AAVhu.t 19、AAVrh.2、AAVrh.2R、AAVrh.8、AAVrh.8R、AAVrh.10、AAVrh.12、AAVrh.13、AAVrh.13R、AAVrh.14、AAVrh.17、AAVrh.18、AAVrh.19、AAVrh.20、AAVrh.21、AAVrh.22、AAVrh.23、AAVrh.24、AAVrh.25、AAVrh.31、AAVrh.32、AAVrh.33、AAVrh.34、AAVrh.35、AAVrh.36、AAVrh.37、AAVrh.37R2、AAVrh.38、AAVrh.39、AAVrh.40、AAVrh.46、AAVrh.48、AAVrh.48.1、AAVrh.48.1.2、AAVrh.48.2、AAVrh.49、AAVrh.51、AAVrh.52、AAVrh.53、AAVrh.54、AAVrh.56、AAVrh.57、AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, goat AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV shuffling 100-1, AAV shuffling 100-3, AAV shuffling 100-7, AAV shuffling 10-2, AAV shuffling 10-6, AAV shuffling 10-8, AAV shuffling 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8 / rh.64, AAVLG-9 / hu.39, AAV54.5 / hu.23, AAV54.2 / hu.22, AAV54.7 / hu.24, AAV54.1 / hu.21, AAV54.4R / hu.27, AAV46.2 / hu.28, AAV46.6 / hu.29, AAV128.1 / hu.43True form AAV (ttAAV), UPenn AAV 10, Japanese AAV 10 serotype, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAVCBr-B7.4, AAV CBr-E1, AAV CBr-E2, AAV CBr-E3, AAV CBr-E4, AAV CBr-E5, AAV CBr-e5, AAV CBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAV CHt-6.1, AAV CHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAV CHt-P1, AAVCHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAV CKd-1, AAV CKd-10, AAVCKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAV CKd-8, AAV CKd-B1, AAV CKd-B2, AAV CKd-B3, AAV CKd-B4, AAV CKd-B5, AAV CKd-B6, AAV CKd-B7, AAV CKd-B8, AAV CKd-H1, AAV CKd-H2, AAV CKd-H3, AAV CKd-H4, AAV CKd-H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAV CKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAV CLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLv1-1, AAV Clv1-10, AAV CLv1-2, AAV CLv-12, AAV CLv1-3, AAV CLv-13, AAV CLv1-4, AAV Clv1-7, AAV Clv1-8, AAV Clv1-9, AAV CLv-2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAV CLv-8, AAV CLv-D1, AAV CLv-D2, AAV CLv-D3, AAV CLv-D4AAV CLv-D5, AAV CLv-D6, AAV CLv-D7, AAV CLv-D8, AAV CLv-E1, AAV CLv-K1, AAV CLv-K3, AAV CLv-K6, AAV CLv-L4, AAV CLv-AAV-5 CLv-L6, AAV CLv-M1, AAV CLv-M11, AAV CLv-M2, AAV CLv-M5, AAV CLv-M6, AAV CLv-M7, AAV CLv-M8, AAV CLv-M9, AAV CLv-1, AAV CLv-1 CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, AAV CLv-R7, AAVCLv-R8, AAV CLv-R9, AAV CSp-1, AAV CSp-10AAV CSp-11、AAV CSp-2、AAV CSp-3、AAVCSp-4、AAV CSp-6、AAV CSp-7、AAV CSp-8、AAV CSp-8.10、AAV CSp-8.2、AAV CSp-8.8、AAV CSp-8. CSp-8.6、AAV CSp-8.7、AAV CSp-8.8、AAV CSp-8.9、AAV CSp-9, AAV.hu.48R3, AAV.VR-355, AAV3B, AAV4, AAV5, AAVF1 / HSC1, AAVF 11 / HSC11、AAVF12 / HSC12、AAVF13 / HSC13、AAVF14 / HSC14、AAVF15 / HSC15、 AAVF16 / HSC16、AAVF17 / HSC17、AAVF2 / HSC2、AAVF3 / HSC3、AAVF4 / HSC4、A AVF5 / HSC5, AAVF6 / HSC6, AAVF7 / HSC7, AAVF8 / HSC8, AAVF9 / HSC9
[0121] In some embodiments, the serotype can be AAVDJ or a variant thereof, such as AAVDJ8 (or AAV-DJ8), as described in Grimm et al. (Journal of Virology 82(12):5887-5911 (2008), U.S. Publication No. US20140359799, and U.S. Patent No. 7,588,772, which are incorporated herein by reference in their entireties). The amino acid sequence of AAVDJ8 can comprise two or more mutations to remove the heparin binding domain (HBD). As a non-limiting example, the AAV-DJ sequence is described in U.S. Patent No. 7,588,772 (the contents of which are incorporated herein by reference in their entirety) by SEQ ID NO: 1, and the AAVDJ8 sequence may comprise two mutations: (1) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln) and (2) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr). As another non-limiting example, the AAVDJ8 sequence may comprise three mutations: (1) K406R, wherein the lysine (K; Lys) at amino acid 406 is changed to arginine (R; Arg), (2) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln) and (3) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr).
[0122] In one embodiment, the parent AAV capsid sequence comprises an AAV9 sequence.
[0123] In one embodiment, the parent AAV capsid sequence comprises a K449R AAV9 sequence.
[0124] In one embodiment, the parent AAV capsid sequence comprises an AAVDJ sequence.
[0125] In one embodiment, the parent AAV capsid sequence comprises an AAVDJ8 sequence.
[0126] In one embodiment, the parent AAV capsid sequence comprises an AAVrh10 sequence.
[0127] In one embodiment, the parent AAV capsid sequence comprises an AAV1 sequence.
[0128] In one embodiment, the parent AAV capsid sequence comprises an AAV5 sequence.
[0129] Without wishing to be bound by theory, it is understood that the parent AAV capsid sequence comprises the VP1 region. In one embodiment, the parent AAV capsid sequence comprises the VP1, VP2 and / or VP3 regions, or any combination thereof. The parent VP1 sequence can be considered synonymous with the parent AAV capsid sequence.
[0130] The present disclosure relates to structural capsid proteins (including VP1, VP2 and VP3) encoded by capsid (Cap) genes. These capsid proteins form the outer protein structural shell (i.e., capsid) of viral vectors such as AAV. The VP capsid proteins synthesized by Cap polynucleotides typically include methionine as the first amino acid (Met1) in the peptide sequence, which is associated with the start codon (AUG or ATG) in the corresponding Cap nucleotide sequence. However, the first methionine (Met1) residue or generally any first amino acid (AA1) is usually cleaved off by protein processing enzymes such as Met-aminopeptidases after or during protein synthesis. This "Met / AA-cleavage" process is typically associated with the corresponding acetylation of the second amino acid (e.g., alanine, valine, serine, threonine, etc.) in the polypeptide sequence. Met-cleavage typically occurs on VP1 and VP3 capsid proteins, but may also occur on VP2 capsid protein.
[0131] When Met / AA cleavage is incomplete, a mixture of one or more (one, two, or three) VP capsid proteins comprising the viral capsid may be produced, some of which may contain Met1 / AA1 amino acids (Met+ / AA+), and some of which may lack Met1 / AA1 amino acids (Met- / AA-) due to Met / AA cleavage. For further discussion of Met / AA cleavage in capsid proteins, see Jin et al. Direct Liquid Chromatography / Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins. Hum Gene Ther Methods. 2017 Oct. 28(5): 255-267; Hwang et al. N-Terminal Acetylation of Cellular Proteins Creates Specific Degradation Signals. Science. 2010 February 19. 327(5968): 973–977; the contents of which are incorporated herein by reference in their entirety.
[0132] According to the present disclosure, reference to a capsid protein is not limited to cleaved (Met- / AA-) or uncleaved (Met+ / AA+), and in the context may refer to an independent capsid protein, a viral capsid including a mixture of capsid proteins, and / or a polynucleotide sequence (or fragment thereof) encoding, describing, producing, or leading to a capsid protein of the present disclosure. Direct reference to a "capsid protein" or "capsid polypeptide" (e.g., VP1, VP2, or VP2) may also include a VP capsid protein including Met1 / AA1 amino acids (Met+ / AA+) as well as a corresponding VP capsid protein lacking Met1 / AA1 amino acids (Met- / AA-) due to Met / AA cleavage.
[0133] Further in accordance with the present disclosure, reference to a particular SEQ ID NO: (whether protein or nucleic acid) comprising or encoding one or more capsid proteins comprising Met1 / AA1 amino acids (Met+ / AA+) should be understood to teach VP capsid proteins which, upon inspection of the sequence, lack the Met1 / AA1 amino acids, and obviously any sequence lacking only the first listed amino acid (whether or not having Met1 / AA1).
[0134] As a non-limiting example, a reference to a VP1 polypeptide sequence that is 736 amino acids in length and includes the "Met1" amino acid (Met+) encoded by the AUG / ATG start codon can also be understood to teach a VP1 polypeptide sequence that is 735 amino acids in length and does not include the "Met1" amino acid (Met-) of the 736 amino acid Met+ sequence. As a second non-limiting example, a reference to a VP1 polypeptide sequence that is 736 amino acids in length and includes the "AA1" amino acid (AA1+) encoded by any NNN start codon can also be understood to teach a VP1 polypeptide sequence that is 735 amino acids in length and does not include the "AA1" amino acid (AA1-) of the 736 amino acid AA1+ sequence.
[0135] Reference to a viral capsid formed by a VP capsid protein (e.g., reference to a specific AAV capsid serotype) can incorporate a VP capsid protein comprising the Met1 / AA1 amino acid (Met+ / AA1+), the corresponding VP capsid protein lacking the Met1 / AA1 amino group due to Met / AA1 cleavage (Met- / AA1-), and combinations thereof (Met+ / AA1+ and Met- / AA1-).
[0136] As non-limiting examples, the AAV capsid serotype may include VP1 (Met+ / AA1+), VP1 (Met- / AA1-), or a combination of VP1 (Met+ / AA1+) and VP1 (Met- / AA1-). The AAV capsid serotype may also include VP3 (Met+ / AA1+), VP3 (Met- / AA1-), or a combination of VP3 (Met+ / AA1+) and VP3 (Met- / AA1-); and may also include similar optional combinations of VP2 (Met+ / AA1) and VP2 (Met- / AA1-).
[0137] In one embodiment, the parent AAV capsid sequence can comprise an amino acid sequence that is 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the above sequences.
[0138] In one embodiment, the parent AAV capsid sequence can be encoded by a nucleotide sequence that is 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the above sequences.
[0139] In one embodiment, the parent sequence is not an AAV capsid sequence, but a different vector (e.g., lentivirus, plasmid, etc.). In another embodiment, the parent sequence is a delivery vehicle (e.g., nanoparticle) and the targeting peptide is attached thereto.
[0140] Targeting peptides
[0141] Disclosed herein are targeting peptides and related AAV particles comprising capsid proteins having one or more targeting peptide inserts for enhancing or improving transduction of target tissues (e.g., cells of the CNS or PNS).
[0142] In one embodiment, the targeting peptide can guide the AAV particles to cells or tissues of the CNS. The cells of the CNS can be, but are not limited to, neurons (e.g., excitatory, inhibitory, motor, sensory, autonomous, sympathetic, parasympathetic, Purkinje, Bates, etc.), glial cells (e.g., microglia, astrocytes, oligodendrocytes) and / or supporting cells of the brain, such as immune cells (e.g., T cells). The tissues of the CNS can be, but are not limited to, cortex (e.g., frontal lobe, parietal lobe, occipital lobe, temporal lobe), thalamus, hypothalamus, striatum, putamen, caudate nucleus, hippocampus, entorhinal cortex, basal ganglia, or deep cerebellar nuclei.
[0143] In one embodiment, the targeting peptide can direct the AAV particles to cells or tissues of the PNS. The cells or tissues of the PNS can be, but are not limited to, dorsal root ganglia (DRG).
[0144] Following intravenous administration, the targeting peptide can direct AAV particles to the CNS (e.g., the cortex).
[0145] Following intravenous administration, the targeting peptide can direct AAV particles to the PNS (eg, DRG).
[0146] The length of targeting peptide can change.In one embodiment, the length of targeting peptide is 3-20 amino acid.As limiting examples, the length of targeting peptide can be 3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20 or 3-5,3-8,3-10,3-12,3-15,3-18,3-20,5-10,5-15,5-20,10-12,10-15,10-20,12-20 or 15-20 amino acid.
[0147] The targeting peptides disclosed herein can be identified and / or designed by any method known in the art. As non-limiting examples, such as Deverman et al. (Nature Biotechnology 34 (2): 204-209 (2016)), Chan et al. (Nature Neuroscience 20 (8): 1172-1179 (2017)), and the CREATE system described in International Patent Application Publication Nos. WO2015038958 and WO0100100671 (each of which is incorporated herein by reference in its entirety), can be used as a means for identifying targeting peptides in mice or other research animals (such as, but not limited to, non-human primates).
[0148] Targeting peptides and related AAV particles can be identified from a library of AAV capsids comprising targeting peptide variants. In one embodiment, the targeting peptide can be a 7 amino acid sequence (7 aggressiveness). In another embodiment, the targeting peptide can be a 9 amino acid sequence (9 aggressiveness). The creation or design method of the targeting peptide may also be different, and non-limiting examples include random peptide selection, site saturation mutagenesis and / or optimization of specific regions (such as flanking regions or central core) of the peptide.
[0149] In one embodiment, the targeting peptide library comprises targeting peptides of 7 amino acids in length (7-mers) randomly generated by PCR.
[0150] In one embodiment, the targeting peptide library comprises targeting peptides with 3 mutant amino acids. In one embodiment, these 3 mutant amino acids are continuous amino acids. In another embodiment, these 3 mutant amino acids are not continuous amino acids. In one embodiment, the parent targeting peptide is a 7-aggressor. In another embodiment, the parent peptide is a 9-aggressor.
[0151] In one embodiment, the targeting peptide library comprises 7-mer targeting peptides, wherein the amino acids of the targeting peptide and / or flanking sequences are formed by site saturation mutagenesis of 3 consecutive amino acids. In one embodiment, the NNK (N=any base; K=G or T) codon is used to generate site saturation mutant sequences.
[0152] AAV particles containing capsid proteins with targeting peptide inserts are produced, and a viral genome encoding a reporter gene (e.g., GFP) is encapsulated therein. These AAV particles (or AAV capsid libraries) are then administered to transgenic mice via intravenous delivery to the tail vein. Due to Cre expression, administration of these capsid libraries to cre-expressing mice results in expression of the reporter gene payload in target tissues.
[0153] AAV particles and / or viral genomes can be recovered from target tissues to identify targeting peptides and enriched associated AAV particles, which indicate enhanced target tissue transduction. Enrichment can be determined using standard methods in the art, such as, but not limited to, next generation sequencing (NGS), viral genome quantification, biochemical assays, immunohistochemistry, and / or imaging of target tissue samples.
[0154] The target tissue can be any cell, tissue or organ of the subject. As non-limiting examples, samples can be collected from the brain, spinal cord, dorsal root ganglia and associated nerve roots, liver, heart, gastrocnemius muscle, soleus muscle, pancreas, kidney, spleen, lung, adrenal gland, stomach, sciatic nerve, saphenous nerve, thyroid gland, eye (with or without optic nerve), pituitary gland, skeletal muscle (rectus muscle), colon, duodenum, ileum, jejunum, leg skin, superior cervical ganglion, bladder, ovary, uterus, prostate, testicle and / or any site where a lesion or concern is found.
[0155] Targeting peptide sequence
[0156] In one embodiment, the targeting peptide may comprise a sequence as shown in Table 2. In Table 2, "_1" refers to a NNM codon, wherein A or C is at the third position, and "_2" refers to a NNK codon, wherein G or T is at the third position. In addition, since Met or Trp can only be encoded by the codons ATG and TGG, respectively, the NNM codons cannot cover the entire amino acid library. Therefore, some "NNM" sequences also contain some codons ending in G.
[0157] Table 2. Peptides
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170] In one embodiment, the targeting peptide can comprise an amino acid sequence that is 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the sequences shown in Table 2.
[0171] In one embodiment, the targeting peptide may comprise 4 or more consecutive amino acids of any targeting peptide disclosed herein. In one embodiment, the targeting peptide may comprise 4 consecutive amino acids of any sequence listed in Table 2. In one embodiment, the targeting peptide may comprise 5 consecutive amino acids of any sequence listed in Table 2. In one embodiment, the targeting peptide may comprise 6 consecutive amino acids of any sequence listed in Table 2.
[0172] In one embodiment, the AAV particle of the present disclosure comprises an AAV capsid having a targeting peptide insert, wherein the targeting peptide has an amino acid sequence as listed in any one of Table 2.
[0173] In one embodiment, the AAV particle of the present disclosure comprises an AAV capsid having a targeting peptide insert, wherein the targeting peptide has an amino acid sequence comprising at least 4 consecutive amino acids of any sequence listed in any one of Table 2.
[0174] In one embodiment, the AAV particle of the present disclosure comprises an AAV capsid having a targeting peptide insert, wherein the targeting peptide has an amino acid sequence that essentially comprises any of the sequences listed in any one of Table 2.
[0175] In one embodiment, an AAV particle of the present disclosure comprises an AAV capsid polynucleotide having a targeting nucleic acid insert, wherein the targeting nucleic acid insert has a nucleotide sequence that essentially comprises the nucleotide sequence listed in any one of Table 2.
[0176] The AAV particles of the present disclosure comprising a targeting nucleic acid insert can have a polynucleotide sequence having 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the parental capsid sequence.
[0177] The AAV particles of the present disclosure comprising a targeting peptide insert can have an amino acid sequence that is 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the parental capsid sequence.
[0178] In any DNA and RNA sequences cited and / or described herein, the single letter symbols have the following descriptions: A for adenine; C for cytosine; G for guanine; T for thymine; U for uracil; W for a weak base, such as adenine or thymine; S for a strong nucleotide, such as cytosine and guanine; M for an amino nucleotide, such as adenine and cytosine; K for a keto nucleotide, such as guanine and thymine; and R for a purine, such as adenine and cytosine. Guanine; Y represents the pyrimidines cytosine and thymine; B represents any base that is not A (e.g., cytosine, guanine, and thymine); D represents any base that is not C (e.g., adenine, guanine, and thymine); H represents any base that is not G (e.g., adenine, cytosine, and thymine); V represents any base that is not T (e.g., adenine, cytosine, and guanine); N represents any nucleotide (not a vacancy); and Z represents zero.
[0179] In any amino acid sequence referred to and / or described herein, the single-letter symbols have the following descriptions: G (Gly) represents glycine; A (Ala) represents alanine; L (Leu) represents leucine; M (Met) represents methionine; F (Phe) represents phenylalanine; W (Trp) represents tryptophan; K (Lys) represents lysine; Q (Gln) represents glutamine; E (Glu) represents glutamic acid; S (Ser) represents serine; P (Pro) represents proline; V (Val) represents valine; I (Ile) represents leucine; represents isoleucine; C (Cys) represents cysteine; Y (Tyr) represents tyrosine; H (His) represents histidine; R (Arg) represents arginine; N (Asn) represents asparagine; D (Asp) represents aspartic acid; T (Thr) represents threonine; B (Asx) represents aspartic acid or asparagine; J (Xle) represents leucine or isoleucine; O (Pyl) represents pyrrolysine; U (Sec) represents selenocystine; X (Xaa) represents any amino acid; Z (Glx) represents glutamine or glutamic acid.
[0180] Use of targeting peptides in AAV particles
[0181] The targeting peptide can be an independent peptide, or can be inserted into or linked to a parent sequence. In one embodiment, the targeting peptide is inserted into the capsid protein of the AAV particle.
[0182] One or more targeting peptides can be inserted into the parent AAV capsid sequence to produce the AAV particles of the disclosure.
[0183] The targeting peptide can be inserted into the parent AAV capsid sequence at any position that produces a fully functional AAV particle. The targeting peptide can be inserted into VP1, VP2 and / or VP3. The numbering of amino acid residues varies depending on the AAV serotype, so the exact amino acid position of the targeting peptide insertion may not be critical. As used herein, the amino acid positions of the parent AAV capsid sequence are described using AAV9 (SEQ ID NO: 2) as a reference.
[0184] In one embodiment, the targeting peptide is inserted into a hypervariable region of the AAV capsid sequence. Non-limiting examples of such hypervariable regions include loop IV and loop VIII of the parent AAV capsid. Without wishing to be bound by theory, these surface-exposed loops are unstructured and poorly conserved, making them ideal regions for insertion of targeting peptides.
[0185] In one embodiment, the targeting peptide is inserted into loop IV. In another embodiment, the targeting peptide is used to replace a portion or all of loop IV. As a non-limiting example, the addition of the targeting peptide to the parent AAV capsid sequence can result in the replacement or mutation of at least one amino acid of the parent AAV capsid.
[0186] In one embodiment, the targeting peptide is inserted into loop VIII. In another embodiment, the targeting peptide is used to replace a portion or all of loop VIII. As a non-limiting example, the addition of the targeting peptide to the parent AAV capsid sequence can result in the replacement or mutation of at least one amino acid of the parent AAV capsid.
[0187] In one embodiment, more than one targeting peptide is inserted into the parent AAV capsid sequence. As a non-limiting example, the targeting peptide can be inserted at loop IV and loop VIII in the same parent AAV capsid sequence.
[0188] The targeting peptide can be inserted into any amino acid position of the parent AAV capsid sequence, such as, but not limited to, 586-592, 588-589, 586-589, 452-458, 262-269, 464-473, 491-495, 546-557, and / or 659-668.
[0189] In a preferred embodiment, the targeting peptide is inserted into the parent AAV capsid sequence between amino acids at positions 588 and 589 (loop VIII). In one embodiment, the parent AAV capsid is AAV9 (SEQ ID NO: 2). In a second embodiment, the parent AAV capsid is K449R AAV9 (SEQ ID NO: 3).
[0190] The targeting peptides described herein can increase transduction of the AAV particles of the present disclosure to the target tissue compared to the parent AAV particles lacking the targeting peptide insert. In one embodiment, the targeting peptide increases transduction of the AAV particles to the target tissue by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more compared to the parent AAV particles lacking the targeting peptide insert.
[0191] In one embodiment, the targeting peptide increases transduction of the AAV particles into cells or tissues of the CNS by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more compared to a parent AAV particle lacking the targeting peptide insert.
[0192] In one embodiment, the targeting peptide increases transduction of AAV particles into cells or tissues of the PNS by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more compared to a parent AAV particle lacking the targeting peptide insert.
[0193] In one embodiment, the targeting peptide increases transduction of the AAV particles into cells or tissues of the DRG by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 300%, 400%, 500% or more compared to a parental AAV particle lacking the targeting peptide insert.
[0194] AAV production
[0195] The virus production disclosed herein describes processes and methods for producing AAV particles with enhanced, improved, and / or increased tropism for target tissues, which can be used to contact target cells to deliver a payload.
[0196] The present disclosure provides a method for producing AAV particles comprising a targeting peptide. In one embodiment, AAV particles are prepared by carrying out viral genome replication in viral replicating cells. Any method known in the art can be used to prepare AAV particles. In one embodiment, AAV particles are produced in mammalian cells (e.g., HEK293). In another embodiment, AAV particles are produced in insect cells (e.g., Sf9).
[0197] Methods for preparing AAV particles are well known in the art and are described in, for example, U.S. Patent Nos. 6,204,059, 5,756,283, 6,258,595, 6,261,551, 6,270,996, 6,281,010, 6,365,394, 6,475,769, 6,482,634, 6,485,966, 6,943,019, 6,953,690, 7,022,519, 7,238,526, and 7,271,010. 291498 and US7491508, US5064764, US6194191, US6566118, US8137948; or International Publication Nos. WO1996039530, WO1998010088, WO1999014354, WO1999015685, WO1999047691, WO2000055342, WO2000075353, and WO2001023597; Methods In Molecular Biology, ed. Richard, Humana Press, NJ (1995); O'Reilly et al., Baculovirus Expression Vectors, A Laboratory Manual, Oxford Univ. Press (1994); Samulski et al., J. Vir. 63:3822-8 (1989); Kajigaya et al., Proc. Nat'l. Acad. Sci. USA 88:4646-50 (1991); Ruffing et al., J. Vir. 66:6922-30 (1992); Kimbauer et al., Vir., 219:37-44 (1996); Zhao et al., Vir. 272:382-93 (2000), the contents of each of which are incorporated herein by reference in their entirety. In one embodiment, AAV particles are prepared using the methods described in International Patent Publication No. WO2015191508, the contents of which are incorporated herein by reference in their entirety.
[0198] Therapeutic applications
[0199] The present disclosure provides a method for treating a disease, disorder, and / or condition in a mammalian subject, including a human subject, comprising administering to the subject an AAV particle described herein, wherein the AAV particle comprises a novel capsid defined by the present disclosure ("TRACER AAV particle"); or administering to the subject any of the compositions described herein, including the pharmaceutical compositions described herein.
[0200] In one embodiment, TRACER AAV particles of the present disclosure are prophylactically administered to a subject to prevent the onset of disease. In another embodiment, TRACER AAV particles of the present disclosure are administered to treat a disease or symptom (mitigation of its impact). In yet another embodiment, TRACER AAV particles of the present disclosure are administered to cure (eliminate) a disease. In another embodiment, TRACER AAV particles of the present disclosure are administered to prevent or slow down the progress of a disease. In yet another embodiment, TRACER AAV particles of the present disclosure are used to reverse the deleterious effects of a disease. Disease state and / or progression can be determined or monitored by standard methods known in the art.
[0201] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate neurological diseases and / or disorders.
[0202] In some embodiments, the TRACER AAV particles of the present disclosure are used in medicine to treat, prevent, alleviate, or ameliorate tauopathy.
[0203] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate Alzheimer's disease.
[0204] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate Friedreich's ataxia or any disease caused by the loss or partial loss of Frataxin protein.
[0205] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate Parkinson's disease.
[0206] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate amyotrophic lateral sclerosis.
[0207] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate Huntington's disease.
[0208] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate chronic or neuropathic pain.
[0209] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate diseases related to the central nervous system.
[0210] In some embodiments, the TRACER AAV particles of the present disclosure are used in the medical field to treat, prevent, alleviate, or ameliorate diseases associated with the peripheral nervous system.
[0211] In one embodiment, a TRACER AAV particle of the present disclosure is administered to a subject suffering from at least one of the diseases or symptoms described herein.
[0212] As used herein, any disease associated with the central or peripheral nervous system and its components (eg, neurons) can be considered a "neurological disease."
[0213] Any neurological disease can be treated with the TRACER AAV particles of the present disclosure or pharmaceutical compositions thereof, including but not limited to Absence of the Septum Pellucidum, Acid Lipase Disease, Acid Maltase Deficiency, Acquired Epileptiform Aphasia, Acute Disseminated Encephalomyelitis, Attention Deficit-Hyperactivity Disorder (ADHD), Adie's Pupil, Adie's Syndrome, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Aicardi-Goutieres Syndrome, Disorder, AIDS-Neurological Complications, Alexander Disease, Alpers' Disease, Alternating Hemiplegia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Anencephaly, Aneurysm, Angelman Syndrome, Angiomatosis, Anoxia, Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Arnold-Chiari Malformation, Arteriovenous Malformation, Asperger Syndrome, Ataxia, Ataxia-telangiectasiaTelangiectasia, Ataxia and Cerebellar or Spinocerebellar Degeneration, Atrial Fibrillation and Stroke, Attention Deficit-Hyperactivity Disorder, Autism Spectrum Disorder, Autonomic Dysfunction, Back Pain, Barth Syndrome, Batten Disease, Becker's Myotonia, Bechet's Disease, Bell's Palsy, Benign Essential Blepharospasm, Benign Focal Amyotrophy, Benign Intracranial Hypertension, Bernhardt-Roth syndrome Syndrome, Binswanger's Disease, Blepharospasm, Bloch-Sulzberger Syndrome, Brachial Plexus Birth Injuries, Brachial Plexus Injuries, Bradbury-Eggleston Syndrome, Brain and Spinal Tumors, Brain Aneurysm, Brain Injury, Brown-Sequard Syndrome, Bulbarpalsy, Bulbospinal Muscular Atrophy, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukocytic EncephalopathyInfarcts and Leukoencephalopathy (CADASIL), Canavan Disease, Carpal Tunnel Syndrome, Causalgia, Cavernous Angioma, Cavernous Malformation, Central Cervical Cord Syndrome, Central Cord Syndrome, Central Pain Syndrome, Central Pontine Myelinolysis, Cephalic Disorders, Ceramidase Deficiency, Cerebellar Degeneration, Cerebellar Hypoplasia, Cerebral Aneurysms, Cerebral Arteriosclerosis, Cerebral Atrophy, Cerebral Beriberi, Cerebral Cavernous Malformation, Cerebral Gigantism, Cerebral Hypoxia, Cerebral Palsy, Cerebro-Oculo-Facio-Skeletal Syndrome (COFS), Charcot-Marie-Tooth Disease, Chiari Malformation, Cholesterol Ester Storage Disease, Chorea, Choreoacanthocytosis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Orthostatic Intolerance, Chronic Pain, Cockayne Syndrome Type IISyndrome Type II, Coffin-Lowry Syndrome, Colpocephaly, Coma, Complex Regional Pain Syndrome, Concentric sclerosis (Baló's sclerosis), Congenital Facial Diplegia, Congenital Myasthenia, Congenital Myopathy, Congenital Vascular Cavernous Malformations, Corticobasal Degeneration, Cranial Arteritis, Craniosynostosis, Cree encephalitis, Creutzfeldt-Jakob Disease, Chronic progressive external ophtalmoplegia, Cumulative Trauma Disorders, Cushing's Syndrome, Cytomegalic Inclusion Body Disease, Cytomegalovirus Infection, Dancing Eyes-Dancing Feet Syndrome, Dandy-Walker Syndrome, Dawson Disease, De Morsier's Syndrome, Dejerine-Klumpke Palsy, Dementia, Dementia-Multi-Infarct, Dementia-Semantic, Dementia-Subcortical, Dementia with Lewy Bodies, Demyelinationdiseases), Dentate Cerebellar Ataxia, Dentatorubral Atrophy, Dermatomyositis, Developmental Dyspraxia, Devic's Syndrome, Diabetic Neuropathy, Diffuse Sclerosis, Distal Hereditary Motor Neuropathies, Dravet Syndrome, Dysautonomia, Dysgraphia, Dyslexia, Dysphagia, Dyspraxia, Dyssynergia Cerebellaris Myoclonica, Dyssynergia Cerebellaris Progressiva), Dystonias, Early Infantile Epileptic Encephalopathy, Empty Sella Syndrome, Encephalitis, Encephalitis Lethargica, Encephaloceles, Encephalomyelitis, Encephalopathy, Encephalopathy (familial infantile), Encephalotrigeminal Angiomatosis, Epilepsy, Epileptic Hemiplegia, Episodic ataxia, Erb's Palsy, Erb-Duchenne and Dejerine-Klumpke Palsies, Essential Tremor Tremor, Extrapontine Myelinolysis, Faber's disease, Fabry diseaseDisease), Fahr's Syndrome, Fainting, Familial Dysautonomia, Familial Hemangioma, Familial Idiopathic Basal Ganglia Calcification, Familial Periodic Paralyses, Familial Spastic Paralysis, Farber's Disease, Febrile Seizures, Fibromuscular Dysplasia, Fisher Syndrome, Floppy Infant Syndrome, Foot Drop, Friedreich's Ataxia, Frontotemporal Dementia, Gaucher Disease, Generalized Gangliosidosis (GM1, GM2) Gangliosidoses (GM1, GM2), Gerstmann's Syndrome, Gerstmann-Straussler-Scheinker Disease; Giant Axonal Neuropathy; Giant Cell Arteritis; Giant Cell Inclusion Disease, Globoid Cell Leukodystrophy, Glossopharyngeal Neuralgia, Glycogen Storage Disease, Guillain-Barré Syndrome, Hallervorden-Spatz Disease, Head Injury, Headache, Hemicrania Continua, Hemifacial SpasmSpasm, Hemiplegia Alterans, Hereditary Neuropathies, Hereditary Spastic Paraplegia, Heredopathia Atactica Polyneuritiformis, Herpes Zoster, Herpes Zoster Oticus, Hirayama Syndrome, Holmes-Adie Syndrome, Holoprosencephaly, HTLV-1 Associated Myelopathy, Hughes Syndrome, Huntington's Disease, Hurler Syndrome, Hydrocephalus, Hydrocephalus-Normal Pressure, Hydromyelia, Hypercortisolism, Hypersomnia, Hypertonia, Hypotonia, Hypoxia, Immune-Mediated Encephalomyelitis, Inclusion Body Myositis, Incontinentia Pigmenti, Infantile Hypotonia, Infantile Neuroaxonal Dystrophy, Infantile Phytanic Acid Storage Disease, Infantile Refsum Disease, Infantile Spasms, Inflammatory Myopathies, Iniencephaly, Intestinal Lipodystrophy, Intracranial Cysts Cysts), intracranial hypertensionHypertension), Isaacs' Syndrome, Joubert Syndrome, Kearns-Sayre Syndrome, Kennedy's Disease, Kinsbourne syndrome, Kleine-Levin Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome, Korsakoff's Amnesic Syndrome, Krabbe Disease, Kugelberg-Welander Disease, Kuru, Lambert-Eaton Myasthenic Syndrome Syndrome, Landau-Kleffner Syndrome, Lateral Femoral Cutaneous Nerve Entrapment, Lateral Medullary Syndrome, Learning Disabilities, Leigh's Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-Critchley Syndrome, Lewy Body Dementia, Lichtheim's disease, Lipid Storage Diseases, Lipoid Proteinosis, Lissencephaly, Locked-In Syndrome, Lou Gehrig's diseaseDisease), Lupus-Neurological Sequelae, Lyme Disease-Neurological Complications, Lysosomal storage disorders, Machado-Joseph Disease, Macroencephaly, Megalencephaly, Melkersson-Rosenthal Syndrome, Meningitis, Meningitis and Encephalitis, Menkes Disease, Meralgia Paresthetica, Metachromatic Leukodystrophy, Microcephaly, Migraine, Miller Fisher Syndrome, Mini Stroke, Mitochondrial Myopathy, Mitochondrial DNA Deletion Syndrome Depletion syndrome, Moebius syndrome, Monomelic amyotrophy, Morvan syndrome, Motor Neuron diseases, Moyamoya disease, Mucolipidoses, Mucopolysaccharidoses, Multi-infarct dementia, Multifocal motor neuropathy, Multiple sclerosis, Multiple system atrophy, Multiple system atrophy with orthostatic hypotension, Muscular dystrophyDystrophy), Myasthenia-Congenital, Myasthenia Gravis, Myelinoclastic Diffuse Sclerosis, Myelitis, Myoclonic Encephalopathy of Infants, Myoclonus, Myoclonus epilepsy, Myopathy, Myopathy-Congenital, Myopathy-Thyrotoxic, Myotonia, Myotonia Congenita, Narcolepsy, NARP (Neuropathy, Ataxia and Retinitis Pigmentosa), Neuroacanthocytosis, Neurodegeneration with Brain Iron Accumulation, Neurodegenerative Diseases disease), Neurofibromatosis, Neuroleptic Malignant Syndrome, Neurological Complications of AIDS, Neurological Complications of Lyme Disease, Neurological Consequences of Cytomegalovirus Infection, Neurological Manifestations of Pompe Disease, Neurological Sequelae of Lupus, Neuromyelitis Optica, Neuromyotonia, Neuronal Ceroid Lipofuscinosis, Neuronal Migration DisordersDisorders, Neuropathic Pain, Neuropathy-Hereditary, Neuropathy, Neurosarcoidosis, Neurosyphilis, Neurotoxicity, Nevus Cavernosus, Niemann-Pick Disease, O'Sullivan-McLeod Syndrome, Occipital Neuralgia, Ohtahara Syndrome, Olivopontocerebellar Atrophy, Opsoclone Myoclonus, Orthostatic Hypotension, Overuse Syndrome, Pain-Chronic, Pantothenate Kinase-Associated Neurodegenerative Diseases Neurodegeneration), Paraneoplastic Syndromes, Paresthesia, Parkinson's Disease, Paroxysmal Choreoathetosis, Paroxysmal Hemicrania, Parry-Romberg Disease, Pelizaeus-Merzbacher Disease, Pena Shokeir II Syndrome, Perineural Cysts, Peroneal Muscular Atrophy, Periodic Paralyses, Peripheral Neuropathy, Periventricular Leukomalacia, Persistent Vegetative State, Pervasive Developmental Disorders, Phytanic Storage DiseaseAcid Storage Disease, Pick's Disease, Pinched Nerve, Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease, Porencephaly, Post-Polio Syndrome, Postherpetic Neuralgia, Postinfectious Encephalomyelitis, Postural Hypotension, Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Primary Dentatum Atrophy, Primary Lateral Sclerosis, Primary Progressive Aphasia Aphasia), Prion Diseases, Progressive bulbar palsy, Progressive hemifacial atrophy, Progressive locomotor ataxia, Progressive multifocal leukoencephalopathy, Progressive muscular atrophy, Progressive sclerosing poliodystrophy, Progressive supranuclear palsy, Prosopagnosia, Pseudobulbar palsy, Pseudo-Torch syndrome, Pseudotoxoplasmosis syndrome, Pseudotumor cerebri, PsychogenicMovement, Ramsay Hunt Syndrome I, Ramsay Hunt Syndrome II, Rasmussen's Encephalitis, Reflex Sympathetic Dystrophy Syndrome, Refsum Disease, Refsum Disease-Infantile, Repetitive Motion Disorders, Repetitive Stress Injuries, Restless Legs Syndrome, Retrovirus-Associated Myelopathy, Rett Syndrome, Reye's Syndrome, Rheumatic Encephalitis, Riley-Day Syndrome, Sacral Nerve Root Cysts Cysts, Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder's Disease, Schizencephaly, Seitelberger Disease, Seizure Disorder, Semantic Dementia, Septo-Optic Dysplasia, Severe Myoclonic Epilepsy of Infancy (SMEI), Shaken Baby Syndrome, Shingles, Shy-Drager Syndrome, Sjogren's Syndrome Syndrome, Sleep Apnea, Sleeping Sickness, Sotos Syndrome, Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury, Spinal Cord Tumors, Spinal Muscular Atrophy, Spinocerebellar Ataxia, Spinocerebellar Atrophy, Spinocerebellar Degeneration, Sporadic ataxia, Steele-Richardson-Olszewski Syndrome, Stiff-Person Syndrome, Striatonigral Degeneration, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, short-lasting unilateral neuralgiform (SUNCT) headache, swallowing disorders, Sydenham chorea, syncope, syphilitic spinal sclerosis, syringohydromyelia, syringomyelia, systemic lupus erythematosus, tabes dorsalis, tardive dyskinesia, Tarlov cyst Cysts), Tay-Sachs disease, temporal arteritisArteritis, Tethered Spinal Cord Syndrome, Thomsen's Myotonia, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, TicDouloureux, Todd's Paralysis, Tourette Syndrome, Transient Ischemic Attack, Transmissible Spongiform Encephalopathies, Transverse Myelitis, Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical Spastic Paraparesis, Troyer Syndrome, Tuberous Sclerosis, Vascular Erectile Tumors Tumor, Vasculitis Syndromes of the Central and Peripheral Nervous Systems, Vitamin B12 deficiency, Von Economo's Disease, Von Hippel-Lindau Disease (VHL), Von Recklinghausen's Disease, Wallenberg's Syndrome, Werdnig-Hoffman Disease, Wernicke-Korsakoff Syndrome, West Syndrome, Whiplash, Whipple's Disease, Williams SyndromeSyndrome), Wilson Disease, Wolman's Disease, and X-Linked Spinal and Bulbar Muscular Atrophy.
[0214] Treatments for neurological disorders
[0215] TRACER AAV particles encoding protein payloads
[0216] The present disclosure provides methods for introducing the TRACER AAV particles of the present disclosure into cells, the methods comprising introducing into the cells any vector in an amount sufficient to increase target mRNA and protein production. In some aspects, the cells can be neurons, such as, but not limited to, motor, hippocampal, entorhinal, thalamic, cortical, sensory, sympathetic, or parasympathetic neurons, and glial cells, such as astrocytes, microglia, and / or oligodendrocytes.
[0217] The present disclosure discloses a method for treating a neurological disease related to the function / existence of a target protein (e.g., ApoE, FXN) in a subject in need of treatment. The method optionally includes administering a therapeutically effective amount of a composition comprising the TRACER AAV particles of the present disclosure to the subject. As a non-limiting example, the TRACER AAV particles can increase the expression of the target gene, increase the generation of the target protein, and therefore reduce one or more symptoms of a neurological disease in the subject, thereby treating the subject.
[0218] In one embodiment, a composition comprising a TRACER AAV particle of the present disclosure is administered to the central nervous system of a subject by systemic administration. In one embodiment, the systemic administration is intravenous injection.
[0219] In some embodiments, a composition comprising a TRACER AAV particle of the present disclosure is administered to the central nervous system of a subject. In other embodiments, a composition comprising a TRACER AAV particle of the present disclosure is administered to a CNS tissue of a subject (e.g., the putamen, thalamus, or cortex of a subject).
[0220] In one embodiment, a composition comprising a TRACER AAV particle of the present disclosure is administered to the central nervous system of a subject by intraparenchymal injection. Non-limiting examples of intraparenchymal injection include intraputamen, intracortical, intrathalamic, intrastriatal, intrahippocampal, or entorhinal cortex.
[0221] In one embodiment, a composition comprising a TRACER AAV particle of the present disclosure is administered to the central nervous system of a subject by intraparenchymal and intravenous injection.
[0222] In one embodiment, the TRACER AAV particles of the present disclosure can be delivered to specific types of target cells, including but not limited to thalamic, hippocampal, entorhinal, cortical, motor, sensory, excitatory, inhibitory, sympathetic, or parasympathetic neurons; glial cells, including oligodendrocytes, astrocytes, and microglia; and / or other cells surrounding neurons, such as T cells.
[0223] In one embodiment, the TRACER AAV particles of the present disclosure can be delivered to neurons in the nucleocapsid, thalamus, and / or cortex.
[0224] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for neurological diseases.
[0225] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for tauopathies.
[0226] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for Alzheimer's disease.
[0227] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for amyotrophic lateral sclerosis.
[0228] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for Huntington's disease.
[0229] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for Parkinson's disease.
[0230] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for Friedreich's ataxia.
[0231] In some embodiments, the TRACER AAV particles of the present disclosure can be used as a therapy for chronic or neuropathic pain.
[0232] In one embodiment, administration of the TRACER AAV particles described herein to a subject can increase the level of a target protein in the subject. In a subject (e.g., but not limited to, the CNS, a CNS region, or a specific cell of the CNS of a subject), the level of the target protein can be increased by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 In some embodiments, the TRACER AAV particles can increase the protein level of a target protein by at least 50%. As a non-limiting example, the TRACER AAV particle can increase the protein level of the target protein by at least 40%. As a non-limiting example, a subject can have a 10% increase in the target protein. As a non-limiting example, the TRACER AAV particle can increase the protein level of the target protein by several times over baseline. In one embodiment, the TRACER AAV particle causes the target protein level to increase by 5-6 times.
[0233] In one embodiment, administration of the TRACER AAV particles described herein to a subject can increase the expression of a target protein in the subject. In a subject (e.g., but not limited to, the CNS, a CNS region, or a specific cell of the CNS of a subject), the expression of the target protein can be increased by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 100%, 80-90%, 80-95%, 80-100%, 90-95%, 90-100%, or 95-100%. As a non-limiting example, the TRACER AAV particles can increase expression of a target protein by at least 50%. As a non-limiting example, the TRACER AAV particle can increase expression of a target protein by at least 40%.
[0234] In one embodiment, intravenous administration of the TRACER AAV particles described herein to a subject can increase CNS expression of a target protein in a subject. In a subject (e.g., but not limited to the CNS, a CNS region, or a specific cell of the CNS of a subject), expression of the target protein can be increased by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 100%, 80-90%, 80-95%, 80-100%, 90-95%, 90-100%, or 95-100%. As a non-limiting example, the TRACER AAV particles can increase expression of a target protein in the CNS by at least 50%. As a non-limiting example, the TRACER AAV particles can increase expression of a target protein in the CNS by at least 40%.
[0235] In some embodiments, the TRACER AAV particles of the present disclosure can be used to increase target protein expression in astrocytes to treat neurological diseases. The target protein in astrocytes can be increased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10- 45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20 -70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 3 5-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%,50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0236] In some embodiments, TRACER AAV particles can be used to increase target protein in microglia. The increase in target protein in microglia can independently increase by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, or more than 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-50%, or more. -45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-7 0%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60 %, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%,55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0237] In some embodiments, TRACER AAV particles can be used to increase target protein in cortical neurons. The increase in target protein in cortical neurons can independently increase by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10- -45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-7 0%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60 %, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%,55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0238] In some embodiments, TRACER AAV particles can be used to increase target protein in hippocampal neurons. The increase in target protein in hippocampal neurons can independently increase by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10- -45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-7 0%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60 %, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%,55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0239] In some embodiments, TRACER AAV particles can be used to increase target protein in DRG and / or sympathetic neurons. The increase in target protein in DRGs and / or sympathetic neurons can independently be increased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10- 40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-6 5%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55 %, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%,50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0240] In some embodiments, the TRACER AAV particles of the present disclosure can be used to increase target proteins in sensory neurons to treat neurological diseases. The target protein in sensory neurons can be increased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-4 5%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20- 70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 3 5-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%,50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0241] In some embodiments, the TRACER AAV particles of the present disclosure can be used to increase the target protein and alleviate the symptoms of a neurological disease in a subject. The increase in target protein and / or the alleviation of neurological disease symptoms can independently change (increase the production of target protein and reduce the symptoms of neurological disease) by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-2 0%, 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20- 45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 3 0-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%,50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0242] In one embodiment, the TRACER AAV particles of the present disclosure can be used to reduce the decline in functional ability and activities of daily living as measured by standard assessment systems, such as, but not limited to, the Total Functional Capacity (TFC) scale.
[0243] In one embodiment, the TRACER AAV particles of the present disclosure can be used to improve the performance of any assessment used to measure symptoms of a neurological disease. Such assessments include, but are not limited to, ADAS-cog (Alzheimer's Disease Assessment Scale - Cognition), MSE (Mini-Mental State Examination), GDS (Geriatric Depression Scale), FAQ (Functional Activities Questionnaire), ADL (Activities of Daily Living), GPCOG (General Practitioner Assessment of Cognition), Mini-Cog, AMTS (Abbreviated Mental Test Score), Clock-drawing test, 6-CIT (6-item Cognitive Impairment Test), TYM (Test Your Memory), MoCa (Montreal Cognitive Assessment), ACE-R (Addenbrookes Cognitive Assessment), MIS (Memory Impairment Screen), BADLS (Bristol Activities of Daily Living) Scale, Bristol Activities of Daily Living Scale), Barthel Index, Functional Independence Measure, Instrumental Activities of Daily Living, IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly,Questionnaire on Cognitive Decline in the Elderly), Neuropsychiatric Inventory, The Cohen-Mansfield Agitation Inventory, BEHAVE-AD, EuroQol, Short Form-36, and / or MBR Caregiver Strain Instrument, or any other test described in Sheehan B (Ther Adv Neurol Disord. 5(6):349-358 (2012)), the contents of which are incorporated herein by reference in their entirety.
[0244] In some embodiments, the compositions of the present disclosure are administered as sole therapy or in combination therapy for the treatment of neurological diseases.
[0245] TRACER AAV particles encoding a target protein can be used in combination with one or more other therapeutic agents. "In combination with" does not mean that the agents must be administered simultaneously and / or formulated for delivery together, although such delivery methods fall within the scope of this disclosure. The composition can be administered concurrently with, before, or after one or more other desired therapeutic agents or medical procedures. Typically, the agents will be administered at a dose and / or on a schedule determined for each agent.
[0246] Therapeutic agents that can be used in combination with the TRACER AAV particles of the present disclosure can be small molecule compounds that are antioxidants, anti-inflammatory agents, anti-apoptotic agents, calcium regulators, anti-glutamatergic agents, structural protein inhibitors, compounds involved in muscle function, and compounds involved in metal ion regulation. As non-limiting examples, combination therapy can be combined with one or more neuroprotectants (e.g., small molecule compounds, growth factors, and hormones) that have been tested for their neuroprotective effects on motor neuron degeneration.
[0247] Compounds tested for treating neurological disorders that can be used in combination with the TRACER AAV particles described herein include, but are not limited to, cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (such as memantine), antipsychotics, antidepressants, anticonvulsants (such as sodium valproate and levetiracetam for myoclonus), secretase inhibitors, amyloid aggregation inhibitors, copper or zinc modulators, BACE inhibitors, tau aggregation inhibitors (such as methylene blue, phenothiazines, anthraquinones, n-aniline or rhodamine), microtubule stabilizers (e.g., NAP, taxol, or paclitaxel), kinase or phosphatase inhibitors (e.g., inhibitors targeting GSK3β (lithium) or PP2A), Aβ peptide or tau phospho-epitope immunization, anti-tau or anti-amyloid antibodies, dopamine-depleting agents (e.g., tetrabenazine for chorea), benzodiazepines (e.g., clonazepam for myoclonus, chorea, dystonia, spasticity, and / or spasticity), amino acid precursors of dopamine (e.g., dapoxetine for spasticity), Levodopa), skeletal muscle relaxants (e.g., baclofen, tizanidine for spasticity and / or spasticity), inhibitors of acetylcholine release at the neuromuscular junction to cause muscle paralysis (e.g., botulinum toxin for bruxism and / or dystonia), atypical neuroleptics (e.g., olanzapine and quetiapine for psychosis and / or dysphoria; risperidone, sulpiride, and haloperidol for psychosis, chorea, and / or dysphoria; clozapine for resistant psychosis; and phenobarbital for dysphoric syndromes associated with aripiprazole for psychosis with prominent negative symptoms), selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, fluoxetine, paroxetine, sertraline, mirtazapine, venlafaxine for depression, anxiety, compulsive behavior, and / or irritability), hypnotics (e.g., zopiclone and / or zolpidem to alter the sleep-wake cycle), anticonvulsants (e.g., sodium valproate and carbamazepine for mania or hypomania), and mood stabilizers (e.g., lithium for mania or hypomania).
[0248] Neurotrophic factors can be used in combination therapy with the TRACER AAV particles of the present disclosure to treat neurological diseases. Generally, neurotrophic factors are defined as substances that promote the survival, growth, differentiation, proliferation, and / or maturation of neurons or stimulate increased neuronal activity. In some embodiments, the method further comprises delivering one or more trophic factors to a subject in need of treatment. Trophic factors can include, but are not limited to, IGF-I, GDNF, BDNF, CTNF, VEGF, Colivelin, Zaliroden, thyrotropin-releasing hormone, and ADNF and variants thereof.
[0249] In one aspect, the TRACER AAV particles described herein can be co-administered with TRACER AAV particles expressing neurotrophic factors, such as AAV-IGF-I (see, e.g., Vincent et al., Neuromolecular medicine, 2004, 6, 79-85; the contents of which are incorporated herein by reference in their entirety) and AAV-GDNF (see, e.g., Wang et al., J Neurosci., 2002, 22, 6920-6928; the contents of which are incorporated herein by reference in their entirety)).
[0250] In one embodiment, administration of the TRACER AAV particle to a subject will increase expression of the target protein in the subject, and the increase in target protein expression will reduce the effects and / or symptoms of a neurological disease in the subject.
[0251] As a non-limiting example, the target protein may be an antibody or a fragment thereof.
[0252] TRACER AAV particles containing RNAi agents or regulatory polynucleotides
[0253] The present disclosure provides a method of introducing a TRACER AAV particle of the present disclosure comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules into a cell, the method comprising introducing any vector into the cell in an amount sufficient to cause target mRNA degradation, thereby activating target-specific RNAi in the cell. In some aspects, the cell can be a neuron, such as, but not limited to, a motor, hippocampal, entorhinal, thalamic, cortical, sensory, sympathetic, or parasympathetic neuron, and a glial cell, such as an astrocyte, microglia, and / or oligodendrocyte.
[0254] The present disclosure discloses a method for treating a neurological disease associated with a dysfunction of a target protein in a subject in need of treatment. The method optionally includes administering to the subject a therapeutically effective amount of a composition comprising TRACER AAV particles of the present disclosure, wherein the TRACER AAV particles comprise a viral genome having a nucleic acid sequence encoding one or more siRNA molecules. As non-limiting examples, siRNA molecules can silence the expression of a target gene, inhibit the production of a target protein, and reduce one or more symptoms of a neurological disease in a subject, thereby treating the subject.
[0255] In some embodiments, compositions comprising TRACER AAV particles of the present disclosure comprising a viral genome encoding one or more siRNA molecules comprise an AAV capsid that allows for enhanced transduction of CNS and / or PNS cells following intravenous administration.
[0256] In some embodiments, a composition comprising TRACER AAV particles of the present disclosure having a viral genome encoding at least one siRNA molecule is administered to a subject's central nervous system. In other embodiments, a composition comprising TRACER AAV particles of the present disclosure is administered to a subject's tissue (e.g., the subject's putamen, thalamus, or cortex).
[0257] In one embodiment, a composition comprising a TRACER AAV particle of the present disclosure comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules is administered to the central nervous system of a subject by systemic administration. In one embodiment, systemic administration is intravenous injection.
[0258] In one embodiment, a composition comprising TRACER AAV particles of the present disclosure comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules is administered to the central nervous system of a subject by intraparenchymal injection. Non-limiting examples of intraparenchymal injection include intraputamen, intracortex, intrathalamus, intrastriatum, hippocampus, or entorhinal cortex.
[0259] In one embodiment, a composition comprising TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules is administered to the central nervous system of a subject by intraparenchymal injection or intravenous injection.
[0260] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be delivered to specific types of target cells, including but not limited to thalamic, hippocampal, entorhinal, cortical, motor, sensory, excitatory, inhibitory, sympathetic, or parasympathetic neurons; glial cells, including oligodendrocytes, astrocytes, and microglia; and / or other cells surrounding neurons, such as T cells.
[0261] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be delivered to neurons in the nucleocapsid, thalamus, and / or cortex.
[0262] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for neurological diseases.
[0263] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for tauopathy.
[0264] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for Alzheimer's disease.
[0265] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for amyotrophic lateral sclerosis.
[0266] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for Huntington's disease.
[0267] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for Parkinson's disease.
[0268] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used as a therapy for Friedreich's ataxia.
[0269] In one embodiment, administering to a subject a TRACER AAV particle comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can reduce the level of a target protein in the subject. The level of the target protein can be reduced by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or by at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 In some embodiments, the TRACER AAV particles can reduce the protein level of a target protein by at least 50%. As a non-limiting example, the TRACER AAV particle can reduce protein levels of a target protein by at least 40%.
[0270] In one embodiment, administration of a TRACER AAV particle comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules to a subject can reduce the expression of a target protein in the subject. In a subject (e.g., but not limited to, the CNS, a CNS region, or a specific cell of the CNS of a subject), the expression of the target protein can be reduced by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or by at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 100%, 80-90%, 80-95%, 80-100%, 90-95%, 90-100%, or 95-100%. As a non-limiting example, the TRACER AAV particles can reduce the expression of a target protein by at least 50%. As a non-limiting example, the TRACER AAV particle can reduce expression of a target protein by at least 40%.
[0271] In one embodiment, administration of a TRACER AAV particle comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules to a subject can reduce the expression of a target protein in the CNS of the subject. In a subject (e.g., but not limited to, the CNS, a CNS region, or a specific cell of the CNS of a subject), the expression of the target protein can be reduced by about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and 100%, or at least 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 20-80%, 20-90%, 20-95%, 20-100%, 30-40%, 30-50%, 30-60%, 30-70%, 30-80%, 30-90%, 30-95%, 30-1 100%, 80-90%, 80-95%, 80-100%, 90-95%, 90-100%, or 95-100%. As a non-limiting example, the TRACER AAV particles can reduce the expression of a target protein by at least 50%. As a non-limiting example, the TRACER AAV particle can reduce expression of a target protein by at least 40%.
[0272] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in astrocytes to treat neurological diseases. The target protein in astrocytes can be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10- 40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20 -60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 3 5-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%,or 90-95%. The target protein in astrocytes can be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15- 75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75 %, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%,40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55- 65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0273] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in microglia. Inhibition of a target protein in microglia can independently inhibit 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, or more than 10-20%. -40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-6 0%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45 %, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%,or 90-95%. The reduction can be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20% , 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-8 5%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25 -90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%,40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0274] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in cortical neurons. Inhibition of the target protein in cortical neurons can be independently inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 1 0-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20- 60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45 %, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%,or 90-95%. The reduction can be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20% , 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-8 5%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25 -90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%,40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0275] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in hippocampal neurons. Inhibition of the target protein in hippocampal neurons can independently inhibit 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10- -40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-6 0%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45 %, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%,or 90-95%. The reduction can be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20% , 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-8 5%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25 -90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%,40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0276] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in DRG and / or sympathetic neurons. Inhibition of the target protein in DRGs and / or sympathetic neurons can independently be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%,or 90-95%. The reduction can be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10 -20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-8 0%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80 %, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%,40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0277] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein in sensory neurons to treat neurological diseases. The target protein in sensory neurons may be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10-30%, 10-35%, 10- 40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20 -60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 3 5-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%,or 90-95%. The target protein in sensory neurons may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5- 95%, 10-20%, 10-25%, 10-30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20-50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25- 80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 30-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%,40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%, 50-65%, 50-70%, 50-75%, 50-80%, 50-85%, 50-90%, 50-95%, 55-65%, 55-70%, 55-75%, 55-80%, 55-85%, 55-90%, 55-95%, 60-70%, 60-75%, 60-80%, 60-85%, 60-90%, 60-95%, 65-75%, 65-80%, 65-85%, 65-90%, 65-95%, 70-80%, 70-85%, 70-90%, 70-95%, 75-85%, 75-90%, 75-95%, 80-90%, 80-95% or 90-95%.
[0278] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to inhibit a target protein and alleviate symptoms of a neurological disease in a subject. Inhibition of the target protein and / or alleviation of symptoms of a neurological disorder may independently reduce or inhibit 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more than 95%, 5-15%, 5-20%, 5-25%, 5-30%, 5-35%, 5-40%, 5-45%, 5-50%, 5-55%, 5-60%, 5-65%, 5-70%, 5-75%, 5-80%, 5-85%, 5-90%, 5-95%, 10-20%, 10-25%, 10- 30%, 10-35%, 10-40%, 10-45%, 10-50%, 10-55%, 10-60%, 10-65%, 10-70%, 10-75%, 10-80%, 10-85%, 10-90%, 10-95%, 15-25%, 15-30%, 15-35%, 15-40%, 15-45%, 15-50%, 15-55%, 15-60%, 15-65%, 15-70%, 15-75%, 15-80%, 15-85%, 15-90%, 15-95%, 20-30%, 20-35%, 20-40%, 20-45%, 20 -50%, 20-55%, 20-60%, 20-65%, 20-70%, 20-75%, 20-80%, 20-85%, 20-90%, 20-95%, 25-35%, 25-40%, 25-45%, 25-50%, 25-55%, 25-60%, 25-65%, 25-70%, 25-75%, 25-80%, 25-85%, 25-90%, 25-95%, 30-40%, 30-45%, 30-50%, 30-55%, 30-60%, 30-65%, 30-70%, 30-75%, 30-80%, 30-85%, 3 0-90%, 30-95%, 35-45%, 35-50%, 35-55%, 35-60%, 35-65%, 35-70%, 35-75%, 35-80%, 35-85%, 35-90%, 35-95%, 40-50%, 40-55%, 40-60%, 40-65%, 40-70%, 40-75%, 40-80%, 40-85%, 40-90%, 40-95%, 45-55%, 45-60%, 45-65%, 45-70%, 45-75%, 45-80%, 45-85%, 45-90%, 45-95%, 50-60%,or 90-95%. 、
[0279] In one embodiment, TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used to reduce the decline in functional ability and activities of daily living as measured by standard assessment systems, such as, but not limited to, the Total Functional Capacity (TFC) scale.
[0280] In some embodiments, the compositions of the present disclosure are administered as sole therapy or in combination therapy for the treatment of neurological diseases.
[0281] The TRACER AAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be used in combination with one or more other therapeutic agents. "In combination with" does not mean that the agents must be administered simultaneously and / or formulated for delivery together, although such delivery methods fall within the scope of this disclosure. The composition can be administered simultaneously with, before, or after one or more other desired therapeutic agents or medical procedures. Typically, the agent will be administered at a dose determined for each agent and / or on a schedule.
[0282] Therapeutic agents that can be used in combination with TRACERAAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules can be small molecule compounds that are antioxidants, anti-inflammatory agents, anti-apoptotic agents, calcium regulators, anti-glutamatergic agents, structural protein inhibitors, compounds involved in muscle function, and compounds involved in metal ion regulation.
[0283] Compounds tested for treating neurological diseases that can be used in combination with TRACERAAV particles comprising a viral genome having a nucleic acid sequence encoding one or more siRNA molecules include, but are not limited to, cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (such as memantine), antipsychotics, antidepressants, anticonvulsants (such as sodium valproate and levetiracetam for myoclonus), secretase inhibitors, amyloid aggregation inhibitors, copper or zinc modulators, BACE inhibitors antidepressants, tau aggregation inhibitors (e.g., methylene blue, phenothiazines, anthraquinones, n-aniline, or rhodamine), microtubule stabilizers (e.g., NAP, taxol, or paclitaxel), kinase or phosphatase inhibitors (e.g., inhibitors targeting GSK3β (lithium) or PP2A), Aβ peptide or tau phospho-epitope immunization, anti-tau or anti-amyloid antibodies, dopamine-depleting agents (e.g., tetrabenazine for chorea), benzodiazepines (e.g., clonazepam for myoclonus, chorea, dystonia, rigidity, and / or spasticity) , amino acid precursors of dopamine (e.g., levodopa for spasticity), skeletal muscle relaxants (e.g., baclofen, tizanidine for spasticity and / or spasticity), inhibitors of acetylcholine release at the neuromuscular junction to cause muscle paralysis (e.g., botulinum toxin for bruxism and / or dystonia), atypical neuroleptics (e.g., olanzapine and quetiapine for psychosis and / or dysphoria; risperidone, sulpiride, and haloperidol for psychosis, chorea, and / or dysphoria; dapoxetine for resistant psychotic disorders), clozapine for psychosis; aripiprazole for psychosis with prominent negative symptoms), selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, fluoxetine, paroxetine, sertraline, mirtazapine, venlafaxine for depression, anxiety, compulsive behavior, and / or irritability), hypnotics (e.g., zopiclone and / or zolpidem to alter the sleep-wake cycle), anticonvulsants (e.g., sodium valproate and carbamazepine for mania or hypomania), and mood stabilizers (e.g., lithium for mania or hypomania).
[0284] Neurotrophic factors can be used in combination therapy with TRACER AAV particles containing a viral genome containing a nucleic acid sequence encoding one or more siRNA molecules for the treatment of neurological diseases. Generally, neurotrophic factors are defined as substances that promote the survival, growth, differentiation, proliferation and / or maturation of neurons or stimulate an increase in neuronal activity. In some embodiments, the method further comprises delivering one or more trophic factors to a subject in need of treatment. Trophic factors may include, but are not limited to, IGF-I, GDNF, BDNF, CTNF, VEGF, Colivelin, Zaliroden, thyrotropin-releasing hormone, and ADNF and variants thereof.
[0285] In one aspect, TRACER AAV particles encoding a nucleic acid sequence of at least one siRNA duplex targeting a gene of interest can be co-administered with TRACER AAV particles expressing a neurotrophic factor, such as AAV-IGF-I (see, e.g., Vincent et al., Neuromolecular medicine, 2004, 6, 79-85; the contents of which are incorporated herein by reference in their entirety) and AAV-GDNF (see, e.g., Wang et al., J Neurosci., 2002, 22, 6920-6928; the contents of which are incorporated herein by reference in their entirety)).
[0286] In one embodiment, administration of the TRACER AAV particle to a subject will reduce expression of the target protein in the subject, and the reduction in target protein expression will reduce the effects and / or symptoms of a neurological disease in the subject.
[0287] definition
[0288] Adeno-associated virus: As used herein, the term "adeno-associated virus" or "AAV" refers to a member of the genus Dependentovirus, including any particle, sequence, gene, protein, or component derived therefrom.
[0289] AAV particle: As used herein, an "AAV particle" is a virus comprising a capsid and a viral genome having at least one payload region and at least one ITR. As described herein, an "AAV particle of the present disclosure" is a virus comprising a parent capsid sequence having at least one targeting peptide insert. The AAV particles of the present disclosure can be recombinantly produced and can be based on a parent or reference sequence of an adeno-associated virus (AAV). AAV particles can be derived from any serotype described herein or known in the art, including combinations of serotypes (i.e., "pseudotyped" AAV) or multiple genomes (e.g., single-stranded or self-complementary). In addition, AAV particles may be replication-defective and / or targeted. In one embodiment, the AAV particles may have a targeting peptide inserted into the capsid to enhance tropism for a desired target tissue. It should be understood that reference to the AAV particles of the present disclosure also includes pharmaceutical compositions thereof, even if not explicitly stated.
[0290] Administer: As used herein, the term "administer" refers to providing an agent or composition to a subject.
[0291] Amelioration: As used herein, the term "amelioration" or "ameliorating" refers to a lessening of the severity of at least one condition or disease indicator. For example, in the context of neurodegenerative diseases, amelioration includes a reduction in neuronal loss.
[0292] Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to a human being at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In some embodiments, the non-human animal is a mammal (e.g., a rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, cow, primate, or pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and worms. In some embodiments, the animal is a transgenic animal, a genetically engineered animal, or a clone.
[0293] Antisense strand: As used herein, the term "antisense strand" or "first strand" or "guide strand" of an siRNA molecule refers to a strand that is substantially complementary to a segment of about 10-50 nucleotides (e.g., about 15-30, 16-25, 18-23, or 19-22 nucleotides) of an mRNA targeted for silencing a gene. The antisense strand or first strand has a sequence that is sufficiently complementary to the desired target mRNA sequence to guide target-specific silencing, e.g., complementarity sufficient to trigger the RNAi mechanism or process to destroy the desired target mRNA.
[0294] Approximately: As used herein, as applied to one or more values, the term "approximately" or "about" refers to a value that is similar to the reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the reference value in either direction (greater or less), unless otherwise specified or obvious from the context (unless the number exceeds 100% of the possible values).
[0295] Capsid: As used herein, the term "capsid" refers to the protein shell of a viral particle.
[0296] Complementary and substantially complementary: The term "complementary" as used herein refers to the ability of polynucleotides to form base pairs with each other. Base pairs are generally formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide chains. Complementary polynucleotide chains can form base pairs in a Watson-Crick manner (e.g., A to T, A to U, C to G) or in any other manner that allows the formation of a duplex. Those skilled in the art will appreciate that, when RNA is used instead of DNA, uracil (instead of thymine) is considered to be a base complementary to adenine. However, when U is mentioned in the context of this disclosure, the ability to replace T is implied, unless otherwise stated. Perfect complementarity or 100% complementarity represents a situation in which each nucleotide unit of one polynucleotide chain can form hydrogen bonds with a nucleotide unit of a second polynucleotide chain. Less than perfect complementarity represents a situation in which some (but not all) nucleotide units of the two chains can form hydrogen bonds with each other. For example, for two 20-mers, if only two base pairs on each chain can form hydrogen bonds with each other, then the polynucleotide chains exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can form hydrogen bonds with each other, then the polynucleotide strands exhibit 90% complementarity. As used herein, the term "substantially complementary" means that the siRNA has a sequence (e.g., in the antisense strand) sufficient to bind to a desired target mRNA and trigger RNA silencing of the target mRNA.
[0297] Control elements: As used herein, "control elements," "regulatory elements," or "regulatory sequences" refer to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, replication origins, internal ribosome entry sites ("IRES"), enhancers, and the like, which provide for the replication, transcription, and translation of a coding sequence in a recipient cell. Not all of these control elements are always required, as long as the selected coding sequence is capable of replication, transcription, and / or translation in an appropriate host cell.
[0298] Delivery: As used herein, "delivery" refers to the act or manner of delivering an AAV particle, compound, substance, entity, moiety, cargo, or payload.
[0299] Element: As used herein, the term "element" refers to a distinct portion of an entity. In some embodiments, an element may be a polynucleotide sequence with a specific purpose that is incorporated into a longer polynucleotide sequence.
[0300] Encapsulate: As used herein, the term "encapsulate" means to enclose, surround, or enclose. For example, capsid proteins typically encapsulate the viral genome.
[0301] Engineered: As used herein, an embodiment of the present disclosure is "engineered" when it is designed to have features or properties that differ from the starting point, wild-type, or original molecule.
[0302] Effective amount: As used herein, the term "effective amount" of an agent is an amount sufficient to achieve a beneficial or desired result, e.g., a clinical result, and thus, an "effective amount" depends on the context in which it is used. For example, in the context of administering an agent to treat cancer, an effective amount of the agent is, for example, an amount sufficient to achieve treatment as defined herein, as compared to the response obtained without the agent.
[0303] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, 5' cap formation, and / or 3' end processing); (3) translation of the RNA into a polypeptide or protein; and (4) post-translational modification of the polypeptide or protein.
[0304] Characteristic: As used herein, a "characteristic" refers to a characteristic, property, or unique element.
[0305] Formulation: As used herein, a "formulation" comprises at least one AAV particle (active ingredient) and excipients and / or inactive ingredients.
[0306] Fragment: As used herein, "fragment" refers to a portion. For example, an antibody fragment may include a CDR or a heavy chain variable region or a scFv, etc.
[0307] Functional: As used herein, a "functional" biomolecule is a biomolecule that is in a form that exhibits the properties and / or activities that characterize it.
[0308] Gene expression: The term "gene expression" refers to the process by which a nucleic acid sequence is successfully transcribed and (in most cases) translated to produce a protein or peptide. For clarity, when reference is made to measurement of "gene expression," this should be understood to mean that either the nucleic acid product of transcription (e.g., RNA or mRNA) or the amino acid product of translation (e.g., polypeptide or peptide) can be measured. Methods for measuring the amount or level of RNA, mRNA, polypeptides, and peptides are well known in the art.
[0309] Homology: As used herein, the term "homology" refers to the overall relatedness between polymer molecules, such as polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules. In some embodiments, polymer molecules are considered to be "homologous" to each other if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identical or similar. The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). According to the present disclosure, two polynucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50%, 60%, 70%, 80%, 90%, 95% or at least 99% of at least one fragment of at least about 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode fragments of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a fragment of at least 4-5 uniquely specified amino acids. According to the present disclosure, two protein sequences are considered homologous if the proteins are at least about 50%, 60%, 70%, 80% or 90% identical for at least one fragment of about 20 amino acids.
[0310] Identity: As used herein, the term "identity" refers to the overall correlation between polymer molecules, such as polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules. For example, the percentage identity of two polynucleotide sequences can be calculated by comparing the two sequences for the purpose of achieving optimal alignment (e.g., gaps can be introduced in one or both of the first and second nucleic acid sequences to achieve optimal alignment, and for the purpose of alignment, non-identical sequences can be ignored). In certain embodiments, the length of the sequence compared for the purpose of alignment is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. Taking into account the number of gaps and the length of each gap, the percentage identity between the two sequences is a function of the number of identical positions shared by the sequences, and the gaps need to be introduced to achieve optimal alignment of the two sequences. The alignment of sequences and the determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be calculated using methods such as those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, AM and Griffin, HG, eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; the contents of each of which are incorporated herein by reference in their entirety.For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Alternatively, the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package using the NWSgapdna.CMP matrix. Methods commonly used to determine percent identity between sequences include, but are not limited to, those disclosed in Carillo, H. and Lipman, D., SIAM J Applied Math., 48: 1073 (1988), which is incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software for determining homology between two sequences includes, but is not limited to, the GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN and FASTA (Altschul, SF et al., J. Molec. Biol., 215, 403 (1990)).
[0311] Inhibit gene expression: As used herein, the phrase "inhibit gene expression" refers to causing a decrease in the amount of an expression product of a gene. The expression product can be RNA (e.g., mRNA) transcribed from the gene or a polypeptide translated from the mRNA transcribed from the gene. Typically, a decrease in mRNA levels results in a decrease in the level of the polypeptide translated therefrom. The level of expression can be determined using standard techniques for measuring mRNA or protein.
[0312] Insertion: As used herein, the term "insertion" may refer to the addition of a targeting peptide sequence to a parent AAV capsid sequence. An "insertion" may result in the replacement of one or more amino acids of the parent AAV capsid sequence. Alternatively, an insertion may result in no change to the parent AAV capsid sequence other than the addition of the targeting peptide sequence.
[0313] Inverted terminal repeat: As used herein, the term "inverted terminal repeat" or "ITR" refers to cis-regulatory elements that serve to package a polynucleotide sequence into a viral capsid.
[0314] Library: As used herein, the term "library" refers to a diverse collection of linear polypeptides, polynucleotides, viral particles, or viral vectors. As an example, the library can be a DNA library or an AAV capsid library.
[0315] Nervous system disease: As used herein, a "nervous system disease" is any disease related to the central or peripheral nervous system and its components (eg, neurons).
[0316] Naturally occurring: As used herein, "naturally occurring" or "wild-type" refers to occurring in nature without artificial assistance or human intervention.
[0317] Open reading frame: As used herein, "open reading frame" or "ORF" refers to a sequence in a given reading frame that does not contain a stop codon.
[0318] Parent sequence: As used herein, a "parent sequence" is a nucleic acid or amino acid sequence from which a variant is derived. In one embodiment, the parent sequence is the sequence into which the heterologous sequence is inserted. In other words, the parent sequence can be considered a receptor or receptor sequence. In one embodiment, the parent sequence is the AAV capsid sequence into which the targeting sequence is inserted.
[0319] Particle: As used herein, a "particle" is a virus composed of at least two components: a protein capsid and a polynucleotide sequence enclosed within the capsid.
[0320] Patient: As used herein, "patient" refers to a subject who may seek or is in need of treatment, is in need of treatment, is receiving treatment, is about to receive treatment, or is being cared for by a trained professional for a particular disease or illness.
[0321] Payload region: As used herein, a "payload region" is any nucleic acid sequence (e.g., within a viral genome) encoding one or more "payloads" of the present disclosure. As a non-limiting example, the payload region can be a nucleic acid sequence within the viral genome of an AAV particle that encodes a payload, wherein the payload is an RNAi agent or a polypeptide. The payload of the present disclosure can be, but is not limited to, a peptide, polypeptide, protein, antibody, RNAi agent, etc.
[0322] Peptide: As used herein, a "peptide" is less than or equal to 50 amino acids in length, eg, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids in length.
[0323] Pharmaceutically acceptable: As used herein, the phrase "pharmaceutically acceptable" is used herein to refer to compounds, substances, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0324] Prophylaxis: As used herein, the terms "preventing" or "prevention" refer to partially or completely delaying the onset of an infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or clinical manifestations of a specific infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or manifestations of a specific infection, disease, disorder, and / or condition; partially or completely delaying the progression of an infection, specific disease, disorder, and / or condition; and / or reducing the risk of developing pathology associated with an infection, disease, disorder, and / or condition.
[0325] Prophylactic: As used herein, "prophylactic" refers to a treatment or course of action intended to prevent the spread of disease.
[0326] Prophylaxis: As used herein, "prophylaxis" refers to measures taken to maintain health and prevent the spread of disease.
[0327] Region: As used herein, the term "region" refers to a zone or general area. In some embodiments, when referring to a protein or protein module, a region may comprise a linear sequence of amino acids along the protein or protein module, or may comprise a three-dimensional region, an epitope, and / or an epitope cluster. In some embodiments, a region comprises a terminal region. As used herein, the term "terminal region" refers to a region located at the endpoint or end of a given agent. When referring to a protein, a terminal region may comprise the N-terminus and / or the C-terminus.
[0328] In some embodiments, when referring to a polynucleotide, a region can include a linear sequence of nucleic acids along the polynucleotide, or can include a three-dimensional region, a secondary structure, or a tertiary structure. In some embodiments, a region includes a terminal region. As used herein, the term "terminal region" refers to a region located at the endpoint or end of a given agent. When referring to a polynucleotide, a terminal region can include the 5' and 3' ends.
[0329] RNA or RNA molecule: As used herein, the terms "RNA" or "RNA molecule" or "ribonucleic acid molecule" refer to a polymer of ribonucleotides; the terms "DNA" or "DNA molecule" or "deoxyribonucleic acid molecule" refer to a polymer of deoxyribonucleotides. DNA and RNA can be synthesized naturally (e.g., by DNA replication and transcription of DNA, respectively) or chemically. DNA and RNA can be single-stranded (i.e., ssRNA or ssDNA, respectively) or multi-stranded (e.g., double-stranded, i.e., dsRNA and dsDNA, respectively). As used herein, the term "mRNA" or "messenger RNA" refers to single-stranded RNA that encodes the amino acid sequence of one or more polypeptide chains.
[0330] RNA interference or RNAi: The term "RNA interference" or "RNAi" as used herein refers to a sequence-specific regulatory mechanism mediated by RNA molecules, which results in the inhibition or interference or "silencing" of the expression of the corresponding protein-coding gene. RNAi has been observed in many types of organisms, including plants, animals and fungi. RNAi occurs naturally in cells to remove foreign RNA (e.g., viral RNA). Natural RNAi is carried out via fragments cut from free dsRNA, which direct the degradation mechanism to other similar RNA sequences. RNAi is controlled by the RNA-induced silencing complex (RISC) and is initiated by short / small dsRNA molecules in the cytoplasm, where they interact with the catalytic RISC component argonaute. dsRNA molecules can be introduced exogenously into cells. Exogenous dsRNA initiates RNAi by activating the ribonuclease protein Dicer, which binds and cuts dsRNA to produce double-stranded fragments of 21-25 base pairs with several unpaired overhanging bases on each end. These short double-stranded fragments are called small interfering RNAs (siRNAs).
[0331] RNAi agent: As used herein, the term "RNAi agent" refers to an RNA molecule or derivative thereof that can induce inhibition, interference, or "silencing" of expression of a target gene and / or its protein product. RNAi agents can knock out (actually eliminate or eliminate) expression, or knock down (reduce or reduce) expression. RNAi agents can be, but are not limited to, dsRNA, siRNA, shRNA, pre-miRNA, pri-miRNA, miRNA, stRNA, lncRNA, piRNA, or snoRNA.
[0332] Sample: As used herein, the term "sample" or "biological sample" refers to a subset of tissues, cells, or components thereof (e.g., body fluids, including but not limited to blood, serum, mucus, lymph, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid, and semen). A sample may also include a homogenate, lysate, or extract prepared from a whole organism or a subset of its tissues, cells, or components, or a portion or part thereof, including but not limited to, for example, plasma, serum, spinal fluid, lymph, skin, external areas of the respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs. A sample also refers to a culture medium, such as a nutrient broth or gelatin, that may contain cellular components (e.g., proteins or nucleic acid molecules).
[0333] Self-complementary viral particle: As used herein, a "self-complementary viral particle" is a particle composed of at least two components: a protein capsid and a self-complementary viral genome encapsidated within the capsid.
[0334] Sense strand: As used herein, the term "sense strand," "second strand," or "passenger strand" of an siRNA molecule refers to the strand that is complementary to the antisense strand or first strand. The antisense and sense strands of an siRNA molecule hybridize to form a duplex structure. As used herein, an "siRNA duplex" includes an siRNA strand that has sufficient complementarity to a stretch of about 10-50 nucleotides of the mRNA of a gene targeted for silencing and an siRNA strand that has sufficient complementarity to form a duplex with another siRNA strand.
[0335] Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymer molecules, such as between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of percent similarity between polymer molecules can be performed in the same manner as calculation of percent identity, except that the calculation of percent similarity takes into account conservative substitutions known in the art.
[0336] Short interfering RNA or siRNA: As used herein, the terms "short interfering RNA," "small interfering RNA," or "siRNA" refer to RNA molecules (or RNA analogs) comprising about 5-60 nucleotides (or nucleotide analogs) that are capable of directing or mediating RNAi. Preferably, the siRNA molecule comprises about 15-30 nucleotides or nucleotide analogs, such as about 16-25 nucleotides (or nucleotide analogs), about 18-23 nucleotides (or nucleotide analogs), about 19-22 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides or nucleotide analogs), about 19-25 nucleotides (or nucleotide analogs), and about 19-24 nucleotides (or nucleotide analogs). The term "short" siRNA refers to an siRNA comprising 5-23 nucleotides, preferably 21 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides). The term "long" siRNA refers to an siRNA comprising 24-60 nucleotides, preferably about 24-25 nucleotides (e.g., 23, 24, 25, or 26 nucleotides). In some cases, short siRNA can comprise less than 19 nucleotides, e.g., 16, 17, or 18 nucleotides, or as few as 5 nucleotides, with the prerequisite that shorter siRNA retains the ability to mediate RNAi. Similarly, in some cases, long siRNA can comprise more than 26 nucleotides, e.g., 27, 28, 29, 30, 35, 40, 45, 50, 55, or even 60 nucleotides, with the prerequisite that longer siRNA retains the ability to mediate RNAi or translation inhibition without the need to further process (e.g., enzymatic processing) into short siRNA. siRNA can be a single-stranded RNA molecule (ss-siRNA) or a double-stranded RNA molecule (ds-siRNA) comprising a sense strand and an antisense strand, which hybridizes to form a duplex structure referred to as a siRNA duplex.
[0337] Subject: As used herein, the term "subject" or "patient" refers to any organism to which a composition according to the present disclosure can be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants.
[0338] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting a full or nearly full degree or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena are rarely, if ever, completely complete and / or proceed to perfection or to achieve or avoid an absolute result. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0339] Targeting peptide: As used herein, "targeting peptide" refers to a peptide with a length of 3-20 amino acids. These targeting peptides can be inserted into or linked to a parent amino acid sequence to alter the properties (e.g., tropism) of the parent protein. As a non-limiting example, a targeting peptide can be inserted into an AAV capsid sequence to enhance targeting to a desired cell type, tissue, organ, or organism. It should be understood that the targeting peptide is encoded by a targeting polynucleotide that can be similarly inserted into a parent polynucleotide sequence. Thus, a "targeting sequence" refers to a peptide or polynucleotide sequence that is used to insert into a suitable parent sequence (amino acid or polynucleotide, respectively).
[0340] Target cell: As used herein, "target cell" or "target tissue" refers to any one or more cells of interest. The cells can be found in vitro, in vivo, in situ, or in a tissue or organ of an organism. The organism can be an animal, preferably a mammal, more preferably a human, and most preferably a patient.
[0341] Therapeutic agent: The term "therapeutic agent" refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and / or prophylactic effect and / or elicits a desired biological and / or pharmacological effect.
[0342] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" refers to an amount of an agent (e.g., a nucleic acid, a drug, a therapeutic agent, a diagnostic agent, a prophylactic agent, etc.) to be delivered that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat, diagnose, prevent, ameliorate symptoms of, and / or delay the onset of the infection, disease, disorder, and / or condition. In some embodiments, the therapeutically effective amount is provided in a single dose.
[0343] Therapeutically effective outcome: As used herein, the term "therapeutically effective outcome" refers to an outcome sufficient to treat, diagnose, prevent, ameliorate symptoms of, and / or delay the onset of an infection, disease, disorder, and / or condition in a subject suffering from or susceptible to the infection, disease, disorder, and / or condition.
[0344] Treat: As used herein, the term "treat" refers to partially or completely alleviating, ameliorating, improving, resolving, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or features of a particular infection, disease, disorder, and / or condition. For example, "treating" cancer can refer to inhibiting the survival, growth, and / or spread of a tumor. Treatment can be administered to subjects who do not exhibit signs of the disease, disorder, and / or condition and / or to subjects who exhibit only early signs of the disease, disorder, and / or condition in order to reduce the risk of developing pathology associated with the disease, disorder, and / or condition.
[0345] Vector: As used herein, the term "vector" refers to any molecule or moiety that transports, transduces, or otherwise acts as a vehicle for a heterologous molecule. In some embodiments, the vector can be a plasmid. In some embodiments, the vector can be a virus. An AAV particle is an example of a vector. The vectors of the present disclosure can be recombinantly produced and can be based on and / or can comprise an adeno-associated virus (AAV) parent or reference sequence. The heterologous molecule can be a polynucleotide and / or a polypeptide.
[0346] Viral genome: As used herein, the term "viral genome" or "vector genome" refers to the nucleic acid sequence encapsulated in an AAV particle. The viral genome comprises a nucleic acid sequence having at least one payload region encoding a payload and at least one ITR.
[0347] Equivalence and scope
[0348] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments of the disclosure described herein.The scope of the present disclosure is not intended to be limited to the description above, but is instead set forth in the claims appended hereto.
[0349] In the claims, articles such as "a," "an," and "the" may refer to one or more than one, unless indicated to the contrary or otherwise obvious from the context. A claim or description including "or" between one or more members of a group is considered satisfied if one, more than one, or all of the members of the group are present in, used in, or otherwise related to a specified product or process, unless indicated to the contrary or otherwise obvious from the context. The present disclosure includes embodiments in which exactly one member of the group is present in, used in, or otherwise related to a given product or method. The present disclosure includes embodiments in which more than one or all of the members of the group are present in, used in, or otherwise related to a given product or method.
[0350] It should also be noted that the term "comprising" is intended to be open ended and allows but does not require the inclusion of additional elements or steps. Thus, when the term "comprising" is used herein, the term "consisting of" is also included and disclosed.
[0351] Where ranges are given, the endpoints are included. In addition, it should be understood that, unless otherwise indicated or otherwise apparent from the context and understanding of one of ordinary skill in the art, values expressed in ranges may represent any specific value or sub-range within the range in various embodiments of the present disclosure, accurate to the tenth of the unit of the lower limit of the range, unless the context clearly indicates otherwise.
[0352] In addition, it should be understood that any specific embodiment of the present disclosure that falls within the prior art can be explicitly excluded from any one or more claims. Because such embodiments are considered to be known to those of ordinary skill in the art, they can be excluded even if the exclusion is not explicitly set forth herein. Any specific embodiment of the composition of the present disclosure (e.g., any antibiotic, therapeutic agent or active ingredient; any production method; any method of use, etc.) can be excluded from any one or more claims for any reason, whether or not related to the existence of the prior art.
[0353] It is to be understood that the words which have been used are words of description rather than limitation and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the disclosure in its broader aspects.
[0354] Although the present disclosure has been described with considerable detail and with considerable particularity with respect to several described embodiments, it is not intended that the invention be limited to any such detail or embodiment or to any particular embodiment, but rather that the invention should be construed with reference to the appended claims, thereby providing the broadest possible interpretation of such claims in view of the prior art and thereby effectively encompassing the intended scope of the present disclosure.
[0355] The present disclosure is further illustrated by the following non-limiting examples. Example
[0356] Example 1. TRACER Proof of Concept: Promoter Selection
[0357] Proof-of-concept experiments were performed by placing the gene encoding the AAV9 peptide display capsid library under the control of the neuron-specific synaptobrevin promoter (SYN) or the astrocyte-specific GFAP promoter. After intravenous administration to C57BL / 6 mice, RNA was recovered from brain tissue and used for further library evolution. After only two rounds of selection, next-generation sequencing (NGS) showed sequence convergence between animals. Interestingly, several variants highly similar to the PHP.eB capsid were recovered, indicating that our approach allows for rapid selection of high-performance capsids. A subset of capsids with peptide sequences with high CNS enrichment was selected for further study. It should be understood that any promoter can be selected based on the desired tropism. Examples of such promoters are shown in Table 3.
[0358] Table 3 Promoters, tissues and cell types
[0359]
[0360]
[0361]
[0362]
[0363]
[0364] Capsid pools were injected into three rodent species, followed by RNA enrichment analysis to characterize transduction efficiency and cross-species performance in neurons or astrocytes. The top-ranked capsids were then tested individually, and several variants showed similar or improved CNS transduction compared to the PHP.eB benchmark. These results demonstrate that the TRACER platform allows for rapid in vivo evolution of AAV capsids in non-transgenic animals with a high degree of tropism improvement. The following examples illustrate this finding in more detail.
[0365] Example 2. Generation of AAV vectors capable of capsid mRNA expression in the absence of helper virus
[0366] To perform in vivo evolution of cell-type-restricted and transduction-restricted AAV capsid libraries, a capsid library system was engineered in which the capsid mutant genes can be transcribed in a specific cell type in the absence of a helper virus. In wild-type AAV virus, mRNAs encoding the capsid proteins VP1, VP2, and VP3 and the AAP accessory protein are expressed from the P40 promoter located in the 3' region of the REP gene ( Figure 1A ), which is only active in the presence of REP protein and helper virus function (Berns et al., 1996). In order to express the capsid mRNA in animal tissues or cultured cells, another promoter must be inserted upstream or downstream of the CAP gene. Due to the limited packaging capacity of the AAV capsid, a portion of the REP gene must be deleted to accommodate the additional promoter insertion, and the REP gene must be provided in trans by another plasmid to produce the virus. The minimum viral sequence required for high-titer AAV production was determined by introducing the CMV promoter at various positions upstream of the CAP gene of AAV9 ( Figure 1B). The REP protein is provided in trans by the pREP2 plasmid, which is obtained by deleting the CAP gene from the REP2-CAP2 packaging vector using EcoNI and ClaI (SEQ.ID NO: 4). For small-scale viral production tests, HEK-293T cells grown in DMEM supplemented with 5% FBS and 1X pen / strep were plated in 15 cm culture dishes and co-transfected with 15 ug pHelper (pFdelta6) plasmid, 10 ug pREP2 plasmid, and 1 ug ITR-CMV-CAP plasmid using calcium phosphate transfection. After 72 hours, cells were harvested by scraping, pelleted by brief centrifugation, and suspended in 1 ml of buffer containing 10 mM Tris and 2 mM MgCl2. Cells were lysed by adding Triton X-100 to a final concentration of 0.1% and treated with 50 U of benzonase for 1 hour. Viruses from the supernatant were precipitated with 8% polyethylene glycol and 0.5 M NaCl, suspended in 1 ml of 10 mM TRIS-2 mM MgCl2, and combined with the cell lysate. The combined virus was adjusted to 0.5 M NaCl, clarified by centrifugation at 4,000 x g for 15 minutes, and fractionated at 40,000 rpm for 3 hours using a gradient of 15%, 25%, 40%, and 60% iodixanol (Zolotukhin et al., 1999). The 40% fraction containing purified AAV particles was harvested and viral titers were measured by real-time PCR using a Taqman primer / probe mix shared by all constructs (specific for the 3' end of all REPs). Viral yields were significantly lower than those of the fully wild-type ITR-REP2-CAP9-ITR used as a reference (1.7% to 8.8%), but the CMV-BstEII construct allowed the highest yield of all three CMV constructs. See Figures 2A-2B The CMV-HindIII construct, in which most of the P40 promoter sequence was deleted, produced the lowest yield (1.7% of wtAAV9), indicating that even the potent CMV promoter cannot replace the P40 promoter without severely reducing viral yield. Based on these observations, the BstEII construct (SEQ. ID NO: 5), which retains the minimal P40 sequence and the CAP mRNA splice donor, was used in all further experiments.
[0367] The REP expression plasmid was then improved by retaining the AAP reading frame and most of the capsid gene from the REP2-CAP9 helper vector, which likely contains sequences necessary for regulating CAP transcription and / or splicing. To eliminate the capsid-encoding potential of the vector, the C-terminal fragment of the capsid gene was deleted by triple cleavage with the MscI restriction enzyme, followed by self-ligation, to obtain the pREP-AAP plasmid ( Figure 3A , SEQ.ID NO:6).
[0368] Iterations of this construct were designed by introducing premature stop codons immediately after the start codons of VP1, VP2, and VP3 without disturbing the amino acid sequence of the syntenic AAP reading frame ( Figure 3A This construct was named pREP-3stop (SEQ. ID NO: 7). The neuron-specific syn-CAP9 vector (SEQ. ID NO: 8) was derived from the CMV9-BstEII plasmid by exchanging the CMV promoter with the neuron-specific human synapsin 1 promoter.
[0369] As previously described, the production efficiency of Syn-CAP9 was tested using pREP, pREP-AAP, or pREP-3stop plasmids to provide REP in trans. Figure 3B As shown, REP plasmids with longer capsid sequences and AAP increased viral yields approximately threefold compared to pREP plasmids. Viral titers obtained with pREP-AAP or pREP-3stop vectors reached ~30% of wild-type AAV9. A significant concern with plasmids carrying long homology regions is the potential for undesired recombination with ITR-CAP vectors, which could reconstitute the wild-type ITR-REP-CAP vector and contaminate the combinatorial library.
[0370] To assess the risk of wild-type virus reconstitution, Figure 3B The virus preparation obtained was subjected to real-time PCR using a Taqman probe located at the N-terminus of REP. The percentage of capsids containing detectable full-length REP was less than 0.03% of that of wild-type virus ( Figure 3C ), which is even lower than the 0.1% abnormal REP-CAP packaging routinely detected in most recombinant AAV products obtained from 293T cell transfection ( Figure 3C , our unpublished observations). Because the premature stop codon of the pREP-3stop vector provides an additional layer of safety against potential recombination of wild-type capsids and prevents translation of truncated capsid proteins, the 3stop plasmid was used for all subsequent studies.
[0371] Subsequently, the feasibility of RNA-driven biopanning in C57BL / 6 mice was tested using AAV9-packaged vectors in which the AAV9 capsid gene was driven by the CMV promoter, the synapsin promoter, or the astrocyte-specific GFabc1D promoter (SEQ. ID NO: 9), hereafter referred to as the GFAP promoter (Brenner et al., 2008) ( Figure 4A). As previously described, the three vectors were produced in HEK-293T cells and analyzed by PAGE-silver staining. Figure 4B As shown, all vectors displayed normal ratios of VP1, VP2, and VP3 capsid proteins, indicating that specific promoter structures do not disrupt the balance of capsid protein expression. Six-week-old male C57BL / 6 mice were intravenously injected with le 12VG / mouse and sacrificed 28 days later. DNA biodistribution and capsid mRNA expression were tested in brain, liver, and heart tissues.
[0372] Total DNA was extracted from brain, liver, and heart tissue using Qiagen DNeasy blood and tissue columns, and viral DNA was quantified by real-time PCR using a Taqman probe located in the N-terminal region of VP3. DNA abundance was normalized using a pre-designed probe (Life Technologies No. 4458366) that detects a single copy of the transferrin receptor gene. Viral DNA was highly abundant in the liver and less abundant in the heart. DNA distribution did not show any significant differences between the three vectors ( Figure 4C RNA was extracted using the Qiagen RNeasy plus universal kit according to the manufacturer's instructions, treated with ezDNAse (Qiagen) to remove residual DNA, and then reverse transcribed using Superscript IV (Life Technologies).
[0373] RNA expression was assessed using the same VP3 probe used for quantification of viral DNA and normalized using TBP as a reference RNA (Life Technologies Mm0277042_ml). In the brain, the GFAP promoter allowed the strongest expression levels, while the synapsin promoter allowed expression comparable to the potent CMV promoter. In the liver, all promoters resulted in similar expression levels, which may be a result of leaky expression at very high copy numbers ( Figure 4D In the heart, the cell type specificity of the Syn and GFAP promoters is evident, as despite their similar DNA biodistribution, they allow only ∼3% and 10% of CMV expression, respectively.
[0374] Overall, this experiment demonstrates that mRNA from transduction-competent capsids can be recovered from various animal organs, including weakly transduced tissues such as the brain.
[0375] Example 3. AAV vector configuration
[0376] Various vector configurations were explored to increase RNA expression, thereby maximizing library recovery. The CMV promoter was replaced with a hybrid CMV enhancer / chicken β-actin promoter sequence (Niwa et al., 1991) and a potent cytomegalovirus-β-globin hybrid intron derived from the AAV-MCS cloning vector (Stratagene) was inserted between the promoter sequence and the capsid gene, as introns have been shown to enhance mRNA processing and stability (Powell et al., 2015). This resulted in constructs CAG9 (SEQ. ID NO: 10), SYNG9 (SEQ. ID NO: 11), and GFAPG (SEQ. ID NO: 12).
[0377] A reverse vector configuration was also tested, in which the helper-independent promoter was placed downstream of the capsid gene in a reverse orientation to avoid potential interference with the P40 promoter ( Figure 5A This configuration allows for the expression of antisense capsid transcripts in animal tissues. Since most polyadenylation signals (AATAAA) are orientation-dependent, it can be assumed that the native AAV capsid polyA does not terminate transcription prematurely when placed in the reverse orientation. All constructs were co-transfected with pHelper and pREP-3stop plasmids to generate AAV9-packaged virions, which were used to transduce HEK-293T cells at an MOI of 1e4 VG / cell. RNA was extracted 48 hours after transfection and reverse transcribed using the Quantitect kit (Qiagen).
[0378] PCR was performed using primers that allowed amplification of the full-length capsid or a partial sequence located near the C-terminus ( Figure 5B Overall, the presence of the intron had little effect on the expression of the low-activity promoters Syn and GFAP, suggesting that mRNA splicing does not relieve the repression of the promoters in non-permissive cells. The combination of the CMV enhancer with the chicken β-actin promoter and the hybrid intron resulted in significantly higher mRNA expression (>10-fold) compared to the CMV promoter alone ( Figure 5B 、 5C ).
[0379] When comparing endpoint PCR amplification between forward and reverse intron vectors, clear differences were observed between full-length and partial capsid amplicons ( Figure 5B , right lane), which made us question the integrity of the capsid RNA. When the cDNA from the reverse iCAG9 genome was amplified using primers flanking the full-length capsid, multiple low molecular weight bands were detected, while the forward oriented vector allowed the amplification of a single product of the expected length ( Figure 5D Sanger sequencing of low-molecular-weight amplicons revealed that each band corresponded to an abnormally spliced product from the antisense capsid RNA.
[0380] Based on these results, the forward tandem promoter construct was used in subsequent experiments.
[0381] Splice-specific PCR amplification was tested to avoid amplifying residual DNA present in RNA preparations. Two candidate PCR primers were designed that overlapped the CMV / globin exon-exon junction and tested for amplification of either cDNA (spliced) or plasmid DNA (still containing intronic sequences). Figure 5E As shown in , the GloSpliceF6 primer (SEQ ID NO: 13) allows completely specific amplification from cDNA without generating detectable amplicons from plasmid DNA sequences. This primer was used in subsequent assays to determine the absence of amplification from contaminating DNA.
[0382] The tandem constructs were then tested for potential interference of the P40 promoter with a cell-specific promoter located upstream. To this end, two series of AAV genomes were tested for transgene mRNA expression in HEK-293T cells. A series of transgenes in which the GFP gene was placed immediately downstream of the CAG, SYNG, or GFAPG promoters without the P40 sequence were tested and compared to library constructs in which the AAV9 capsid was placed downstream of the P40 promoter ( Figure 6 All genomes were packaged into AAV9 capsids and used to infect HEK-293T cells at an MOI of 1e4 VG / cell. RNA was extracted 48 hours after infection, and transgenic RNA was quantified using a Taqman primer / probe mix specific for spliced globin exon-exon junctions. Figure 6 As shown, expression from the CAG promoter was similar between the GFP and p40-CAP9 constructs (within the error of the AAV titration and 2-fold lower in p40-CAP9). Expression from the synapsin promoter was significantly reduced for both constructs, and expression of the GFAP-driven mRNA was even lower ( Figure 6 This is to be expected since HEK-293T cells do not allow expression of the synapsin or GFAP promoters. Overall, this experiment demonstrates that the presence of the P40 sequence does not alter the cell type specificity of the synapsin or GFAP promoters.
[0383] This novel platform is called TRACER (AAV tropism redirection through cell-type-specific expression of RNA). T ropism R edirection of A AV by C ell type-specific E Expression ofR NA). The TRACER platform addresses issues with standard methods, including transduction and cell type limitations. ( Figure 7 The use of the TRACER system is well suited for capsid discovery using targeted peptide libraries. Figure 8 Screening of this library was performed as outlined in .
[0384] Although several variations of AAV vectors encoding capsids as payloads are taught herein, Figure 9 、 Figure 12A and Figure 12B A standard design is shown.
[0385] Other advantages of the TRACER platform are related to the nature of the viral reservoir and the recovery of RNA only from fully transduced cells ( Figure 10 Thus, capsid discovery can be accelerated in a manner that results in cell- and / or tissue-specific tropism ( Figure 11 ).
[0386] Example 4. Generation and cloning-free expansion of peptide display libraries
[0387] By inserting seven consecutive random amino acids into the AAV5, AAV6 or AAV-DJ8 capsid ( Figure 13 and Figure 39 ) and AAV9( Figure 13 ) were used to generate several peptide display capsid libraries based on the surface-exposed hypervariable loop VIII region of the AAV9 vector. For the AAV9 library, two additional libraries were generated by modifying the residues at positions −2, −1, and +1 of the insert to match the flanking sequences of the highly neurotrophic PHP.eB vector (Chan et al., 2018). To facilitate insertion of the various loops and prevent contamination with wild-type capsids, defective shuffling vectors were generated in which the C-terminal region of the capsid gene contained between loop VIII and the stop codon was deleted and replaced with a unique BsrGI restriction site ( Figure 15A 、 15B). Degenerate primers containing random NNK (K=T or G) sequences capable of encoding all amino acids were synthesized by IDT, and gBlock (IDT) double-stranded linear DNA was used as a template to amplify the deleted capsid fragment (SEQ.ID NO 14, SEQ ID NO: 14, 15, 16, 17). Linear PCR templates are more preferred than plasmids to completely prevent the possibility of plasmid carryover in the PCR reaction. Within 30 minutes at 50°C, 100ul NEBuilder HiFi DNA assembly premix (NEB) was used to insert the amplicon (500ng) containing the random library sequence into the shuffled plasmid (2ug) linearized by BsrGI. Unassembled linear templates were eliminated by adding 5ul T5 exonuclease to the reaction and digested at 37°C for 30 minutes. The entire reaction was purified with DNA Clean and Concentrator-5 and quantified with nanodrop to estimate the assembly efficiency. This method can typically recover 0.5-1ug of assembly material.
[0388] gBlock templates were designed by introducing silent mutations to remove unique restriction sites, allowing for the selective elimination of wild-type viral contaminants from the library by restriction enzyme treatment. For example, the AAV9 gBlock was engineered to remove the BamHI and AfeI sites present in the parental sequence (SEQ. ID NO 17).
[0389] Example 5. No clonal expansion
[0390] Transformation of assembled library DNA into competent bacteria represents a major bottleneck for library diversity, as even highly competent strains rarely yield more than 1e7-1e8 colonies per transformation. In comparison, 100 ng of a 6-kilobase plasmid contains 1.50e10 DNA molecules. Thus, bacterial transformation can arbitrarily eliminate >99% of the DNA species in a given pool. A cloning-free method was therefore created that allows for >100-fold amplification of DNA by Gibson assembly while bypassing the bacterial transformation bottleneck ( Figure 16A protocol based on rolling circle amplification (RCA) has been optimized, allowing unbiased exponential amplification of circular DNA templates with very low error rates (Hutchinson et al., 2005). One problem with RCA is that it produces very large (average approximately 70 kilobases) heavily branched concatemers that must be cleaved into monomers for efficient cell transfection. This process can be accomplished in a variety of ways, for example, by using restriction enzymes to generate open linear templates (Hutchinson et al., 2005; Huovinen, 2012), or by CRE-Lox recombination to generate self-ligating circular templates (Huovinen et al., 2011). However, open DNA is sensitive to degradation by cytoplasmic exonucleases, and CRE recombination methods show relatively low efficiency (our unpublished observations). Therefore, an alternative monomer resolution method was chosen based on the use of TelN telomerase (Rybchin et al., 1999), which catalyzes the formation of closed linear “dogbone” DNA monomers that are well-suited for mammalian cell transfection (Heinrich et al., 2002).
[0391] To this end, the telomerase recognition sequence TATCAGCACACAATTGCCCATTATA CGC*GCGTATAATGGACTATTGTGTGCTGATA (SEQ ID NO: 176) was introduced outside the two ITRs of all BsrGI shuffling vectors used for capsid library insertion (the asterisk indicates the position where the two complementary chains are covalently linked to each other) to obtain the following plasmids: TelN-Syn9-BsrGI (SEQ ID NO 18), TelN-GFAP9-BsrGI (SEQ ID NO 19), TelN-Syn5-BsrGI (SEQ ID NO 20), TelN-GFAP5-BsrGI (SEQ ID NO 21), TelN-Syn6-BsrGI (SEQ ID NO 22), TelN-GFAP6-BsrGI (SEQ ID NO 23), TelN-SynDJ8-BsrGI (SEQ ID NO 24), TelN-GFAPDJ8-BsrGI (SEQ ID NO 25). 25). Several rolling circle amplification methods were tested, and the best results (high yield and low nonspecific amplification) were obtained using TruePrime technology (Expedeon), which relies on primer-free amplification (Picher et al., 2016).
[0392] Briefly, the entire column-purified assembly reaction was used in a 900 ul TruePrime reaction and incubated overnight at 30°C, following the manufacturer's instructions. The next day, the rolling circle reaction product was incubated at 65°C for 10 minutes to inactivate the enzyme and diluted 5-fold in 1X ThermoPol buffer with 50 μl telomerase (NEB) in a 4.5 ml reaction. After 1 hour at 30°C, the reaction was heat-treated at 70°C for 10 minutes to inactivate the telomerase, and a 4.5 ul aliquot was run on an agarose gel. The entire reaction was then purified on multiple (10-12) Qiagen QiaPrep 2.0 columns, following the manufacturer's instructions. The typical yield obtained using this method was DNA, which showed >100-fold amplification of starting material (typically 0.5 μg) and provided enough DNA to transfect 200 cell culture dishes ( Figure 16 ).
[0393] The composition of all libraries was tested by next-generation sequencing on the Illumina NextSeq sequencing platform to assess the number of variants and the extent of eventual contamination with wild-type virus. Amplicons were generated by PCR with Q5 polymerase (NEB) using primers containing Illumina TruSeq adapters and index barcodes. Amplicons were obtained by low-cycle PCR amplification (15 cycles), run on 3% agarose gels and purified using Zymo gel extraction reagent. Libraries were quantified using nanodrop, pooled into equimolar mixtures, and re-quantified using the KAPA library quantification kit according to the manufacturer's instructions. Libraries were mixed with 20-40% PhiX control libraries to increase sequence diversity.
[0394] All DNA libraries generated by rolling circles showed high sequence diversity (typically >1e8 unique variants, beyond the range of NextSeq sequencing). In contrast, plasmid libraries generated by bacterial transformation rarely exceeded 1-2e7 variants.
[0395] Example 6. Prevention and / or Reduction of Pollution
[0396] In another embodiment, a primer / vector system was created that was designed to completely prevent contamination of the AAV9 library with wild-type virus that might be recovered from environmental contamination or from naturally infected primate tissue. This was achieved by introducing a maximum number of silent mutations in the sequence surrounding the library insertion site and just before the CAP stop codon used for PCR amplification ( Figure 17These libraries showed very low amounts of wild-type AAV9 detected by NGS (less than 2 AAV9 reads per 5e7 total reads), indicating that altering the codons surrounding the library amplification and cloning sites is a very effective way to protect the library from environmental or experimental contamination.
[0397] Libraries were produced by calcium phosphate transfection of HEK-293T cells, double iodixanol gradient fractionation, and membrane ultrafiltration using a 100,000 Da MWCO Amicon-15 membrane (Millipore) as described previously and quantified by real-time PCR, with aliquots used for NGS amplicon production and NextSeq sequencing. The diversity of the viral library was significantly lower than that of the DNA library (typically ∼1-2e7 unique variants) and showed very strong counterselection of variants containing stop codons (from 20% in the DNA library to 10% in the viral library). This indicates that the cis-packaging rate is very high, as observed in previous studies ( Nonnenmacher et al., 2014 ).
[0398] Example 7. In vivo selection of AAV9 libraries for mouse brain transduction
[0399] We then developed an RNA-driven library selection for increased brain transduction in a murine model. AAV9 libraries generated as described above were intravenously injected into male C57BL / 6 mice at a dose of 2e12 VG / mouse. Two groups of mice were injected with individual SYN-driven or GFAP-driven libraries derived from wild-type AAV9 flanking sequences, and the other two groups received a pooled library containing wild-type and PHP.eB-derived flanking sequences ( Figure 18 One month later, RNA was extracted from 200 mg of brain tissue corresponding to the entire hemisphere using the RNeasy Universal Plus procedure (Qiagen). To minimize the possibility of undersampling RNA, the entire RNA preparation was eluted using Obgotex beads (Qiagen) according to the manufacturer's recommendations. mRNA enrichment was performed. The entire preparation of enriched mRNA (~5 μg, equivalent to 2% of total RNA) was then reverse transcribed in a 40 μl Superscript IV reaction (Life Technologies) using a library-specific primer with the following sequence: 5'-GAAACGAATTAAACGGTTTATTGATTAACAATCGA TTA -3' (SEQ ID NO: 415) (CAP stop codon is underlined) Figure 19The entire cDNA pool was then subjected to 30 cycles of 55°C annealing and 2-minute extension in a 500 μl PCR reaction assembled with Q5 Master Mix, GloSpliceF6 forward primer, and CAP9-specific reverse primer: 5'-CGGTTTATTGATTAACA ATCGA TTA CAGATTACGAGTCAGGTATC-3' (SEQ ID NO: 416) (CAP stop codon is underlined). This method allowed the recovery of abundant amplicons from all brain samples ( Figure 20 ).
[0400] The full-length capsid amplicons were then used as templates for NGS library generation and cloning into P1 DNA libraries for the next round of bio-panning using the exact same assembly and cloning-free procedures. NGS analysis of the PCR amplicons showed that library diversity decreased by ~25-fold (from 1e7 to 4e5) after the first round of bio-panning for both Syn-driven and GFAP-driven libraries ( Figures 21A-21C ). The number of first-round variants recovered (P1) was too high to show any significant sequence convergence at this time, and there was little overlap between the compositions of the pools recovered from individual animals. Therefore, a second round of selection was performed. After the second biopanning (P2), the total number of unique variants dropped further by 4-5 fold to <1e5 peptides. Importantly, some libraries recovered after the first round of biopanning showed significant counts of wild-type AAV9 and AAV-PHP.eB sequences, likely due to environmental contamination. These later became useful benchmarks in the second round of enrichment.
[0401] After RNA recovery and PCR amplification, systematic enrichment analysis was performed by NGS by calculating the ratio of P2 / P1 reads and comparing it with the ratio of AAV9 or PHP.eB P2 / P1. Figure 22 , Table 4, Figure 23 As shown in Table 5 , multiple capsids showed higher enrichment rates than the benchmark PHP.eB in both Syn-driven and GFAP-driven libraries, and sequence convergence was evident, as represented by consensus sequence generation.
[0402] Table 4. Capsid analysis results
[0403]
[0404]
[0405]
[0406] Table 5. Capsid analysis results
[0407]
[0408]
[0409]
[0410] Importantly, there was also strong sequence convergence between different animals, suggesting that effective selection can occur after only two passages. Figure 24 and Figure 25 An assessment of brain / liver specificity among GFAP-AAV9 peptide library candidates is provided.
[0411] Example 8. Multiple Selection
[0412] For the final multiplex in vivo screening by pooling of individual variants in equimolar libraries, e.g. Figure 26 As shown, a subset of variants with promising properties (such as, but not limited to, enrichment factors, liver off-target, high counts in more than one mouse, etc.) can be selected, and then an equimolar pool of primers can be synthesized that encodes all 7-mers (microchip solid phase synthesis, up to 3,800 primers per chip). Limited diversity libraries can be generated that include internal controls such as, but not limited to, PHP.N, PHP.B, wild-type AAV9 (wtAAV9), and / or any other serotype, including those taught herein. Mice are injected, and RNA enrichment is then compared to internal controls in a manner similar to barcoding studies, which are known in the art and described herein.
[0413] Example 9. Codon Optimization
[0414] When using synthetic libraries, codon variants can be used to improve data strength. Table 6 provides a list of NNK codons, NNM codons, and optimal NNM codons for various amino acids in mammals. In Table 6, * indicates that no NNM codon is available, and ** indicates "avoid homopolymer segments if possible."
[0415] Table 6. Codon variants
[0416]
[0417]
[0418] In order to have a balanced library, it is recommended to create a list of potential candidates. Then, by using Table 6, the combined primer library contains each peptide variant encoded by NNK codons (original codons from the library) and non-NNK codons (maximum variation). If similar behavior is seen between two variants of the same peptide, this will strengthen the analysis of that peptide. In addition, it is recommended to select the optimal NNM codon (M = A or C).
[0419] Example 10. Library Generation
[0420] The top 330 peptide variants that showed enhanced performance relative to the parental AAV9 were selected from the SYN-driven and GFAP-driven libraries. A new library was generated by primer synthesis of all 330 peptide sequences and AAV9, AAV-PHP.B and AAV-PHP.eB controls (Table 7). In order to exclude potential artifacts due to DNA sequence and improve the robustness of the assay, each peptide variant was encoded by two different DNA sequences, one in which all amino acids were encoded by NNK codons (same as the original library) and the other in which NNM codons (M=C or A, Table 6) were used whenever possible.
[0421] Table 7. Peptide variants selected after two rounds of RNA-driven mouse brain biopanning
[0422]
[0423]
[0424]
[0425]
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447] The primer pool was generated by Twist biosciences using solid phase synthesis and used to generate a balanced library of 666 nucleotide variants by PCR amplification of the CAP C terminus and Gibson assembly, as Figure 27 As shown. 666 primers were provided, each at 1 fmole, resulting in 0.6 pmoles (conventional PCR requires ~25 pmoles of primers). Primer-free amplification of the capsid gBlock template was performed for 10 cycles. Forward and reverse primers were added, followed by 10, 15, or 20 additional PCR cycles. The construct was then cloned into the AAV9 backbone plasmid by Gibson / RCA (similar to conventional libraries).
[0448] NGS analysis of SYN- and GFAP-driven AAV libraries generated with pooled DNA showed good correlation between codon variants for each peptide, suggesting that the DNA sequence itself has little effect on virus production ( Figure 28 and Figure 29 The combined synthetic library was intravenously injected into C57BL / 6 mice (5e11 VG / mouse, N=9), BALB / C mice (5e11 VG / mouse, N=6) and rats (5e12 VG / rat, N=6), and one month later, in-life RNA was extracted from brain and spinal cord, and DNA was extracted from liver and heart tissue samples for biodistribution analysis ( Figure 30Because the synapsin and GFAP promoters are not fully active in non-CNS tissues, DNA rather than RNA was analyzed from peripheral organs. The initial focus was on analysis of C57BL / 6 mice, as this is the mouse strain in which the library was evolved.
[0449] The enrichment score for each capsid was determined by NGS analysis and was defined as the ratio of reads per million (RPM) in the target tissue to the RPM in the inoculum. Figure 31A An example of the analysis performed on control capsids is shown in . As expected from the published data, PHP.B and PHP.eB (also known as PHP.N) capsids allowed significantly higher RNA expression in neurons (8-fold and 25-fold, respectively) compared to the AAV9 parental capsid. There was a very high correlation between the codon variants for each peptide class in each animal (r = 0.92, 0.93, and 0.95), confirming the robustness of the NGS assay ( Figures 31B-31D ).
[0450] Examples of enrichment analysis are given in Figure 32A – Figure 36 The 333 capsid variants were ranked by the average brain enrichment score across all animals, with individual enrichment values indicated by a color scale. As indicated by the position of the reference capsid, a new set of variants showed higher enrichment scores than the PHP.eB benchmark capsid in both neurons (Syn driven) and astrocytes (GFAP driven). Interestingly, many variants showed different enrichment scores in neurons vs. astrocytes, as indicated by the moderate level of correlation between Syn driven and GFAP driven RNAs. This suggests that some capsids show enhanced tropism for neurons, while others show enhanced tropism for astrocytes ( Figure 33 ).
[0451] A panel of 38 capsids exhibited potentially interesting properties based on their tropism for neurons, astrocytes, or both (Tables 8A and 8B) ( Figure 38 ) and showed strong shared peptide sequence similarity, with differences between neuron-targeted and astrocyte-targeted variants ( Figures 45A-45C and Figures 46A-46B ).
[0452] Table 8A Top 38 candidates from C57BL / 6 screen #1 (N=3)
[0453]
[0454]
[0455] Table 8B. Variant 9-mers and coding sequences
[0456]
[0457]
[0458]
[0459]
[0460] Example 11. Phylogenetic grouping
[0461] Phylogenetic grouping of peptide sequences showed a clear correlation between sequence homology clusters and capsid phenotypes ( Figures 37A-37B For example, a 9-mer variant with the sequence DGTxxxPFK / R (SEQ ID NO: 1181) exhibited similar behavior to the PHP.eB capsid (high transduction of both neurons and astrocytes), while a variant with the sequence DGTxxxYDS / A (SEQ ID NO: 1182) showed a preference for neuronal transduction. In contrast, peptides with the consensus DGTxxxxGW (SEQ ID NO: 1183) or CGTxxxPPR / K (SEQ ID NO: 1184) had a higher tropism for astrocytes.
[0462] Example 12. Capsid test
[0463] Capsid variants representing different sequence clusters were selected (in Figure 37B Each capsid was generated as a recombinant AAV packaged with a ubiquitous promoter-driven self-complementary EGFP transgene ( Figure 49A 、 49B Groups of mice (N=3) were injected intravenously with 6e10 VG, and transduction efficiency was assessed 1 month later by quantification of EGFP mRNA in brain, spinal cord, and liver tissues. EGFP mRNA expression was normalized using mouse TBP as a housekeeping gene, and DNA biodistribution was normalized to that of a single-copy mouse TfR gene ( Figures 50A-50C Reverse transcription was performed using the Quantitect kit and included DNA removal. All capsid variants demonstrated significant improvements in brain and spinal cord mRNA expression compared to the parental AAV9 capsid, and three of the seven variants (9P16, 9P31, and 9P35) showed similar or higher transduction than the PHP.eB benchmark capsid. Figure 49C , Table 10). Biodistribution of viral DNA showed that 9P31 and 9P35 had very strong tropism for the brain and spinal cord, but all variants showed a 40-260-fold increase in biodistribution compared to AAV9 ( Figure 49D, Table 10).
[0464] Use NGS screening to test expected cell tropism by labeling for the neuronal NeuN marker ( Figure 51 Within the cortex, the top capsids from the GFAP screen showed GFP expression primarily in NeuN-negative cells with glial morphology. In contrast, the top capsids from the SYN screen showed very high transduction of NeuN-positive cells, while the bispecific capsids 9P08 and 9P16 (which ranked highly in both assays) showed a mixed cell preference with multiple NeuN+ cells and glial cells.
[0465] Cell tropism was also tested using mouse brain microvascular EC (mBMVEC) binding relative to AAV9. The results are shown in Table 9.
[0466] Table 9. mBMVEC binding results
[0467]
[0468] Fluorescent EGFP expression in whole brain, cerebellum, cortex, and hippocampus revealed transduction patterns across the entire aspectrum and demonstrated the identification of tissue-specific capsids. Figures 52-56 ).
[0469] Liver transduction, as measured by mRNA expression and whole tissue GFP expression, showed that several variants outperformed AAV9, which was unexpected given the NGS results. Some variants (e.g., 9P08 or 9P23) showed relative liver off-targeting compared to AAV9 ( Figure 57A-Figure 57B ).
[0470] Table 10. Brain and spinal cord tropism
[0471]
[0472]
[0473]
[0474] *EGFP mRNA expression was normalized to TBP as a housekeeping marker
[0475] **GFP DNA normalized to single-copy TfR DNA
[0476] ***N=1
[0477] Example 13. Multi-rodent testing (cross-species)
[0478] 333 capsid variants were tested for their efficacy in transducing the CNS in other rodent strains or species ( Figure 47 A side-by-side comparison of neuronal and astroglial transduction in C57BL / 6 mice, BALB / C mice, and rats revealed major differences in the enrichment scores of multiple variants between the two mouse strains, with even more pronounced differences between mice and rats ( Figures 48A-48C Strikingly, the most efficient rat brain-transducing capsid was the parental AAV9, suggesting that directed evolution is “stuck” in capsid variants that excel in a given species, distinct from the diversity of wild-type AAV capsids.
[0479] Correlation analysis showed that some capsids shared high CNS transduction between C57BL / 6 and BALB / C mice, whereas other capsids were restricted to one strain ( Figure 48B ).
[0480] Interestingly, PHP.B and PHP.eB capsids showed poor brain transduction in BALB / C mice, which is consistent with a recent publication (Hordeaux et al., 2018). When focusing on capsids that showed more than a 10-fold increase in brain transduction, only 62 variants improved in C57BL / 6 mice, 28 variants improved in BALB / C mice, and 30 variants showed improvement in brain transduction in both strains (Table 11). Consensus sequence analysis showed that the "C57BL / 6 signature" was very similar to the PHP.eB peptide (DGTxxxPFR (SEQ ID NO: 1185)), while the BALB / C signature showed a different consensus sequence (DGTxxxxGW (SEQ ID NO: 1183)), suggesting the use of different cellular receptors ( Figure 48C ).
[0481] Table 11. Top 30 candidates from C57BL / 6 and BALB / C mouse screening
[0482]
[0483]
[0484]
[0485]
[0486]
[0487] The efficacy of 333 capsid variants of C57BL / 6 mouse BMVEC and human BMVEC in transducing the CNS was also compared ( Figure 58A and Figure 58B ).
[0488] Example 14. Engineering of an NGS-driven full-length capsid variant selection system
[0489] Engineered barcoding systems to allow enrichment studies of full-length capsid modifications. Although the TRACER platform described here was originally developed for use with peptide display libraries, where random peptide sequences are inherently amenable to Illumina NGS analysis due to their short length, Illumina sequencing technology generally does not allow sequencing of more than 300 contiguous bases, and therefore our platform cannot be used for NGS analysis of full-length capsid variants, such as those generated by DNA shuffling techniques or error-prone PCR.
[0490] Another RNA-driven platform was designed for full-length capsid libraries, where unique molecular identifiers (UMIs) were placed outside the capsid gene and were available for NGS enrichment analysis ( Figures 59A-59C Once variants with desired properties are identified from animal tissues by UMI enrichment analysis, the UMI sequence must allow highly specific recovery of full-length capsids from the starting material with minimal error rates. This system should possess one or more of the following properties to be effective: 1) the UMI should be transcribed under the control of a cell-type-specific promoter; 2) the UMI should not interfere with capsid expression or splicing during viral production; 3) the UMI should be short enough for Illumina NGS sequencing (typically less than 60 nt for standard single-end 75 nt sequencing), and 4) the UMI should allow sequence-specific recovery of the desired full-length capsid from the starting DNA / viral library with minimal error rates.
[0491] To address these peculiarities: 1) the UMIs were placed in the transcribed region of the capsid library (i.e., anywhere between the transcription start site and the polyadenylation signal), 2) the UMIs were placed at various positions within AAV introns (which are largely unspliced in the absence of helper functions) or between the capsid stop codon and the polyadenylation signal, 3) the UMI cassette consisted of two random 21-nt sequences separated by a 15-nt spacer, for a total length of 57 nt, which provided 18 additional nucleotides for primer annealing, and 4) the UMI random sequence was formed from NSW trimers (N = A, T, G, C; S = G, C; W = A, T) to prevent large changes in the annealing temperature of the amplification primers, avoid homopolymer segments, and prevent the formation of premature polyA signals (AATAAA).
[0492] Importantly, the UMI box contains two random sequences in series. The first sequence (outermost) is used to design matching capsid recovery primers, and the second sequence (innermost) is used to confirm the identity of the capsid amplicons after cloning. This method should allow the elimination of all clones containing nonspecific amplification products. In another embodiment, the innermost sequence can also be used to design nested PCR primers to increase the specificity of amplification ( Figures 59A-59C ).
[0493] Several insertion sites for the tandem barcodes were explored to test the effects on viral viability and titer. A series of constructs ( Figure 60A Since AAV introns are spliced during viral production, the presence of the barcode should have little effect on yield. In contrast, in the absence of helper functions, AAV splicing is very inefficient (Mouw et al., 2000), so the barcode sequence will be retained in RNA recovered from animal tissues. All intron barcode constructs were tested for their ability to produce high-titer AAV progeny by co-transfection with pHelper and pREP3stop plasmids. All constructs allowed high-titer AAV production, ranging from 50% to 80% of non-barcoded CAG9 virus ( Figure 60B ).
[0494] RNA splicing analysis from transfected cells showed that the rate of AAV intron splicing varied slightly between constructs and was more efficient when the intron barcode was inserted after a conserved insertion sequence downstream of the splice donor ( Figure 60C , above).
[0495] Globin intron splicing was 100% efficient under all conditions tested ( Figure 60C , lower panel). As expected, AAV intron splicing was barely detectable in the absence of helper functions.
[0496] An alternative platform was tested in which the tandem barcodes were placed between the capsid stop codon and the polyadenylation signal ( Figure 59B ). The titers generated by the 3' barcoded construct were the same as those of the non-barcoded CAG9 construct.
[0497] Overall, external barcoding of full-length capsids enables efficient AAV production, while the novel tandem barcoding platform allows high-confidence NGS-driven sequence-specific recovery from library preparations.
[0498] Table 12 Sequence
[0499]
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527] Citations
[0528] Berns KI,Giraud C.Biology of adeno-associated virus.Curr TopMicrobiol Immunol.1996;218:1-23.
[0529] Chan KY,Jang MJ,Yoo BB,Greenbaum A,Ravi N,Wu WL,Sánchez-Guardado L,Lois C,Mazmanian SK,Deverman BE,Gradinaru V.Engineered AAVs for efficientnoninvasive gene delivery to the central and peripheral nervous systems.NatNeurosci.2017Aug;20(8):1172-1179.
[0530] Heinrich J,Schultz J,Bosse M,Ziegelin G,Lanka E,Moelling K.Linearclosed mini DNA generated by the prokaryotic cleaving-joining enzyme TelN isfunctional in mammalian cells.J Mol Med(Berl).2002Oct;80(10):648-54.
[0531] Hordeaux J,Wang Q,Katz N,Buza EL,Bell P,Wilson JM.The NeurotropicProperties of AAV-PHP.B Are Limited to C57BL / 6J Mice.Mol Ther.2018Mar7;26(3):664-668.
[0532] Huovinen T,Brockmann EC,Akter S,Perez-Gamarra S, J,Liu Y, U.Primer extension mutagenesis powered by selective rollingcircle amplification.PLoS One.2012;7(2):e31817.
[0533] Huovinen T,Julin M,Sanmark H, U.Enhanced error-prone RCAmutagenesis by concatemer resolution.Plasmid.2011Oct;66(1):47-51.
[0534] Hutchison CA 3rd,Smith HO,Pfannkoch C,Venter JC.Cell-free cloningusing phi29 DNA polymerase.Proc Natl Acad Sci U S A.2005Nov29;102(48):17332-6.
[0535] Miyazaki J,Takaki S,Araki K,Tashiro F,Tominaga A,Takatsu K,YamamuraK.Expression vector system based on the chicken beta-actin promoter directsefficient production of interleukin-5.Gene.1989Jul 15;79(2):269-77.
[0536] Mouw MB,Pintel DJ.Adeno-associated virus RNAs appear in a temporalorder and their splicing is stimulated during coinfection with adenovirus.JVirol.2000 Nov;74(21):9878-88.
[0537] Niwa H,Yamamura K,Miyazaki J.Efficient selection for high-expressiontransfectants with a novel eukaryotic vector.Gene.1991 Dec 15;108(2):193-9.
[0538] Nonnenmacher M,van Bakel H,Hajjar RJ,Weber T.High capsid-genomecorrelation facilitates creation of AAV libraries for directedevolution.Mol Ther.2015 Apr;23(4):675-82.
[0539] Picher Budeus B,Wafzig O,Krüger C,García-Gómez S,Martínez-JiménezMI,Díaz-Talavera A,Weber D,Blanco L,Schneider A.TruePrime is a novel methodfor whole-genome amplification from single cellsbased on TthPrimPol.NatCommun.2016 Nov 29;7:13296.
[0540] Powell SK,Rivera-Soto R,Gray SJ.Viral expression cassette elementstoenhance transgene target specificity and expression in gene therapy.DiscovMed.2015 Jan;19(102):49-57.
[0541] Rybchin VN,Svarchevsky AN.The plasmid prophage N15:a linear DNAwithcovalently closed ends.Mol Microbiol.1999 Sep;33(5):895-903.
[0542] Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer andyield. Gene Ther. 1999 Jun; 6(6):973-85. Sequence Listing <110> VOYAGER THERAPEUTICS, INC. <120> Redirecting the tropism of AAV capsids <130> 2057.1060PCT <140> PCT / US2019 / XXXXXX <141> 2019-10-02 <150> 62 / 839,883 <151> 2019-04-29 <150> 62 / 740,310 <151> 2018-10-02 <160> 1185 <170> PatentIn version 3.5 <210> 1 <211> 2211 <212> DNA <213> Unknown <220> <221> source <223> / remarks="Unknown description: Adeno-associated virus, human clone 9" <400> 1 atggctgccg atggttatct tccagattgg ctcgaggaca accttagtga aggaattcgc 60 gagtggtggg ctttgaaacc tggagcccct caacccaagg caaatcaaca acatcaagac 120 aacgctcgag gtcttgtgct tccgggttac aaataccttg gacccggcaa cggactcgac 180 aaggggagc cggtcaacgc agcagacgcg gcggccctcg agcacgacaa ggcctacgac 240 cagcagctca aggccggaga caacccgtac ctcaagtaca accacgccga cgccgagttc 300 caggagcggc tcaaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 360 gccaaaaaga ggcttcttga acctcttggt ctggttgagg aagcggctaa gacggctcct 420 ggaaagaaga ggcctgtaga gcagtctcct caggaaccgg actctcccgc gggtattggc 480 aaatcgggtg cacagcccgc taaaaagaga ctcaatttcg gtcagactgg cgacacagag 540 tcagtcccag accctcaacc aatcggagaa cctcccgcag ccccctcagg tgtgggatct 600 cttacaatgg cttcaggtgg tggcgcacca gtggcagaca ataacgaagg tgccgatgga 660 gtgggtagtt cctcgggaaa ttggcattgc gattcccaat ggctggggga cagagtcatc 720 accaccagca cccgaacctg ggccctgccc acctacaaca atcacctcta caagcaaatc 780 tccaacagca catctggagg atcttcaaat gacaacgcct acttcggcta cagcacccc 840 tgggggtatt ttgacttcaa cagattccac tgccacttct caccacgtga ctggcagcga 900 ctcatcaaca acaactgggg attccggcct aagcgactca acttcaagct cttcaacatt 960 caggtcaaag aggttacgga caacaatgga gtcaagacca tcgccaataa ccttaccagc 1020 acggtccagg tcttcacgga ctcagactat cagctcccgt acgtgctcgg gtcggctcac 1080 gagggctgcc tcccgccgtt cccagcggac gttttcatga ttcctcagta cgggtatctg 1140 acgcttaatg atggaagcca ggccgtgggt cgttcgtcct tttactgcct ggaatatttc 1200 ccgtcgcaaa tgctaagaac gggtaacaac ttccagttca gctacgagtt tgagaacgta 1260 cctttccata gcagctacgc tcacagccaa agcctggacc gactaatgaa tccactcatc 1320 gaccaatact tgtactatct ctcaaagact attaacggtt ctggacagaa tcaacaaacg 1380 ctaaaattca gtgtggccgg acccagcaac atggctgtcc agggaagaaa ctacatacct 1440 ggacccagct accgacaaca acgtgtctca accactgtga ctcaaaacaa caacagcgaa 1500 tttgcttggc ctggagcttc ttcttgggct ctcaatggac gtaatagctt gatgaatcct 1560 ggacctgcta tggccagcca caaagga gaggaccgtt tctttcttt gtctggatct 1620 ttaattttg gcaaaagg aactggaga vakaacgtgg atgcggacaa agtcatgata 1680 accaacgaag aagaattta acactaac ccggtagcaa cggagtccta tggacaagtg 1740 gccacaaacc accagagtgc ccaagcacag gcgcagaccg gctgggttca aaaccaagga 1800 atactccgg gtatggttg gcaggacaga gatgtgtacc tgcaggacc cattttggggcc 1860 aaaattccctc acacggacgg caacttcac ccttctccgc tgatgggagg gtttggaatg 1920 aagcacccgc cctcagatcagat aacacaccctg tacctgcgga tcccaacg 1980 gccttcaca aggacaagct gaacctttc atcaccagt attctactgg ccaagtcagc 2040 gtggagatcg agtgggagct gcagaaggaaacagcaagc gctggaaccc ggagatccag 2100 tacacttcca actattacaa gtctaataat gttgaatttg ctgttaatac tgaaggtgta 2160 tatagtgaac cccgccccat tgcaccaga tacctgactc gtaatctgta a 2211 <210> 2 <211> 736 <212> PRT <213> Unknown <220> <221> Source <223> / Remark=“Unknown description: capsid of hu.14 / AAV9” <400> 2 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro 20 25 30 Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly 145 150 155 160 Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro 180 185 190 Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly 195 200 205 Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn 260 265 270 Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu 340 345 350 Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp 370 375 380 Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu 405 410 415 Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425 430 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser 435 440 445 Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser 450 455 460 Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro 465 470 475 480 Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn 485 490 495 Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn 500 505 510 Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys 515 520 525 Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly 530 535 540 Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile 545 550 555 560 Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser 565 570 575 Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln 580 585 590 Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln 595 600 605 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met 625 630 635 640 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655 Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr 660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 690 695 700 Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val 705 710 715 720 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 <210> 3 <211> 736 <212> PRT <213> Artificial Sequence <220> <221> source <223> / remarks=”Description of artificial sequence: synthetic AAV9 capsid sequence” <400> 3 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro 20 25 30 Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly 145 150 155 160 Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro 180 185 190 Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly 195 200 205 Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn 260 265 270 Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu 340 345 350 Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp 370 375 380 Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu 405 410 415 Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425 430 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser 435 440 445 Arg Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser 450 455 460 Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro 465 470 475 480 Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn 485 490 495 Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn 500 505 510 Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys 515 520 525 Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly 530 535 540 Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile 545 550 555 560 Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser 565 570 575 Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln 580 585 590 Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln 595 600 605 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met 625 630 635 640 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655 Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr 660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 690 695 700 Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val 705 710 715 720 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 <210> 4 <211> 2470 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 4 cgcagggtct ccattttgaa gcgggaggtt tgaacgcgca gccgccatgc cggggtttta 60 cgagattgtg attaaggtcc ccagcgacct tgacgagcat ctgcccggca tttctgacag 120 ctttgtgaac tgggtggccg agaaggaatg ggagttgccg ccagattctg acatggatct 180 gaatctgatt gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg actttctgac 240 ggaatggcgc cgtgtgagta aggccccgga ggctcttttc tttgtgcaat ttgagaaggg 300 agagagctac ttccacatgc acgtgctcgt ggaaaccacc ggggtgaaat ccatggtttt 360 gggacgtttc ctgagtcaga ttcgcgaaaa actgattcag agaatttacc gcgggatcga 420 gccgactttg ccaaactggt tcgcggtcac aaagaccaga aatggcgccg gaggcgggaa 480 caaggtggtg gatgagtgct acatccccaa ttacttgctc cccaaaaccc agcctgagct 540 ccagtgggcg tggactaata tggaacagta tttaagcgcc tgtttgaatc tcacggagcg 600 taaacggttg gtggcgcagc atctgacgca cgtgtcgcag acgcaggagc agaacaaaga 660 gaatcagaat cccaattctg atgcgccggt gatcagatca aaaacttcag ccaggtacat 720 ggagctggtc gggtggctcg tggacaaggg gattacctcg gagaagcagt ggatccagga 780 ggaccaggcc tcatacatct ccttcaatgc ggcctccaac tcgcggtccc aaatcaaggc 840 tgccttggac aatgcgggaa agattatgag cctgactaaa accgcccccg actacctggt 900 gggccagcag cccgtggagg acatttccag caatcggatt tataaaattt tggaactaaa 960 cgggtacgat ccccaatatg cggcttccgt ctttctggga tgggccacga aaaagttcgg 1020 caagagaac accatctggc tgtttgggcc tgcaactacc gggaagacca acatcgcgga 1080 ggccatagcc cacactgtgc ccttctacgg gtgcgtaaac tggaccaatg agaactttcc 1140 cttcaacgac tgtgtcgaca agatggtgat ctggtgggag gaggggaaga tgaccgccaa 1200 ggtcgtggag tcggccaaag ccattctcgg aggaagcaag gtgcgcgtgg accagaaatg 1260 caagtcctcg gcccagatag acccgactcc cgtgatcgtc acctccaaca ccaacatgtg 1320 cgccgtgatt gacgggaact caacgacctt cgaacaccag cagccgttgc aagaccggat 1380 gttcaaattt gaactcaccc gccgtctgga tcatgacttt gggaaggtca ccaagcagga 1440 agtcaaagac tttttccggt gggcaaagga tcacgtggtt gaggtggagc atgaattcta 1500 cgtcaaaaag ggtggagcca agaaaagacc cgcccccagt gacgcagata taagtgagcc 1560 caaacgggtg cgcgagtcag ttgcgcagcc atcgacgtca gacgcggaag cttcgatcaa 1620 ctacgcagac aggtaccaaa acaaatgttc tcgtcacgtg ggcatgaatc tgatgctgtt 1680 tccctgcaga caatgcgaga gaatgaatca gaattcaaat atctgcttca ctcacggaca 1740 gaaagactgt ttagagtgct ttcccgtgtc agaatctcaa cccgtttctg tcgtcaaaaa 1800 ggcgtatcag aaactgtgct acattcatca tatcatggga aaggtgccag acgcttgcac 1860 tgcctgcgat ctggtcaatg tggatttgga tgactgcatc tttgaacaat aaatgattta 1920 aatcaggtat ggctgccgat ggttatcttc cagattggct cgaggacact ctctctgaag 1980 gaataagaca gtggtggaag ctcaaacctg gcccaccacc accaaagccc gcagagcggc 2040 ataaggacga cagcaggggt cttgtgcttc ctgggtacaa gtacctcgga cccttcaacg 2100 gactcgacaa gggagagccg gtcaacgagg cagacgccgc ggccctcgag cacgacaaag 2160 cctacgaccg gcagctcgac agcggagaca acccgtacct caagtacaac cacgccgacg 2220 cggagtttca ggagcgcctt aaagaagata cgtcttttgg gggcaacctc ggacgagcag 2280 tcttccaggc gaaaaagagg gttcttgaac ctctgggcct ggtccaccat accttcgatt 2340 atccgatttg cttgttaatc aataaaccgt ttaattcgtt tcagttgaac tttggtctct 2400 gcgtatttct ttcttatcta gtttccatgc tctagagcgg ccgccaccgc ggtggagctc 2460 cagcttttgt 2470 <210> 5 <211> 3681 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: Synthetic polynucleotide" <400> 5 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc gtttaaaccg 180 cgtcgttaca taacttacgg taaatggccc gcctggctga ccgcccaacg acccccgccc 240 attgacgtca ataatgacgt atgttcccat agtaacgcca atagggactt tccattgacg 300 tcaatgggtg gagtatttac ggtaaactgc ccacttggca gtacatcaag tgtatcatat 360 gccaagtacg ccccctattg acgtcaatga cggtaaatgg cccgcctggc attatgccca 420 gtacatgacc ttatgggact ttcctacttg gcagtacatc tacgtattag tcatcgctat 480 taccatggtg atgcggtttt ggcagtacat caatgggcgt ggatagcggt ttgactcacg 540 gggatttcca agtctccacc ccattgacgt caatgggagt ttgttttggc accaaaatca 600 acgggacttt ccaaaatgtc gtaacaactc cgccccattg acgcaaatgg gcggtaggcg 660 tgtacggtgg gaggtctata taagcagagc tcgggagcgg tcaccaagca ggaagtcaaa 720 gactttttcc ggtgggcaaa ggatcacgtg gttgaggtgg agcatgaatt ctacgtcaaa 780 aagggtggag ccaagaaaag acccgccccc agtgacgcag atataagtga gcccaaacgg 840 gtgcgcgagt cagttgcgca gccatcgacg tcagacgcgg aagcttcgat caactacgcg 900 gacaggtacc aaaacaaatg ttctcgtcac gtgggcatga atctgatgct gtttccctgc 960 agacaatgcg agagactgaa tcagaattca aatatctgct tcactcacgg tgtcaaagac 1020 tgtttagagt gctttcccgt gtcagaatct caacccgttt ctgtcgtcaa aaaggcgtat 1080 cagaaactgt gctacattca tcacatcatg ggaaaggtgc cagacgcttg cactgcttgc 1140 gacctggtca atgtggactt ggatgactgt gtttctgaac ataaatgac ttaaaccagg 1200 tatggctgcc gatggttatc ttccagattg gctcgaggac aaccttagtg aaaggaattcg 1260 1320 caacgctcga ggtcttgtgc ttccgggtta caaatacctt ggacccggca acggactcga 1380 caagggggag ccggtcaacg cagcagacgc ggcggccctc gagcacgaca aggcctacga 1440 ccagcagctc aaggccggag aaacccgta cctcaagtac aaccacgccg acgccgagtt 1500 ccaggagcgg ctcaaagaag atacgtcttt tggggcaac ctcgggcgag cagtcttcca 1560 ggccaaaaag aggcttcttg aacctcttgg tctggttgag gaagcggcta agacggctcc 1620 tggaaag aggcctgtag agcagtctcc tcaggaaccg gactcctccg cgggtattgg 1680 caaatcgggt gcacagcccg ctaaaaaagag actcaatttc ggtcagactg gcgacacaga 1740 gtcagtccca gaccctcaac caatcggaga acctcccgca gccccctcag gtgtgggatc 1800 tcttacaatg gcttcaggtg gtggcgcacc agtggcagac aataacgaag gtgccgatgg 1860 agtgggtagt tcctcgggaa attggcattg cgattcccaa tggctggggg acagagtcat 1920 caccaccagc acccgaacct gggccctgcc cacctacaac aatcacctct acaagcaaat 1980 ctccaacagc acatctggag gatcttcaaa tgacaacgcc tacttcggct acagcacccc 2040 ctgggggtat tttgacttca acagattcca ctgccacttc tcaccacgtg actggcagcg 2100 actcatcaac aacaactggg gattccggcc taagcgactc aacttcaagc tcttcaacat 2160 tcaggtcaaa gaggttacgg acaacaatgg agtcaagacc atcgccaata accttaccag 2220 cacggtccag gtcttcacgg actcagacta tcagctcccg tacgtgctcg ggtcggctca 2280 cgagggctgc ctcccgccgt tcccagcgga cgttttcatg attcctcagt acgggtatct 2340 gacgcttaat gatggaagcc aggccgtggg tcgttcgtcc ttttactgcc tggaatattt 2400 cccgtcgcaa atgctaagaa cgggtaacaa cttccagttc agctacgagt ttgagaacgt 2460 acctttccat agcagctacg ctcacagcca aagcctggac cgactaatga atccactcat 2520 cgaccaatac ttgtactatc tctcaagac tattaacggt tctggacaga atcacaac 2580 gctaaaatttc agtgtggccg gacccagca catggctgtc cagggaagaa actacatacc 2640 tggacccagc taccgacaac aacgtgtctc aaccactgtg acccaaaca acaacagcga 2700 atttgcttgg cctggagctt cttcttgggc tctcaatgga cgtaatagct tgatgaatcc 2760 tggacctgct atggccagcc aaagaagg agaggaccgt ttctctt tgtctggatc 2820 tttaatttt ggcaacaag gaacggaag agacaacgtg gatgcgaca aagtcatgat 2880 aaccaacgaa gagaaatta aaactacta cccggtagca acggagctcct atggacaagt 2940 ggccacaac caccagagtg cccaagcaca ggcgcagacc ggctgggttc aaaaccaagg 3000 atacttccg ggtatggttt ggcaggacag agatgtgtac ctgcaggac ccatttgggc 3060 caaaatttcct cacacggacg gcaacttca cccttctccg ctgatgggag ggtttggaat 3120 gaagcacccg cctcctcaga tcctcatca aaacacacct gtacctgcgg atcctccac 3180 ggccttcaac aaggacaagc tgaactcttt catcacccag tattctactg gccaagtcag 3240 cgtggagatc gagtggggagc tgcagaagga aaacagcaag cgctggaacc cggagatcca 3300 gtacacttcc aactattaca agtctaataa tgttgaattt gctgttaata ctgaaggtgt 3360 atatagtgaa ccccgcccca ttggcaccag atacctgact cgtaatctgt aatcgattgt 3420 taatcaataa accgtttaat tcgtttcagt tgaactttgg tctctgcgta tttctttctt 3480 atctagtttc catggctacg tagataagta gcatggcggg ttaatcatta actacaagga 3540 acccctagtg atggagttgg ccactccctc tctgcgcgct cgctcgctca ctgaggccgg 3600 gcgaccaaag gtcgcccgac gcccgggctt tgcccgggcg gcctcagtga gcgagcgagc 3660 gcgcagagag ggagtggcca a 3681 <210> 6 <211> 3755 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 6 gtcgacggta tcgggggagc tcgcagggtc tccattttga agcgggggt ttgaacgcgc 60 agccgccatg ccggggtttt acgagattgt gattaaggtc cccagcgacc ttgacgagca 120 tctgcccggc atttctgaca gctttgtgaa ctgggtggcc gagaaggaat gggagttgcc 180 gccagattct gacatggatc tgaatctgat tgagcaggca cccctgaccg tggccgagaa 240 gctgcagcgc gactttctga cggaatggcg ccgtgtgagt aaggccccgg aggctctttt 300 ctttgtgcaa tttgagaagg gagagagcta cttccacatg cacgtgctcg tggaaaccac 360 cggggtgaaa tccatggttt tgggacgttt cctgagtcag attcgcgaaa aactgattca 420 gagaatttac cgcgggatcg agccgacttt gccaaactgg ttcgcggtca caaagaccag 480 aaatggcgcc ggaggcggga acaaggtggt ggatgagtgc tacatcccca attacttgct 540 ccccaaaacc cagcctgagc tccagtgggc gtggactaat atggaacagt atttaagcgc 600 ctgtttgaat ctcacggagc gtaaacggtt ggtggcgcag catctgacgc acgtgtcgca 660 gacgcaggag cagaacaaag agaatcagaa tcccaattct gatgcgccgg tgatcagatc 720 aaaaacttca gccaggtaca tggagctggt cgggtggctc gtggacaagg ggattacctc 780 ggagaagcag tggatccagg aggaccaggc ctcatacatc tccttcaatg cggcctccaa 840 ctcgcggtcc caaatcaagg ctgccttgga caatgcggga aagattatga gcctgactaa 900 aaccgccccc gactacctgg tgggccagca gcccgtggag gacatttcca gcaatcggat 960 ttataaaatt ttggaactaa acgggtacga tccccaatat gcggcttccg tctttctggg 1020 atgggccacg aaaaagttcg gcaagaggaa caccatctgg ctgtttgggc ctgcaactac 1080 cgggaagacc aacatcgcgg aggccatagc ccacactgtg cccttctacg ggtgcgtaaa 1140 ctggaccaat gagaactttc ccttcaacga ctgtgtcgac aagatggtga tctggtggga 1200 ggaggggaag atgaccgcca aggtcgtgga gtcggccaaa gccattctcg gaggaagcaa 1260 ggtgcgcgtg gaccagaaat gcaagtcctc ggcccagata gacccgactc ccgtgatcgt 1320 cacctccaac accaacatgt gcgccgtgat tgacgggaac tcaacgacct tcgaacacca 1380 gcagccgttg caagaccgga tgttcaaatt tgaactcacc cgccgtctgg atcatgactt 1440 tgggaaggtc accaagcagg aagtcaaaga ctttttccgg tgggcaaagg atcacgtggt 1500 tgaggtggag catgaattct acgtcaaaaa gggtggagcc aagaaaagac ccgcccccag 1560 tgacgcagat ataagtgagc ccaaacgggt gcgcgagtca gttgcgcagc catcgacgtc 1620 agacgcggaa gcttcgatca actacgcgga caggtaccaa aacaaatgtt ctcgtcacgt 1680 gggcatgaat ctgatgctgt ttccctgcag acaatgcgag agactgaatc agaattcaaa 1740 tatctgcttc actcacggtg tcaaagactg tttagagtgc tttcccgtgt cagaatctca 1800 acccgtttct gtcgtcaaaa aggcgtatca gaaactgtgc tacattcatc acatcatggg 1860 aaaggtgcca gacgcttgca ctgcttgcga cctggtcaat gtggacttgg atgactgtgt 1920 ttctgaacaa taaatgactt aaaccaggta tggctgccga tggttatctt ccagattggc 1980 tcgaggacaa ccttagtgaa ggaattcgcg agtggtgggc tttgaaacct ggagcccctc 2040 aacccaaggc aaatcaacaa catcaagaca acgctcgagg tcttgtgctt ccgggttaca 2100 aataccttgg acccggcaac ggactcgaca agggggagcc ggtcaacgca gcagacgcgg 2160 cggccctcga gcacgacaag gcctacgacc agcagctcaa ggccggagac aacccgtacc 2220 tcaagtacaa ccacgccgac gccgagttcc aggagcggct caaagaagat acgtcttttg 2280 ggggcaacct cgggcgagca gtttccagg ccaaaaaagag gcttcttgaa cctcttggtc 2340 tggttgagga agcggctaag acggctcctg gaaagaagag gcctgtagag cagtctcctc 2400 aggaaccgga ctcctccgcg ggtattggca aatcgggtgc acagcccgct aaaaagagac 2460 tcaatttcgg tcagactggc gacacagagt cagtcccaga ccctcaacca atcggagaac 2520 ctcccgcagc cccctcaggt gtgggatctc ttacaatggc ttcaggtggt ggcgcaccag 2580 tggcagacaa taacgaaggt gccgatggag tgggtagttc ctcgggaaat tggcattgcg 2640 attcccaatg gctggggac agagtcatca ccaccagcac ccgaacctgg gccctgccca 2700 cctacaacaa tcacctctac aagcaaatct ccaacagcac atctggagga tcttcaaatg 2760 acaacgccta cttcggctac agcaccccct gggggtattt tgacttcaac agattccact 2820 gccactttc accacgtgac tggcagcgac tcatcaacaa caactgggga ttccggccta 2880 agcgactcaa cttcaagctc ttcaacattc aggtcaaaga ggttacggac aacaatggag 2940 tcaagaccat cgccaataac cttaccagca cggtccaggt cttcacggac tcagactatc agctcccgta cgtgctcggg tcggctcacg agggctgcct cccgccgttc ccagcggacg 3060 ttttcatgat tcctcagtac gggtatctga cgcttaatga tggaagccag gccgtgggtc gttcgtcctt ttactgcctg gaatttcc cgtcgcaaat gctaagaacg ggtaacaact tccagttcag ctacgagttt gagaacgtac ctttccatag cagctacgct cacagccaaa gcctggaccg actatgat ccactcatcg accatactt gtactatctc tcaaagacta ttaacggttc tggacagaat caacaaacgc taaaattcag tgtggccgga cccagcaaca tggctgtcca gggaagaaac tacatacctg gacccagcta ccgacaacaa cgtgtctcaa 3480. ccctgtgac tcaaacaac aacagcgaat ttgcttggcc tggagcttct tcttgggctc tcaatggacg taatagcttg atgaatcctg gacctgctat ggccaagtca gcgtggagat cgagtgggag ctgcagaagg aaaacagcaa gcgctggaac ccggagatcc agtacacttc caactattac aagtctaata atgttgaatt tgctgttaat actgaaggtg fathertagtga accccgcccc attggcacca gatacctgac tcgtaatctg taattgcttg ttaatcaata 3720 aaccgtttaa ttcgtttcag ttgaactttg gtctc 3755 <210> 7 <211> 3755 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: synthetic polynucleotide" <400> 7 gtcgacggta tcgggggagc tcgcagggtc tccattttga agcgggaggt ttgaacgcgc 60 agccgccatg ccggggtttt acgagattgt gattaaggtc cccagcgacc ttgacgagca 120 tctgcccggc atttctgaca gctttgtgaa ctgggtggcc gagaaggaat gggagttgcc 180 gccagattct gacatggatc tgaatctgat tgagcaggca cccctgaccg tggccgagaa 240 gctgcagcgc gactttctga cggaatggcg ccgtgtgagt aaggccccgg aggctctttt 300 ctttgtgcaa tttgagaagg gagagagcta cttccacatg cacgtgctcg tggaaaccac 360 cggggtgaaa tccatggttt tgggacgttt cctgagtcag attcgcgaaa aactgattca 420 gagaatttac cgcgggatcg agccgacttt gccaaactgg ttcgcggtca caaagaccag 480 aaatggcgcc ggaggcggga acaaggtggt ggatgagtgc tacatcccca attacttgct 540 ccccaaaacc cagcctgagc tccagtgggc gtggactaat atggaacagt atttaagcgc 600 ctgtttgaat ctcacggagc gtaaacggtt ggtggcgcag catctgacgc acgtgtcgca 660 gacgcaggag cagaacaaag agaatcagaa tcccaattct gatgcgccgg tgatcagatc 720 aaaaacttca gccaggtaca tggagctggt cgggtggctc gtggacaagg ggattacctc 780 ggagaagcag tggatccagg aggaccaggc ctcatacatc tccttcaatg cggcctccaa 840 ctcgcggtcc caaatcaagg ctgccttgga caatgcggga aagattatga gcctgactaa 900 aaccgccccc gactacctgg tgggccagca gcccgtggag gacatttcca gcaatcggat 960 ttataaaatt ttggaactaa acgggtacga tccccaatat gcggcttccg tctttctggg 1020 atgggccacg aaaaagttcg gcaagaggaa caccatctgg ctgtttgggc ctgcaactac 1080 cgggaagacc aacatcgcgg aggccatagc ccacactgtg cccttctacg ggtgcgtaaa 1140 ctggaccaat gagaactttc ccttcaacga ctgtgtcgac aagatggtga tctggtggga 1200 ggaggggaag atgaccgcca aggtcgtgga gtcggccaaa gccattctcg gaggaagcaa 1260 ggtgcgcgtg gaccagaaat gcaagtcctc ggcccagata gacccgactc ccgtgatcgt 1320 cacctccaac accaacatgt gcgccgtgat tgacgggaac tcaacgacct tcgaacacca 1380 gcagccgttg caagaccgga tgttcaaatt tgaactcacc cgccgtctgg atcatgactt 1440 tgggaaggtc accaagcagg aagtcaaaga ctttttccgg tgggcaaagg atcacgtggt 1500 tgaggtggag catgaattct acgtcaaaaa gggtggagcc aagaaaagac ccgcccccag 1560 tgacgcagat ataagtgagc ccaaacgggt gcgcgagtca gttgcgcagc catcgacgtc 1620 agacgcggaa gcttcgatca actacgcgga caggtaccaa aacaaatgtt ctcgtcacgt 1680 gggcatgaat ctgatgctgt ttccctgcag acaatgcgag agactgaatc agaattcaaa 1740 tatctgcttc actcacggtg tcaaagactg tttagagtgc tttcccgtgt cagaatctca 1800 acccgtttct gtcgtcaaaa aggcgtatca gaaactgtgc tacattcatc acatcatggg 1860 aaaggtgcca gacgcttgca ctgcttgcga cctggtcaat gtggacttgg atgactgtgt 1920 ttctgaacaa taaatgactt aaaccaggta tggctgccga tggttagctt ccagattggc 1980 tcgaggacaa ccttagtgaa ggaattcgcg agtggtgggc tttgaaacct ggagcccctc 2040 aacccaaggc aaatcaacaa catcaagaca acgctcgagg tcttgtgctt ccgggttaca 2100 aataccttgg acccggcaac ggactcgaca aggggagcc ggtcaacgca gcagacgcgg 2160 cggccctcga gcacgacaag gcctacgacc agcagctcaa ggccggagac aacccgtacc 2220 tcaagtacaa ccacgccgac gccgagttcc aggagcggct caaagaagat acgtcttttg 2280 ggggcaacct cgggcgagca gtttccagg ccaaaaaagag gcttcttgaa cctcttggtc 2340 tggttgagga agcggctaag acggctcctg gaaagtagag gcctgtagag cagtctcctc 2400 aggaaccgga ctcctccgcg ggtattggca aatcgggtgc acagcccgct aaaaagagac 2460 tcaatttcgg tcagactggc gacacagagt cagtcccaga ccctcaacca atcggagaac 2520 ctcccgcagc cccctcaggt gtgggatctc ttacaatggc ttcaggtggt ggcgcaccag 2580 tggcagacaa taactaaggt gccgatggag tgggtagttc ctcgggaaat tggcattgcg 2640 attcccaatg gctgggggac agagtcatca ccaccagcac ccgaacctgg gccctgccca 2700 cctacaacaa tcacctctac aagcaaatct ccaacagcac atctggagga tcttcaaatg 2760 acaacgccta cttcggctac agcaccccct gggggtattt tgacttcaac agattccact 2820 gccacttctc accacgtgac tggcagcgac tcatcaacaa caactgggga ttccggccta 2880 agcgactcaa cttcaagctc ttcaacattc aggtcaaaga ggttacggac aacaatggag 2940 tcaagaccat cgccaataac cttaccagca cggtccaggt cttcacggac tcagactatc 3000 agctcccgta cgtgctcggg tcggctcacg agggctgcct cccgccgttc ccagcggacg 3060 ttttcatgat tcctcagtac gggtatctga cgcttaatga tggaagccag gccgtgggtc 3120 gttcgtcctt ttactgcctg gaatatttcc cgtcgcaaat gctaagaacg ggtaacaact 3180 tccagttcag ctacgagttt gagaacgtac ctttccatag cagctacgct cacagccaaa 3240 gcctggaccg actaatgaat ccactcatcg accaatactt gtactatctc tcaaagacta 3300 ttaacggttc tggacagaat caacaaacgc taaaattcag tgtggccgga cccagcaaca 3360 tggctgtcca gggaagaaac tacatacctg gacccagcta ccgacaacaa cgtgtctcaa 3420 ccactgtgac tcaaaacaac aacagcgaat ttgcttggcc tggagcttct tcttgggctc 3480 tcaatggacg taatagcttg atgaatcctg gacctgctat ggccaagtca gcgtggagat 3540 cgagtgggag ctgcagaagg aaaacagcaa gcgctggaac ccggagatcc agtacacttc 3600 caactattac aagtctaata atgttgaatt tgctgttaat actgaaggtg tatatagtga 3660 accccgcccc attggcacca gatacctgac tcgtaatctg taattgcttg ttaatcaata 3720 aaccgtttaa ttcgtttcag ttgaactttg gtctc 3755 <210> 8 <211> 3710 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 8 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc tagtatctgc 180 agagggccct gcgtatgagt gcaagtgggt tttaggacca ggatgaggcg gggtgggggt 240 gcctacctga cgaccgaccc cgacccactg gacaagcacc caacccccat tccccaaatt 300 gcgcatcccc tatcagagag ggggagggga aacaggatgc ggcgaggcgc gtgcgcactg 360 ccagcttcag caccgcggac agtgccttcg cccccgcctg gcggcgcgcg ccaccgccgc 420 ctcagcactg aaggcgcgct gacgtcactc gccggtcccc cgcaaactcc ccttcccggc 480 caccttggtc gcgtccgcgc cgccgccggc ccagccggac cgcaccacgc gaggcgcgag 540 ataggggggc acgggcgcga ccatctgcgc tgcggcgccg gcgactcagc gctgcctcag 600 tctgcggtgg gcagcggagg agtcgtgtcg tgcctgagag cgcagctgtg ctcctgggca 660 ccgcgcagtc cgcccccgcg gctcctggcc agaccacccc taggaccccc tgccccaagt 720 cgcagccggt caccaagcag gaagtcaaag actttttccg gtgggcaaag gatcacgtgg 780 ttgaggtgga gcatgaattc tacgtcaaaa agggtggagc caagaaaaga cccgccccca 840 gtgacgcaga tataagtgag cccaaacggg tgcgcgagtc agttgcgcag ccatcgacgt 900 cagacgcgga agcttcgatc aactacgcgg acaggtacca aaacaaatgt tctcgtcacg 960 tgggcatgaa tctgatgctg tttccctgca gacaatgcga gagactgaat cagaattcaa 1020 atatctgctt cactcacggt gtcaaagact gtttagagtg ctttcccgtg tcagaatctc 1080 aacccgtttc tgtcgtcaaa aaggcgtatc agaaactgtg ctacattcat cacatcatgg 1140 gaaaggtgcc agacgcttgc actgcttgcg acctggtcaa tgtggacttg gatgactgtg 1200 tttctgaaca ataaatgact taaaccaggt atggctgccg atggttatct tccagattgg 1260 ctcgaggaca accttagtga aggaattcgc gagtggtggg ctttgaaacc tggagcccct 1320 caacccaagg caaatcaaca acatcaagac aacgctcgag gtcttgtgct tccgggttac 1380 aaataccttg gacccggcaa cggactcgac aagggggagc cggtcaacgc agcagacgcg 1440 gcggccctcg agcacgacaa ggcctacgac cagcagctca aggccggaga caacccgtac 1500 ctcaagtaca accacgccga cgccgagttc caggagcggc tcaaagaaga tacgtctttt 1560 gggggcaacc tcgggcgagc agtcttccag gccaaaaaga ggcttcttga acctcttggt 1620 ctggttgagg aagcggctaa gacggctcct ggaaagaaga ggcctgtaga gcagtctcct 1680 caggaaccgg actcctccgc gggtattggc aaatcgggtg cacagcccgc taaaaagaga 1740 ctcaatttcg gtcagactgg cgacacagag tcagtcccag accctcaacc aatcggagaa 1800 cctcccgcag ccccctcagg tgtgggatct cttacaatgg cttcaggtgg tggcgcacca 1860 gtggcagaca ataacgaagg tgccgatgga gtgggtagtt cctcgggaaa ttggcattgc 1920 gattcccaat ggctggggga cagagtcatc accaccagca cccgaacctg ggccctgccc 1980 acctacaaca atcacctcta caagcaaatc tccaacagca catctggagg atcttcaaat 2040 gacaacgcct acttcggcta cagcacccc tggggtatt ttgacttcaa cagattccac 2100 tgccacttct caccacgtga ctggcagcga ctcatcaaca acaactgggg attccggcct 2160 aagcgactca acttcaagct cttcaacatt caggtcaaag aggttacgga caacaatgga 2220 gtcaagacca tcgccaataa ccttaccagc acggtccagg tcttcacgga ctcagactat 2280 cagctcccgt acgtgctcgg gtcggctcac gagggctgcc tcccgccgtt cccagcggac 2340 gttttcatga ttcctcagta cgggtatctg acgcttaatg atggaagcca ggccgtgggt 2400 cgttcgtcct tttactgcct ggaatatttc ccgtcgcaaa tgctaagaac gggtaacaac 2460 ttccagttca gctacgagtt tgagaacgta cctttccata gcagctacgc tcacagccaa 2520 agcctggacc gactaatgaa tccactcatc gaccaatact tgtactatct ctcaaagact 2580 attaacggtt ctggacagaa tcaacaaacg ctaaaattca gtgtggccgg acccagcaac 2640 atggctgtcc agggaagaaa ctacatacct ggacccagct accgacaaca acgtgtctca 2700 accactgtga ctcaaaacaa caacagcgaa tttgcttggc ctggagcttc ttcttgggct 2760 ctcaatggac gtaatagctt gatgaatcct ggacctgcta tggccagcca caaagaagga 2820 gaggaccgtt tctttccttt gtctggatct ttaatttttg gcaaacaagg aactggaaga 2880 gacaacgtgg atgcggacaa agtcatgata accaacgaag aagaaattaa aactactaac 2940 ccggtagcaa cggagtccta tggacaagtg gccacaaacc accagagtgc ccaagcacag 3000 gcgcagaccg gctgggttca aaaccaagga atacttccgg gtatggtttg gcaggacaga 3060 gatgtgtacc tgcaaggacc catttgggcc aaaattcctc acacggacgg caactttcac 3120 ccttctccgc tgatgggagg gtttggaatg aagcacccgc ctcctcagat cctcatcaaa 3180 aacacacctg tacctgcgga tcctccaacg gccttcaaca aggacaagct gaactctttc 3240 atcacccagt attctactgg ccaagtcagc gtggagatcg agtgggagct gcagaaggaa 3300 aacagcaagc gctggaaccc ggagatccag tacacttcca actattacaa gtctaataat 3360 gttgaatttg ctgttaatac tgaaggtgta tatagtgaac cccgccccat tggcaccaga 3420 tacctgactc gtaatctgta atcgattgtt aatcaataaa ccgtttaatt cgtttcagtt 3480 gaactttggt ctctgcgtat ttctttctta tctagtttcc atggctacgt agataagtag 3540 catggcgggt taatcattaa ctacaaggaa cccctagtga tggagttggc cactccctct 3600 ctgcgcgctc gctcgctcac tgaggccggg cgaccaaagg tcgcccgacg cccgggcttt 3660 gcccgggcgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa 3710 <210> 9 <211> 3852 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: synthetic polynucleotide" <400> 9 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc gatctaacat 180 atcctggtgt ggagtagcgg acgctgctat gacagaggct cgggggcctg agctggctct 240 gtgagctggg gaggaggcag acagccaggc cttgtctgca agcagacctg gcagcattgg 300 gctggccgcc ccccagggcc tcctcttcat gcccagtgaa tgactcacct tggcacagac 360 acaatgttcg gggtgggcac agtgcctgct tcccgccgca ccccagcccc cctcaaatgc 420 cttccgagaa gcccattgag cagggggctt gcattgcacc ccagcctgac agcctggcat 480 cttgggataa aagcagcaca gccccctagg ggctgccctt gctgtgtggc gccaccggcg 540 gtggagaaca aggcttatt cagcctgtgc ccaggaagg ggatcagggg atgcccaggc 600 atggacagtg ggtggcaggg ggggagagga gggctgtctg cttcccagaa gtccaaggac 660 acaaatgggt gaggggag ctctccccat agctggggctg cggcccaacc ccaccccctc 720 aggctatgcc agggggtgtt gccaggggca cccgggcatc gccagcttag cccactcctt 780 cataaagccc tcgcatccca ggagcgagca gagccagagc aggttggaga ggagacgcat 840 cacctccgct gctcgcgggg atcctctagg gtcaccaagc aggagtca agactttc 900 cggtgggcaa aggatcacgt ggttgaggtg gagcatgaat tctacgtcaa aaagggtgga 960 gccaagaaaa gacccgcccc cagtgacgca gatataagtg agcccaacg ggtgcgcgag 1020 tcagttgcgc agccatcgac gtcagacgcg gaagcttcga tcaaccgc ggacaggtac 1080 caaaacaaat gttctcgtca cgtgggcatg aatctgatgc tgtttccctg cagacaatgc 1140 gagagactga atcagaatttc aaataatctgc ttcactcacg gtgtcaaga ctgtttagag 1200 tgcttcccg tgtcagaatc tcaacccgtt tctgtcgtca aaaagcgta tcagaactg 1260 tgctacattc atcacatcat gggaaaggtg ccagacgctt gcactgcttg cgacctggtc 1320 aatgtggact tggatgactg tgtttctgaa caataaatga cttaaaccag gtatggctgc 1380 cgatggttat cttccagatt ggctcgagga caaccttagt gaaggaattc gcgagtggtg 1440 ggctttgaaa cctggagccc ctcaacccaa ggcaaatcaa caacatcaag acaacgctcg 1500 aggtcttgtg cttccgggtt acaaatacct tggacccggc aacggactcg acaaggggga 1560 gccggtcaac gcagcagacg cggcggccct cgagcacgac aaggcctacg accagcagct 1620 caaggccgga gacaacccgt acctcaagta caaccacgcc gacgccgagt tccaggagcg 1680 gctcaaagaa gatacgtctt ttgggggcaa cctcgggcga gcagtcttcc aggccaaaaa 1740 gaggcttctt gaacctcttg gtctggttga ggaagcggct aagacggctc ctggaaagaa 1800 gaggcctgta gagcagtctc ctcaggaacc ggactcctcc gcgggtattg gcaaatcggg 1860 tgcacagccc gctaaaaaga gactcaattt cggtcagact ggcgacacag agtcagtccc 1920 agaccctcaa ccaatcggag aacctcccgc agccccctca ggtgtgggat ctcttacaat 1980 ggcttcaggt ggtggcgcac cagtggcaga caataacgaa ggtgccgatg gagtgggtag 2040 ttcctcggga aattggcatt gcgattccca atggctgggg gacagagtca tcaccaccag 2100 cacccgaacc tgggccctgc ccacctacaa caatcacctc tacaagcaaa tctccaacag 2160 cacatctgga ggatcttcaa atgacaacgc ctacttcggc tacagcaccc cctgggggta 2220 ttttgacttc aacagattcc actgccactt ctcaccacgt gactggcagc gactcatcaa 2280 caacaactgg ggattccggc ctaagcgact caacttcaag ctcttcaaca ttcaggtcaa 2340 agaggttacg gacaacaatg gagtcaagac catcgccaat aaccttacca gcacggtcca 2400 ggtcttcacg gactcagact atcagctccc gtacgtgctc gggtcggctc acgagggctg 2460 cctcccgccg ttcccagcgg acgttttcat gattcctcag tacgggtatc tgacgcttaa 2520 tgatggaagc caggccgtgg gtcgttcgtc cttttactgc ctggaatatt tcccgtcgca 2580 aatgctaaga acgggtaaca acttccagtt cagctacgag tttgagaacg tacctttcca 2640 tagcagctac gctcacagcc aaagcctgga ccgactaatg aatccactca tcgaccaata 2700 cttgtactat ctctcaaaga ctattaacgg ttctggacag aatcaaaaa cgctaaatt 2760 cagtgtggcc ggacccagca acatggctgt ccagggaaga aactacatac ctggacccag 2820 ctaccgacaa caacgtgtct caaccactgt gactcaaaac aacaacagcg aatttgcttg 2880 gcctggagct tcttcttggg ctctcaatgg acgtaatagc ttgatgaatc ctggacctgc 2940 tatggccagc caaagaag gagaggccg tttctttcct ttgtctggat ctttaatttt 3000 tggcaaaca ggaactggaa gagacaacgt ggatgcggac aaagtcatga taaccaacga 3060 agaagaatt aaaactacta accccggtagc aacggagtcc tatggacaag tggccacaaa 3120 ccaccagagt gcccaagcac aggcgcagac cggctggggtt caaaaccaag gaatacttcc 3180 ggggtatggtt tggcaggaca gagatgtgta cctgcaagga cccatttggg ccaaaattcc 3240 tcacacggac ggcaactttc acccttctcc gctgatggga gggtttggaa tgaagcaccc 3300 gcctcctcag atcctcatca aaaacacacc tgtacctgcg gatcctccaa cggccttcaa 3360 caaggacaag ctgaactctt tcatcaccca gtattctact ggccaagtca gcgtggagat 3420 cgagtgggag ctgcagaagg aaaacagcaa gcgctggaac ccggagatcc agtacacttc 3480 caactattac aagtctaata atgttgaatt tgctgttaat actgaaggtg tatatagtga 3540 accccgcccc attggcacca gatacctgac tcgtaatctg taatcgattg ttaatcaata 3600 aaccgtttaa ttcgtttcag ttgaactttg gtctctgcgt atttctttct tatctagttt 3660 ccatggctac gtagataagt agcatggcgg gttaatcatt aactacaagg aacccctagt 3720 gatggagttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg ggcgaccaaa 3780 ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag cgcgcagaga 3840 gggagtggcc aa 3852 <210> 10 <211> 4425 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: Synthetic polynucleotide" <400> 10 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc catgcgtcga 180 cataacgcgt cgacattgat tattgactag ttattaatag yours cggggtcatt agttcatagc ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgcctgg ctgaccgccc aacgacccc gcccattgac gtcaataatg acgtatgttc ccatagtaac 360 gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt 420 ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta 540 catctacgta ttagtcatcg ctattaccat gtcgaggcca cgttctgctt cactctcccc 600 atctcccccc cctccccacc cccaattttg tatttttta ttttttaatt attttgtgca gcgatggggg cgggggggg gggcggcggcgc caggcggggc ggggcggggc gaggggcgggg 720 gcggggcgag gcggagaggt gcggcggcag ccaatcagag cggcgcgctc cgaaagtttc 780 cttttatggc gaggcggcgg cggcggcggc cctataaaaa gcgaagcgcg cggcgggcgg 840 gagcaagctt cgtttagtga accgtcagat cgcctggaga cgccatccac gctgttttga 900 cctccataga agacaccggg accgatccag cctccgcgga ttcgaatccc ggccgggaac 960 ggtgcattgg aacgcggatt ccccgtgcca agagtgacgt aagtaccgcc tatagagtct 1020 ataggcccac aaaaaatgct ttcttcttt aatacttt tttgtttatc ttatttctaa 1080 tactttccct aatctctttc tttcagggca ataatgatac aatgtatcat gcctctttgc 1140 accattctaa agaataacag tgataatttc tgggttaagg caatagcaat atttctgcat 1200 ataaatattt ctgcatataa attgtaactg atgtaagagg tttcatattg ctaatagcag 1260 ctacaatcca gctaccattc tgcttttatt ttatggttgg gataaggctg gattattctg 1320 agtccaagct aggcccttt gctaatcatg ttcatacctc ttatcttcct cccacagctc 1380 ctgggcaacg tgctggtctg tgtgctggcc catcactttg gcaaagaatt gggattcgaa 1440 ccggtcacca agcaggaagt caaagacttt ttccggtggg caaaggatca cgtggttgag 1500 gtggagcatg aattctacgt caaaaagggt ggagccaaga aaagacccgc ccccagtgac 1560 gcagatataa gtgagcccaa acgggtgcgc gagtcagttg cgcagccatc gacgtcagac 1620 gcggaagctt cgatcaacta cgcggacagg taccaaaaca aatgttctcg tcacgtgggc 1680 atgaatctga tgctgtttcc ctgcagacaa tgcgagagac tgaatcagaa ttcaaatatc 1740 tgcttcactc acggtgtcaa agactgttta gagtgctttc ccgtgtcaga atctcaaccc 1800 gtttctgtcg tcaaaaaggc gtatcagaaa ctgtgctaca ttcatcacat catgggaaag 1860 gtgccagacg cttgcactgc ttgcgacctg gtcaatgtgg acttggatga ctgtgtttct 1920 gaacaataaa tgacttaaac caggtatggc tgccgatggt tatcttccag attggctcga 1980 ggacaacctt agtgaaggaa ttcgcgagtg gtgggctttg aaacctggag cccctcaacc 2040 caaggcaaat caacaacatc aagacaacgc tcgaggtctt gtgcttccgg gttacaaata 2100 ccttggaccc ggcaacggac tcgacaaggg ggagccggtc aacgcagcag acgcggcggc 2160 cctcgagcac gacaaggcct acgaccagca gctcaaggcc ggagacaacc cgtacctcaa 2220 gtacaaccac gccgacgccg agttccagga gcggctcaaa gaagatacgt cttttggggg 2280 caacctcggg cgagcagtct tccaggccaa aaagaggctt cttgaacctc ttggtctggt 2340 tgaggaagcg gctaagacgg ctcctggaaa gaagaggcct gtagagcagt ctcctcagga 2400 accggactcc tccgcgggta ttggcaaatc gggtgcacag cccgctaaaa agagactcaa 2460 tttcggtcag actggcgaca cagagtcagt cccagaccct caaccaatcg gagaacctcc 2520 cgcagccccc tcaggtgtgg gatctcttac aatggcttca ggtggtggcg caccagtggc 2580 agacaataac gaaggtgccg atggagtggg tagttcctcg ggaaattggc attgcgattc 2640 ccaatggctg ggggacagag tcatcaccac cagcacccga acctgggccc tgcccaccta 2700 caacaatcac ctctacaagc aaatctccaa cagcacatct ggaggatctt caaatgacaa 2760 cgcctacttc ggctacagca ccccctgggg gtattttgac ttcaacagat tccactgcca 2820 cttctcacca cgtgactggc agcgactcat caacaacaac tggggattcc ggcctaagcg 2880 actcaacttc aagctcttca acattcaggt caaagaggtt acggacaaca atggagtcaa 2940 gaccatcgcc aataacctta ccagcacggt ccaggtcttc acggactcag actatcagct 3000 cccgtacgtg ctcgggtcgg ctcacgaggg ctgcctcccg ccgttcccag cggacgtttt 3060 catgattcct footcgggt atctgacgct taatgatgga agccaggccg tgggtcgttc 3120 gtccttttac tgcctggaat atttcccgtc gcaaatgcta agaacgggta aaacttcca 3180 gttcagctac gagtttgaga acgtaccttt ccatagcagc tacgctcaca gccaaagcct 3240 ggaccgacta atgaatccac tcatcgacca atacttgtac tatctctcaa agactattaa 3300 cggttctgga cagaatcaac aaacgctaaa attcagtgtg gccggaccca gcaacatggc 3360 tgtccaggga agaaactaca tacctggacc cagctaccga caacaacgtg tctcaaccac 3420 tgtgactcaa aacaacaaca gcgaatttgc ttggcctgga gcttcttctt gggctctcaa 3480 tggacgtaat agcttgatga atcctggacc tgctatggcc agccacaaag agaagga 3540 ccgtttcttt cctttgtctg gatctttaat ttttggcaaa caaggaactg gaagacaa 3600 cgtggatgcg gacaaagtca tgataaccaa cgaagaagaa attaaaacta ctaacccggt 3660 agcaacggag tcctatggac aagtggccac aaaccaccag agtgcccaag cacaggcgca 3720 gaccggctgg gttcaaaacc aaaggaatact tccgggtatg gtttggcagg acagagatgt 3780 gtacctgcaa ggacccattt gggccaaaat tcctcacacg gacggcaact ttcacccttc 3840 tccgctgatg ggagggtttg gaatgaagca cccgctcct cagatcctca tcaaaaacac 3900 acctgtacct gcggatcctc caacggcctt caaaggac aagctgaact ctttcatcac 3960 ccagtattct actggccaag tcagcgtgga gatcgagtgg gagctgcaga aggaaaacag 4020 caaccgctgg aacccggaga tccagtacac ttccaactat tacaagtcta ataatgttga 4080 atttgctgtt aatactgaag gtgtatatag tgaaccccgc cccattggca ccagatacct 4140 gactcgtaat ctgtaatcga ttgttaatca ataaaccgtt taattcgttt cagttgaact 4200 ttggtctctg cgtatttctt tcttatctag tttccatggc tacgtagata agtagcatgg 4260 cgggttaatc attaactaca aggaacccct agtgatggag ttggccactc cctctctgcg 4320 cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc cgacgccccgg gctttgcccg 4380 ggcggcctca gtgagcgagc gagcgcgcag agagggagtg gccaa 4425 <210> 11 <211> 4480 <212> DNA <213> Artificial Sequence <220> <221> source <223> / remark="Description of artificial sequence: synthetic polynucleotide" <400> 11 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc catgcgtcga 180 cataacgcgt gatctaacat atcctggtgt ggagtagcgg acgctgctat gacagaggct 240 cgggggcctg agctggctct gtgagctggg gaggaggcag acagccaggc cttgtctgca 300 agcagacctg gcagcattgg gctggccgcc ccccagggcc tcctcttcat gcccagtgaa 360 tgactcacct tggcacagac acaatgttcg gggtgggcac agtgcctgct tcccgccgca 420 ccccagcccc cctcaaatgc cttccgagaa gcccattgag cagggggctt gcattgcacc 480 ccagcctgac agcctggcat cttgggataa aagcagcaca gccccctagg ggctgccctt 540 gctgtgtggc gccaccggcg gtggagaaca aggctctatt cagcctgtgc ccaggaaagg 600 ggatcagggg atgcccaggc atggacagtg ggtggcaggg ggggagagga gggctgtctg 660 cttcccagaa gtccaaggac acaaatgggt gaggggagag ctctccccat agctgggctg 720 cggcccaacc ccaccccctc aggctatgcc agggggtgtt gccaggggca cccgggcatc 780 gccagtctag cccactcctt cataaagccc tcgcatccca ggagcgagca gagccagagc 840 aggttggaga ggagacgcat cacctccgct gctcgcgggg atcctctaga agcttcgttt 900 agtgaaccgt cagatcgcct ggagacgcca tccacgctgt tttgacctcc atagaagaca 960 ccgggaccga tccagcctcc gcggattcga atcccggccg ggaacggtgc attggaacgc 1020 ggattccccg tgccaagagt gacgtaagta ccgcctatag agtctatagg cccacaaaaa 1080 atgctttctt cttttaatat acttttttgt ttatcttatt tctaatactt tccctaatct 1140 ctttctttca gggcaataat gatacaatgt atcatgcctc tttgcaccat tctaaagaat 1200 aacagtgata atttctgggt taaggcaata gcaatatttc tgcatataaa tatttctgca 1260 tataaattgt aactgatgta agaggtttca tattgctaat agcagctaca atccagctac 1320 cattctgctt ttattttatg gttgggataa ggctggatta ttctgagtcc aagctaggcc 1380 cttttgctaa tcatgttcat acctcttatc ttcctcccac agctcctggg caacgtgctg 1440 gtctgtgtgc tggcccatca ctttggcaaa gaattgggat tcgaaccggt cgccaccggt 1500 caccaagcag gaagtcaaag actttttccg gtgggcaaag gatcacgtgg ttgaggtgga 1560 gcatgaattc tacgtcaaaa agggtggagc caagaaaaga cccgccccca gtgacgcaga 1620 tataagtgag cccaaacggg tgcgcgagtc agttgcgcag ccatcgacgt cagacgcgga 1680 agcttcgatc aactacgcgg acaggtacca aaacaaatgt tctcgtcacg tgggcatgaa 1740 tctgatgctg tttccctgca gacaatgcga gagactgaat cagaattcaa atatctgctt 1800 cactcacggt gtcaaagact gtttagagtg ctttcccgtg tcagaatctc aacccgtttc 1860 tgtcgtcaaa aaggcgtatc agaaactgtg ctacattcat cacatcatgg gaaaggtgcc 1920 agacgcttgc actgcttgcg acctggtcaa tgtggacttg gatgactgtg tttctgaaca 1980 ataaatgact taaaccaggt atggctgccg atggttatct tccagattgg ctcgaggaca 2040 accttagtga aggaattcgc gagtggtggg ctttgaaacc tggagcccct caacccaagg 2100 caaatcaaca acatcaagac aacgctcgag gtcttgtgct tccgggttac aaataccttg 2160 gacccggcaa cggactcgac aaggggagc cggtcaacgc agcagacgcg gcggccctcg 2220 agcacgacaa ggcctacgac cagcagctca aggccggaga caacccgtac ctcaagtaca 2280 accacgccga cgccgagttc caggagcggc tcaaagaaga tacgtctttt gggggcaacc 2340 tcgggcgagc agtcttccag gccaaaaaga ggcttcttga acctcttggt ctggttgagg 2400 aagcggctaa gacggctcct ggaaagaaga ggcctgtaga gcagtctcct caggaaccgg 2460 actcctccgc gggtattggc aaatcgggtg cacagcccgc taaaaagaga ctcaatttcg 2520 gtcagactgg cgacacagag tcagtcccag accctcaacc aatcggagaa cctcccgcag 2580 ccccctcagg tgtgggatct cttacaatgg cttcaggtgg tggcgcacca gtggcagaca 2640 ataacgaagg tgccgatgga gtgggtagtt cctcgggaaa ttggcattgc gattcccaat 2700 ggctggggga cagagtcatc accaccagca cccgaacctg ggccctgccc acctacaaca 2760 atcacctcta caagcaaatc tccaacagca catctggagg atcttcaaat gacaacgcct 2820 acttcggcta cagcaccccc tgggggtatt ttgacttcaa cagattccac tgccacttct 2880 caccacgtga ctggcagcga ctcatcaaca acaactgggg attccggcct aagcgactca 2940 acttcaagct cttcaacatt caggtcaaag aggttacgga caacaatgga gtcaagacca 3000 tcgccaataa ccttaccagc acggtccagg tcttcacgga ctcagactat cagctcccgt 3060 acgtgctcgg gtcggctcac gagggctgcc tcccgccgtt cccagcggac gttttcatga 3120 ttcctcagta cgggtatctg acgcttaatg atggaagcca ggccgtgggt cgttcgtcct 3180 tttactgcct ggaatatttc ccgtcgcaaa tgctaagaac gggtaacaac ttccagttca 3240 gctacgagtt tgagaacgta cctttccata gcagctacgc tcacagccaa agcctggacc 3300 gactaatgaa tccactcatc gaccaatact tgtactatct ctcaaagact attaacggtt 3360 ctggacagaa tcaacaaacg ctaaaattca gtgtggccgg acccagcaac atggctgtcc 3420 agggaagaaa ctacatacct ggacccagct accgacaaca acgtgtctca accactgtga 3480 ctcaaaacaa caacagcgaa tttgcttggc ctggagcttc ttcttgggct ctcaatggac 3540 gtaatagctt gatgaatcct ggacctgcta tggccagcca caaagaagga gaggaccgtt 3600 tctttccttt gtctggatct ttaatttttg gcaaacaagg aactggaaga gacaacgtgg 3660 atgcggacaa agtcatgata accaacgaag aagaaattaa aactactaac ccggtagcaa 3720 cggagtccta tggacaagtg gccacaaacc accagagtgc ccaagcacag gcgcagaccg 3780 gctgggttca aaaccaagga atacttccgg gtatggtttg gcaggacaga gatgtgtacc 3840 tgcaaggacc catttgggcc aaaattcctc acacggacgg caactttcac ccttctccgc 3900 tgatgggagg gtttggaatg aagcacccgc ctcctcagat cctcatcaaa aacacacctg 3960 tacctgcgga tcctccaacg gccttcaaca aggacaagct gaactctttc atcacccagt 4020 attctactgg ccaagtcagc gtggagatcg agtgggagct gcagaaggaa aacagcaagc 4080 gctggaaccc ggagatccag tacacttcca actattacaa gtctaataat gttgaatttg 4140 ctgttaatac tgaaggtgta tatagtgaac cccgccccat tggcaccaga tacctgactc 4200 gtaatctgta atcgattgtt aatcaataaa ccgtttaatt cgtttcagtt gaactttggt 4260 ctctgcgtat ttctttctta tctagtttcc atggctacgt agataagtag catggcgggt 4320 taatcattaa ctacaaggaa cccctagtga tggagttggc cactccctct ctgcgcgctc 4380 gctcgctcac tgaggccggg cgaccaaagg tcgcccgacg cccgggcttt gcccgggcgg 4440 cctcagtgag cgagcgagcg cgcagagagg gagtggccaa 4480 <210> 12 <211> 4338 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: synthetic polynucleotide" <400> 12 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgatatc catgcgtcga 180 cataacgcgt tagtatctgc agagggccct gcgtatgagt gcaagtgggt tttaggacca 240 ggatgaggcg gggtgggggt gcctacctga cgaccgaccc cgacccactg gacaagcacc 300 caacccccat tccccaaatt gcgcatcccc tatcagagag ggggagggga aacaggatgc 360 ggcgaggcgc gtgcgcactg ccagcttcag caccgcggac agtgccttcg cccccgcctg 420 gcggcgcgcg ccaccgccgc ctcagcactg aaggcgcgct gacgtcactc gccggtcccc 480 cgcaaactcc ccttcccggc caccttggtc gcgtccgcgc cgccgccggc ccagccggac 540 cgcaccacgc gaggcgcgag ataggggggc acgggcgcga ccatctgcgc tgcggcgccg 600 gcgactcagc gctgcctcag tctgcggtgg gcagcggagg agtcgtgtcg tgcctgagag 660 cgcagctgtg ctcctgggca ccgcgcagtc cgcccccgcg gctcctggcc agaccacccc 720 taggaccccc tgccccaagt cgcagccaag cttcgtttag tgaaccgtca gatcgcctgg 780 agacgccatc cacgctgttt tgacctccat agaagacacc gggaccgatc cagcctccgc 840 ggattcgaat cccggccggg aacggtgcat tggaacgcgg attccccgtg ccaagagtga 900 cgtaagtacc gcctatagag tctataggcc cacaaaaaat gctttcttct tttaatatac 960 ttttttgttt atcttatttc taatactttc cctaatctct ttctttcagg gcaataatga 1020 tacaatgtat catgcctctt tgcaccattc taaagaataa cagtgataat ttctgggtta 1080 aggcaatagc aatatttctg catataaata tttctgcata taaattgtaa ctgatgtaag 1140 aggtttcata ttgctaatag cagctacaat ccagctacca ttctgctttt attttatggt 1200 tgggataagg ctggattatt ctgagtccaa gctaggccct tttgctaatc atgttcatac 1260 ctcttatctt cctcccacag ctcctgggca acgtgctggt ctgtgtgctg gcccatcact 1320 ttggcaaaga attgggattc gaaccggtcg ccaccggtca ccaagcagga agtcaaagac 1380 tttttccggt gggcaaagga tcacgtggtt gaggtggagc atgaattcta cgtcaaaaag 1440 ggtggagcca agaaaagacc cgcccccagt gacgcagata taagtgagcc caaacgggtg 1500 cgcgagtcag ttgcgcagcc atcgacgtca gacgcggaag cttcgatcaa ctacgcggac 1560 aggtaccaaa acaaatgttc tcgtcacgtg ggcatgaatc tgatgctgtt tccctgcaga 1620 caatgcgaga gactgaatca gaattcaaat atctgcttca ctcacggtgt caaagactgt 1680 ttagagtgct ttcccgtgtc agaatctcaa cccgtttctg tcgtcaaaaa ggcgtatcag 1740 aaactgtgct acattcatca catcatggga aaggtgccag acgcttgcac tgcttgcgac 1800 ctggtcaatg tggacttgga tgactgtgtt tctgaacaat aaatgactta aaccaggtat 1860 ggctgccgat ggttatcttc cagattggct cgaggacaac cttagtgaag gaattcgcga 1920 gtggtgggct ttgaaacctg gagcccctca acccaaggca aatcaacaac atcaagacaa 1980 cgctcgaggt cttgtgcttc cgggttacaa ataccttgga cccggcaacg gactcgacaa 2040 gggggagccg gtcaacgcag cagacgcggc ggccctcgag cacgacaagg cctacgacca 2100 gcagctcaag gccggagaca acccgtacct caagtacaac cacgccgacg ccgagttcca 2160 ggagcggctc aaagaagata cgtcttttgg gggcaacctc gggcgagcag tcttccaggc 2220 caaaaagagg cttcttgaac ctcttggtct ggttgaggaa gcggctaaga cggctcctgg 2280 aaagaagagg cctgtagagc agtctcctca ggaaccggac tcctccgcgg gtattggcaa 2340 atcgggtgca cagcccgcta aaaagagact caatttcggt cagactggcg acacagagtc 2400 agtcccagac cctcaaccaa tcggagaacc tcccgcagcc ccctcaggtg tgggatctct 2460 tacaatggct tcaggtggtg gcgcaccagt ggcagacaat aacgaaggtg ccgatggagt 2520 gggtagttcc tcgggaaatt ggcattgcga ttcccaatgg ctgggggaca gagtcatcac 2580 caccagcacc cgaacctggg ccctgcccac ctacaacaat cacctctaca agcaaatctc 2640 caacagcaca tctggaggat cttcaaatga caacgcctac ttcggctaca gcaccccctg 2700 ggggtatttt gacttcaaca gattccactg ccacttctca ccacgtgact ggcagcgact 2760 catcaacaac aactggggat tccggcctaa gcgactcaac ttcaagctct tcaacattca 2820 ggtcaaagag gttacggaca acaatggagt caagaccatc gccaataacc ttaccagcac 2880 ggtccaggtc ttcacggact cagactatca gctcccgtac gtgctcgggt cggctcacga 2940 gggctgcctc ccgccgttcc cagcggacgt tttcatgatt cctcagtacg ggtatctgac 3000 gcttaatgat ggaagccagg ccgtgggtcg ttcgtccttt tactgcctgg aatatttccc 3060 gtcgcaaatg ctaagaacgg gtaacaactt ccagttcagc tacgagtttg agaacgtacc 3120 tttccatagc agctacgctc acagccaaag cctggaccga ctaatgaatc cactcatcga 3180 ccaatacttg tactatctt caaagactat taacggttct ggacagaatc aaaacgct 3240 aaaattcagt gtggccggac ccagcaacat ggctgtccag ggaagaaact acatacctgg 3300 acccagctac cgacaacaac gtgtctcaac cactgtgact caaaacaaca acagcgaatt 3360 tgcttggcct ggagcttctt cttgggctct caatggacgt aatagcttga tgaatcctgg 3420 acctgctatg gccagccaca aagaaggaga ggaccgtttc tttcctttgt ctggatcttt 3480 aatttttggc aaacaaggaa ctggaagaga caacgtggat gcggacaaag tcatgataac 3540 caacgaagaa gaaattaaaa ctactaaccc ggtagcaacg gagtcctatg gacaagtggc 3600 cacaaaccac cagagtgccc aagcacaggc gcagaccggc tgggttcaaa accaaggaat 3660 acttccgggt atggtttggc aggacagaga tgtgtacctg caaggaccca tttgggccaa 3720 aattcctcac acggacggca actttcaccc ttctccgctg atgggagggt ttggaatgaa 3780 gcacccgcct cctcagatcc tcatcaaaaa cacacctgta cctgcggatc ctccaacggc 3840 cttcaacaag gacaagctga actctttcat cacccagtat tctactggcc aagtcagcgt 3900 ggagatcgag tgggagctgc agaaggaaaa cagcaagcgc tggaacccgg agatccagta 3960 cacttccaac tattacaagt ctaataatgt tgaatttgct gttaatactg aaggtgtata 4020 tagtgaaccc cgccccattg gcaccagata cctgactcgt aatctgtaat cgattgttaa 4080 tcaataaacc gtttaattcg tttcagttga actttggtct ctgcgtattt ctttcttatc 4140 tagtttccat ggctacgtag ataagtagca tggcgggtta atcattaact acaaggaacc 4200 cctagtgatg gagttggcca ctccctctct gcgcgctcgc tcgctcactg aggccgggcg 4260 accaaaggtc gcccgacgcc cgggctttgc ccgggcggcc tcagtgagcg agcgagcgcg 4320 cagagaggga gtggccaa 4338 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: synthetic oligonucleotide" <400> 13 gtgccaagag tgacctcctg 20 <210> 14 <211> 444 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 14 actgcccccg cgaccggcac gtacaacctc caggaaatcg tgcccggcag cgtgtggatg 60 gagagggacg tgtacctcca aggacccatc tgggccaaga tcccagagac gggggcgcac 120 tttcacccct ctccggctat gggcggattc ggactcaaac acccaccgcc catgatgctc 180 atcaagaaca cgcctgtgcc cggaaatatc accagcttct cggacgtgcc cgtcagcagc 240 ttcatcaccc agtacagcac cgggcaggtc accgtggaga tggagtggga gctcaagaag 300 gaaaactcca agaggtggaa cccagagatc cagtacacaa acaactacaa cgacccccag 360 tttgtggact ttgccccgga cagcaccggg gaatacagaa ccaccagacc tatcggaacc 420 cgatacctta cccgacccctttaa 444 <210> 15 <211> 440 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 15 accggagatg tgcatgttat gggagcctta cctggaatgg tgtggcaaga cagggacgtc 60 tacctgcagg gtcctatttg ggccaaaatt cctcacacgg atggacactt tcacccatct 120 cctctcatgg gcggctttgg acttaagcac ccgcctcctc agatcctcat caaaaacacg 180 cctgttcctg cgaatcctcc ggcagagttt tcggctacaa agtttgcttc attcatcacc 240 cagtattcca caggacaagt gagcgtggag attgaatggg agctgcagaa agaaaacagc 300 aaacgctgga atcccgaagt gcaatataca tctaactatg caaaatctgc caacgttgat 360 ttcactgtgg acaacaatgg actttatact gagcctcgcc ccattggcac ccgttacctc 420 acccgtcccc tgtaatcgat 440 <210> 16 <211> 447 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 16 acacaagcag ctaccgcaga tgtcaacaca caaggcgttc ttccaggcat ggtctggcag 60 gacagagatg tgtaccttca ggggcccatc tgggcaaaga ttccacacac ggacggacat 120 tttcacccct ctcccctcat gggtggattc ggacttaaac accctccgcc tcagatcctg 180 atcaagaaca cgcctgtacc tgcggaccct ccgaccacct tcaaccagtc aaagctgaac 240 tctttcatca cccagtattc tactggccaa gtcagcgtgg agatcgagtg ggagctgcag 300 aaggaaaaca gcaagcgctg gaaccccgag atccagtaca cctccaacta ctacaaatct 360 acaagtgtgg actttgctgt taatacagaa ggcgtgtact ctgaaccccg ccccattggc 420 acccgttacc tcacccgtaa tctgtaa 447 <210> 17 <211> 447 <212> DNA <213> Artificial Sequence <220> <221> source <223> / remark="Description of artificial sequence: synthetic polynucleotide" <400> 17 gcacaggcgc agaccggctg ggttcaaaac caaggaatac ttccgggtat ggtttggcag 60 gacagagatg tgtacctgca aggacccatt tgggccaaaa ttcctcacac ggacggcaac 120 tttcaccctt ctccgctgat gggagggttt ggaatgaagc acccgcctcc tcagatcctc 180 atcaaaaaca cacctgtacc tgccgatcct ccaacggcct tcaacaagga caagctgaac 240 tctttcatca cccagtattc tactggccaa gtcagcgtgg agatcgagtg ggagctgcag 300 aaggaaaaca gcaagcggtg gaacccggag atccagtaca cttccaacta ttacaagtct 360 aataatgttg aatttgctgt taatactgaa ggtgtatata gtgaaccccg ccccattggc 420 accagatacc tgactcgtaa tctgtaa 447 <210> 18 <211> 4314 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 18 tatcagcaca caatagtcca ttatacgcgc gtataatggg caattgtgtg ctgatacagc 60 tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt 120 tagctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt 180 ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga ttacgccaga 240 tttaattaag gccttaatta ggctagcttg gccactccct ctctgcgcgc tcgctcgctc 300 actgaggccg ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg 360 agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc ctggaggggt 420 ggagtcgtga cgatatccat gcgtcgacat aacgcgttag tatctgcaga gggccctgcg tatgagtgca agtgggtttt aggaccagga tgaggcgggg tgggggtgcc tacctgacga 540 ccgaccccga cccactggac aagcacccaa cccccattcc ccaaattgcg catcccctat 600 cagagagggg gaggggaac aggatgcggc gaggcgcgtg cgcactgcca gcttcagcac 660 cgcggacagt gccttcgccc ccgcctggcg gcgcgcgcca ccgccgcctc agcactgaag 720 gcgcgctgac gtcactcgcc ggtcccccgc aaactcccct tcccggccac cttggtcgcg 780 tccgcgccgc cgccggccca gccggaccgc accacgcgag gcgcgagata ggggggcacg 840 ggcgcgacca tctgcgctgc ggcgccggcg actcagcgct gcctcagtct gcggtgggca 900 gcggaggagt cgtgtcgtgc ctgagagcgc agctgtgctc ctgggcaccg cgcagtccgc 960 ccccgcggct cctggccaga cccccctag gaccccctgc cccaagtcgc agccaagctt cgtttagtga accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga 1080 agacaccggg accgatccag cctccgcgga ttcgaatccc ggccgggaac ggtgcattgg 1140 aacgcggatt ccccgtgcca agagtgacgt aagtaccgcc tatagagtct ataggcccac 1200 aaaaaatgct ttcttcttt aatacttt tttgtttatc ttatttctaa tactttccct 1260 aatctctttc tttcagggca ataatgatac aatgtatcat gcctctttgc accattctaa 1320 agaataacag tgataatttc tgggttaagg caatagcaat atttctgcat ataaatattt 1380 ctgcatataa attgtaactg atgtaagagg tttcatattg ctaatagcag ctacaatcca 1440 gctaccattc tgctttttatt ttatggttgg gataaggctg gattattctg agtccaagct 1500 aggcccttt gctaatcatg ttcatacctc ttatcttcct cccacagctc ctgggcaacg 1560 tgctggtctg tgtgctggcc catcactttg gcaaagaatt gggattcgaa cggtcgcca 1620 ccggtcacca agcaggaagt caaagacttt ttccggtggg caaaggatca cgtggttgag 1680 gtggagcatg aattctacgt caaaaagggt ggagccaaga aaagacccgc ccccagtgac 1740 gcagatataa gtgagcccaa acgggtgcgc gagtcagttg cgcagccatc gacgtcagac 1800 gcggaagctt cgatcaacta cgcggacagg taccaaaaca aatgttctcg tcacgtgggc 1860 atgaatctga tgctgtttcc ctgcagacaa tgcgagagac tgaatcagaa ttcaaatatc 1920 tgcttcactc acggtgtcaa agactgttta gagtgctttc ccgtgtcaga atctcaaccc 1980 gtttctgtcg tcaaaaaggc gtatcagaaa ctgtgctaca ttcatcacat catgggaaag 2040 gtgccagacg cttgcactgc ttgcgacctg gtcaatgtgg acttggatga ctgtgtttct 2100 gaacaataaa tgacttaaac caggtatggc tgccgatggt tatcttccag attggctcga 2160 ggacaacctt agtgaaggaa ttcgcgagtg gtgggctttg aaacctggag cccctcaacc 2220 caaggcaaat caacaacatc aagacaacgc tcgaggtctt gtgcttccgg gttacaaata 2280 ccttggaccc ggcaacggac tcgacaaggg ggagccggtc aacgcagcag acgcggcggc 2340 cctcgagcac gacaaggcct acgaccagca gctcaaggcc ggagacaacc cgtacctcaa 2400 gtacaaccac gccgacgccg agttccagga gcggctcaaa gaagatacgt cttttggggg 2460 caacctcggg cgagcagtct tccaggccaa aaagaggctt cttgaacctc ttggtctggt 2520 tgaggaagcg gctaagacgg ctcctggaaa gaagaggcct gtagagcagt ctcctcagga 2580 accggactcc tccgcgggta ttggcaaatc gggtgcacag cccgctaaaa agagactcaa 2640 tttcggtcag actggcgaca cagagtcagt cccagaccct caaccaatcg gagaacctcc 2700 cgcagccccc tcaggtgtgg gatctcttac aatggcttca ggtggtggcg caccagtggc 2760 agacaataac gaaggtgccg atggagtggg tagttcctcg ggaaattggc attgcgattc 2820 ccaatggctg ggggacagag tcatcaccac cagcacccga acctgggccc tgcccaccta 2880 caacaatcac ctctacaagc aaatctccaa cagcacatct ggaggatctt caaatgacaa 2940 cgcctacttc ggctacagca ccccctgggg gtattttgac ttcaacagat tccactgcca 3000 cttctcacca cgtgactggc agcgactcat caacaacaac tggggattcc ggcctaagcg 3060 actcaacttc aagctcttca acattcaggt caaagaggtt acggacaaca atggagtcaa 3120 gaccatcgcc aataacctta ccagcacggt ccaggtcttc acggactcag actatcagct 3180 cccgtacgtg ctcgggtcgg ctcacgaggg ctgcctcccg ccgttcccag cggacgtttt 3240 catgattcct footcgggt atctgacgct taatgatgga agccaggccg tgggtcgttc 3300 gtccttttac tgcctggaat atttcccgtc gcaaatgcta agaacgggta aaacttcca 3360 gttcagctac gagtttgaga acgtaccttt ccatagcagc tacgctcaca gccaaagcct 3420 ggaccgacta atgaatccac tcatcgacca atacttgtac tatctctcaa agactattaa 3480 cggttctgga cagaatcaac aaacgctaaa attcagtgtg gccggaccca gcaacatggc 3540 tgtccaggga agaaactaca tacctggacc cagctaccga caacaacgtg tctcaaccac 3600 tgtgactcaa aacaacaaca gcgaatttgc ttggcctgga gcttcttctt gggctctcaa 3660 tggacgtaat agcttgatga atcctggacc tgctatggcc agccacaaag agaagga 3720 ccgtttcttt cctttgtctg gatctttaat ttttggcaaa caaggaactg gaagacaa 3780 cgtggatgcg gacaaagtca tgataaccaa cgaagaagaa attaaaacta ctaacccggt 3840 agcaacggag tcctatggac aagtggccac aaaccaccag agtgtacatc gattgttaat 3900 caataaaccg tttaattcgt ttcagttgaa ctttggtctc tgcgtatttc tttctttatct 3960 agtttccatg gctacgtaga taagtagcat ggcgggttaa tcattaacta caaggaaccc 4020 ctagtgatgg agttggccac tccctctctg cgcgctcgct cgctcactga ggccgggcga 4080 ccaaaggtcg cccgacgccc gggctttgcc cgggcggcct cagtgagcga gcgagcgcgc 4140 agagaggggag tggccaagca tgcaattaac tggccgtcgt tttacaacgt cgtgactggg 4200 aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca tccccctttc gccagctgta 4260 tcagcacaca attgcccatt atacgcgcgt ataatggact attgtgtgct gata 4314 <210> 19 <211> 4456 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Comments="Description of artificial sequence: synthetic polynucleotide" <400> 19 tatcagcaca caatagtcca ttatacgcgc gtataatggg caattgtgtg ctgatacagc 60 tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt 120 tagctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt 180 ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga ttacgccaga 240 tttaattaag gccttaatta ggctagcttg gccactccct ctctgcgcgc tcgctcgctc 300 actgaggccg ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg 360 agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc ctggaggggt 420 ggagtcgtga cgatatccat gcgtcgacat aacgcgtgat ctaacatatc ctggtgtgga 480 gtagcggacg ctgctatgac agaggctcgg gggcctgagc tggctctgtg agctggggag 540 gaggcagaca gccaggcctt gtctgcaagc agacctggca gcattgggct ggccgccccc 600 cagggcctcc tcttcatgcc cagtgaatga ctcaccttgg cacagacaca atgttcgggg 660 tgggcacagt gcctgcttcc cgccgcaccc cagcccccct caaatgcctt ccgagaagcc 720 cattgagcag ggggcttgca ttgcacccca gcctgacagc ctggcatctt gggataaaag 780 cagcacagcc ccctaggggc tgcccttgct gtgtggcgcc accggcggtg gagaacaagg 840 ctctattcag cctgtgccca ggaaagggga tcaggggatg cccaggcatg gacagtgggt 900 ggcagggggg gagaggagg ctgtctgctt cccagaagtc caaggacaca aatgggtgag 960 gggagagctc tccccatagc tgggctgcgg cccaacccca ccccctcagg ctatgccagg 1020 gggtgttgcc aggggcaccc gggcatcgcc agtctagccc actcttcat aaagccctcg 1080 catcccagga gcgagcagag ccagagcagg ttggagaga gacgcatcac ctccgctgct 1140 cgcggggatc ctctagaagc ttcgtttagt gaaccgtcag atcgcctgga gacgccatcc 1200 acgctctttt gacctccata gaagacaccg ggaccgatcc agcctccgcg gattcgaatc 1260 ccggccggga acggtgcatt ggaacgcgga ttccccgtgc caagagtgac gtaagtaccg 1320 cctatagagt ctataggccc acaaaaaatg ctttcttctt ttaatatact ttttgttta 1380 tcttatttct aatactttcc ctaatctctt tctttcaggg caataatgat acaatgtatc 1440 atgcctcttt gcaccattct aaagaataac agtgataatt tctggggttaa ggcaatagca 1500 atatttctgc atataaatat ttctgcatat aaattgtaac tgatgtaaga ggtttcatat 1560 tgctaatagc agctacaatc cagctaccat tctgctttta ttttatggtt gggataaggc 1620 tggattattc tgagtccaag ctaggccctt ttgctaatca tgttcatacc tcttatcttc 1680 ctcccacagc tcctgggcaa cgtgctggtc tgtgtgctgg cccatcactt tggcaaagaa 1740 ttgggattcg aaccggtcgc caccggtcac caagcaggaa gtcaaagact ttttccggtg 1800 ggcaaaggat cacgtggttg aggtggagca tgaattctac gtcaaaaagg gtggagccaa 1860 gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt 1920 tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcggaca ggtaccaaaa 1980 caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag 2040 actgaatcag aattcaaata tctgcttcac tcacggtgtc aaagactgtt tagagtgctt 2100 tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta 2160 cattcatcac atcatgggaa aggtgccaga cgcttgcact gcttgcgacc tggtcaatgt 2220 ggacttggat gactgtgttt ctgaacaata aatgacttaa accaggtatg gctgccgatg 2280 gttatcttcc agattggctc gaggacaacc ttagtgaagg aattcgcgag tggtgggctt 2340 tgaaacctgg agcccctcaa cccaaggcaa atcaacaaca tcaagacaac gctcgaggtc 2400 ttgtgcttcc gggttacaaa taccttggac ccggcaacgg actcgacaag ggggagccgg 2460 tcaacgcagc agacgcggcg gccctcgagc acgacaaggc ctacgaccag cagctcaagg 2520 ccggagacaa cccgtacctc aagtacaacc acgccgacgc cgagttccag gagcggctca 2580 aagaagatac gtcttttggg ggcaacctcg ggcgagcagt cttccaggcc aaaaagaggc 2640 ttcttgaacc tcttggtctg gttgaggaag cggctaagac ggctcctgga aagaagaggc 2700 ctgtagagca gtctcctcag gaaccggact cctccgcggg tattggcaaa tcgggtgcac 2760 agcccgctaa aaagagactc aatttcggtc agactggcga cacagagtca gtcccagacc 2820 ctcaaccaat cggagaacct cccgcagccc cctcaggtgt gggatctctt acaatggctt 2880 caggtggtgg cgcaccagtg gcagacaata acgaaggtgc cgatggagtg ggtagttcct 2940 cgggaaattg gcattgcgat tcccaatggc tgggggacag agtcatcacc accagcaccc 3000 gaacctgggc cctgcccacc tacaacaatc acctctcaaa gcaaatctcc aacagcacat 3060 ctggaggatc ttcaaatgac aacgcctact tcggctacag caccccctgg gggtatttttg 3120 acttcaacag attccactgc cacttctcac cacgtgactg gcagcgactc atcaacaaca 3180 actggggatt ccggcctaag cgactcaact tcaagctctt caacattcag gtcaaagagg 3240 ttacggacaa caatggagtc aagaccatcg ccaataacct taccagcacg gtccaggtct 3300 tcacggactc agactatcag ctcccgtacg tgctcgggtc ggctcacgag ggctgcctcc 3360 cgccgttccc agcggacgtt ttcatgattc ctcagtacgg gtatctgacg cttaatgatg 3420 gaagccaggc cgtgggtcgt tcgtccttt actgcctgga atatttcccg tcgcaaatgc 3480 taagaacggg taacaacttc cagttcagct acgagtttga gaacgtacct ttccatagca 3540 gctacgctca cagccaaagc ctggaccgac taatgaatcc actcatcgac caatacttgt 3600 actatctctc aaagactatt aacggttctg gacagaatca acaaacgcta aaattcagtg 3660 tggccggacc cagcaacatg gctgtccagg gaagaacta catacctgga cccagctacc 3720 gacaacaacg tgtctcaacc actgtgactc aaaacaacaa cagcgaattt gcttggcctg 3780 gagcttcttc ttgggctctc aatggacgta atagcttgat gaatcctgga cctgctatgg 3840 ccagccacaa agaaggagag gaccgtttct ttcctttgtc tggatcttta atttttggca 3900 aacaaggaac tggaagagac aacgtggatg cggacaaagt catgataacc aacgaagaag 3960 aaattaaaac tactaacccg gtagcaacgg agtcctatgg acaagtggcc acaaaccacc 4020 agagtgtaca tcgattgtta atcaataaac cgtttaattc gtttcagttg aactttggtc 4080 tctgcgtatt tctttcttat ctagtttcca tggctacgta gataagtagc atggcgggtt 4140 aatcattaac tacaaggaac ccctagtgat ggagttggcc actccctctc tgcgcgctcg 4200 ctcgctcact gaggccgggc gaccaaaggt cgcccgacgc ccgggctttg cccgggcggc 4260 ctcagtgagc gagcgagcgc gcagagaggg agtggccaag catgcaatta actggccgtc 4320 gttttacaac gtcgtgactg ggaaaaccct ggcgttaccc aacttaatcg ccttgcagca 4380 catccccctt tcgccagctg tatcagcaca caattgccca ttatacgcgc gtataatgga 4440 ctattgtgtg ctgata 4456 <210> 20 <211> 4283 <212> DNA <213> Artificial Sequence <220> <221> source <223> / remark="Description of artificial sequence: synthetic polynucleotide" <400> 20 tatcagcaca caatagtcca ttatacgcgc gtataatggg caattgtgtg ctgatacagc 60 tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt 120 tagctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt 180 ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga ttacgccaga 240 tttaattaag gccttaatta ggctagcttg gccactccct ctctgcgcgc tcgctcgctc 300 actgaggccg ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg 360 agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc ctggaggggt 420 ggagtcgtga cgatatccat gcgtcgacat aacgcgttag tatctgcaga gggccctgcg 480 tatgagtgca agtgggtttt aggaccagga tgaggcgggg tgggggtgcc tacctgacga 540 ccgaccccga cccactggac aagcacccaa cccccattcc ccaaattgcg catcccctat 600 cagagagggg gaggggaac aggatgcggc gaggcgcgtg cgcactgcca gcttcagcac 660 cgcggacagt gccttcgccc ccgcctggcg gcgcgcgcca ccgccgcctc agcactgaag 720 gcgcgctgac gtcactcgcc ggtcccccgc aaactcccct tcccggccac cttggtcgcg 780 tccgcgccgc cgccggccca gccggaccgc accacgcgag gcgcgagata ggggggcacg 840 ggcgcgacca tctgcgctgc ggcgccggcg actcagcgct gcctcagtct gcggtgggca 900 gcggaggagt cgtgtcgtgc ctgagagcgc agctgtgctc ctgggcaccg cgcagtccgc 960 ccccgcggct cctggccaga cccccctag gaccccctgc cccaagtcgc agccaagctt cgtttagtga accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga 1080 agacaccggg accgatccag cctccgcgga ttcgaatccc ggccgggaac ggtgcattgg aacgcggatt ccccgtgcca aggtgacgt aagtaccgcc tataggtct ataggcccac aaaaaatgct ttcttctttt aatatacttt tttgtttatc ttattctaa tactttccct aatctctttc tttcagggca ataatgatac aatgtatcat gcctctttgc accattctaa 1320 agaataacag tgataatttc tgggttaagg caatagcaat atttctgcat ataaatattt 1380 ctgcatataa attgtaactg atgtaagagg tttcatattg ctaatagcag ctacaatcca 1440 gctaccattc tgctttttatt ttatggttgg gataaggctg gattattctg agtccaagct 1500 aggcccttt gctaatcatg ttcatacctc ttatcttcct cccacagctc ctgggcaacg 1560 tgctggtctg tgtgctggcc catcactttg gcaaagaatt gggattcgaa cggtcgcca 1620 ccggtcacaa gcaggaagtc aaagactttt tccggtgggc aaaggatcac gtggttgagg 1680 tggagcatga attctacgtc aaaaagggtg gagccaagaa aagacccgcc cccagtgacg 1740 cagatataag tgagcccaaa cgggtgcgcg agtcagttgc gcagccatcg acgtcagacg 1800 cggaagcttc gatcaactac gcggacaggt accaaaacaa atgttctcgt cacgtgggca 1860 tgaatctgat gctgtttccc tgcagacaat gcgagagaat gaatcagaat tcaaatatct 1920 gcttcactca cggacagaaa gactgtttag agtgctttcc cgtgtcagaa tctcaacccg 1980 tttctgtcgt caaaaaggcg tatcagaaac tgtgctacat tcatcatatc atgggaaagg 2040 tgccagacgc ttgcactgcc tgcgatctgg tcaatgtgga tttggatgac tgcatctttg 2100 aacaataaat gatttaaatc aggtatgtct tttgttgatc accctccaga ttggttggaa 2160 gaagttggtg aaggtcttcg cgagtttttg ggccttgaag cgggcccacc gaaaccaaaa 2220 cccaatcagc agcatcaaga tcaagcccgt ggtcttgtgc tgcctggtta taactatctc 2280 ggacccggaa acggtctcga tcgaggagag cctgtcaaca gggcagacga ggtcgcgcga 2340 gagcacgaca tctcgtacaa cgagcagctt gaggcgggag acaaccccta cctcaagtac 2400 aaccacgcgg acgccgagtt tcaggagaag ctcgccgacg acacatcctt cgggggaaac 2460 ctcggaaagg cagtctttca ggccaagaaa agggttctcg aaccttttgg cctggttgaa 2520 gagggtgcta agacggcccc taccggaaag cggatagacg accactttcc aaaaagaaag 2580 aaggcccgga ccgaagagga ctccaagcct tccacctcgt cagacgccga agctggaccc 2640 agcggatccc agcagctgca aatcccagcc caaccagcct caagtttggg agctgataca 2700 atgtctgcgg gaggtggcgg cccattgggc gacaataacc aaggtgccga tggagtgggc 2760 aatgcctcgg gagattggca ttgcgattcc acgtggatgg gggacagagt cgtcaccaag 2820 tccacccgaa cctgggtgct gcccagctac aacaaccacc agtaccgaga gatcaaaagc 2880 ggctccgtcg acggaagcaa cgccaacgcc tactttggat acagcacccc ctgggggtac 2940 tttgacttta accgcttcca cagccactgg agcccccgag actggcaaag actcatcaac 3000 aactactggg gcttcagacc ccggtccctc agagtcaaaa tcttcaacat tcaagtcaaa 3060 gaggtcacgg tgcaggactc caccaccacc atcgccaaca acctcacctc caccgtccaa 3120 gtgtttacgg acgacgacta ccagctgccc tacgtcgtcg gcaacgggac cgagggatgc 3180 ctgccggcct tccctccgca ggtctttacg ctgccgcagt acggttacgc gacgctgaac 3240 cgcgacaaca cagaaaatcc caccgagagg agcagcttct tctgcctaga gtactttccc 3300 agcaagatgc tgagaacggg caacaacttt gagtttacct acaactttga ggaggtgccc 3360 ttccactcca gcttcgctcc cagtcagaac ctcttcaagc tggccaaccc gctggtggac 3420 3480 ctggccggga gatacgccaa cacctacaaa aactggttcc cggggcccat gggccgaacc 3540 cagggctgga acctgggctc cggggtcaac cgcgccagtg tcagcgccctt cgccacgacc 3600 aataggatgg agctcgaggg cgcgagttac caggtgcccc cgcagccgaa cggcatgacc 3660 aacaacctcc agggcagcaa cacctatgcc ctggagaaca ctatgatctt caacagccag 3720 ccggcgaacc cgggcaccac cgccacgtac ctcgagggca acatgctcat caccagcgag 3780 agcgagacgc agccggtgaa ccgcgtggcg tacaacgtcg gcgggcagat ggccaccaac 3840 aaccagagct ctgtacatcg attgttaatc ataaaccgt ttaattcgtt tcagttgaac 3900 tttggtctct gcgtatttct ttcttatcta gtttccatgg ctacgtagat aagtagcatg 3960 gcgggttaat cattaactac aaggaacccc tagtgatgga gttggccact ccctctctgc 4020 gcgctcgctc gctcactgag gccgggcgac caaaggtcgc ccgacgccccg ggctttgccc 4080 gggcggcctc agtgagcgag cgagcgcgca gagagggagt ggccaagcat gcaattaact 4140 ggccgtcgtt ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct 4200 tgcagcacat ccccctttcg ccagctgtat cagcacacaa ttgcccatta tacgcgcgta 4260 taatggacta ttgtgtgctg ata 4283 <210> 21 <211> 4426 <212> DNA <213> Artificial Sequence <220> <221> source <223> / Remark="Description of artificial sequence: Synthetic polynucleotide" <400> 21 tatcagcaca caatagtcca ttatacgcgc gtataatggg caattgtgtg ctgatacagc 60 tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt 120 tagctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt 180 ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga ttacgccaga 240 tttaattaag gccttaatta ggctagcttg gccactccct ctctgcgcgc tcgctcgctc 300 actgaggccg ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg 360 agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc ctggaggggt 420 ggagtcgtga cgatatccat gcgtcgacat aacgcgtgat ctaacatatc ctggtgtgga 480 gtagcggacg ctgctatgac agaggctcgg gggcctgagc tggctctgtg agctgggggag 540 gaggcagaca gccaggcctt gtctgcaagc agacctggca gcattgggct ggccgccccc 600 cagggcctcc tcttcatgcc cagtgaatga ctcaccttgg cacagacaca atgttcgggg 660 tgggcacagt gcctgcttcc cgccgcaccc cagcccccct caaatgcctt ccgagaagcc 720 cattgagcag ggggcttgca ttgcacccca gcctgacagc ctggcatctt gggataaaag 780 cagcacagcc ccctaggggc tgcccttgct gtgtggcgcc accggcggtg gagaagaagg 840 ctctattcag cctgtgccca ggaaagggga tcaggggatg cccaggcatg gacagtgggt 900 ggcagggggg gagaggagg ctgtctgctt cccagaagtc caaggacaca aatgggtgag 960 gggagagctc tccccatagc tgggctgcgg cccaacccca ccccctcagg ctatgccagg 1020 gggtgttgcc aggggcaccc gggcatcgcc agtctagccc actcttcat aaagccctcg 1080 catcccagga gcgagcagag ccagagcagg ttggagaga gacgcatcac ctccgctgct 1140 cgcggggatc cttagaagc tcgtttagt gaaccgtcag atcgcctgga gacgccatcc 1200 acgctgtttt gaccccata gagacaccg gaccgatcc agcctccgcg gattcgaatc 1260 ccggccggga acggtgcatt ggaacgcgga ttccccgtgc caagtgac gtaagtaccg 1320 cctatagagt ctataggcccc acaaaaatg ctttctctt ttatatact ttttgttta 1380 tcttatttct atactttcc ctaatctctt tcttcaggg caataatgat acatgtatc 1440 atgcctcttt gcaccattct aaagaatac agtgatatt tctggtta ggcaatagca 1500 atattctgc ataataat ttctgcatat aattgtaac tgatgtaaga ggtttcatat 1560 tgctaatagc agctacaatc cagctaccat tctgcttta ttttatggtt gggataaggc 1620 tggattattc tgagtccaag ctaggcctt tgctaatca tgttcatacc tcttatctc 1680 ctcccacagc tcctgggcaa cgtgctgtc tgtgtgctg cccatcactt tggcaaagaa 1740 ttgggattcg aaccggtcgc caccggtcac caagcaggaa gtcaagact ttccggtg 1800 ggcaaaggat cacgtggttg aggtggagca tgaatctac gtcaaaagg gtggagccaa 1860 gaaaagaccc gcccccagtg acgcagatat aagtgagccc aaacgggtgc gcgagtcagt 1920 tgcgcagcca tcgacgtcag acgcggaagc ttcgatcaac tacgcggaca ggtaccaaaa 1980 caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgcagac aatgcgagag 2040 aatgaatcag aattcaaata tctgcttcac tcacggacag aaagactgtt tagagtgctt 2100 tcccgtgtca gaatctcaac ccgtttctgt cgtcaaaaag gcgtatcaga aactgtgcta 2160 cattcatcat atcatgggaa aggtgccaga cgcttgcact gcctgcgatc tggtcaatgt 2220 ggatttggat gactgcatct ttgaacaata aatgatttaa atcaggtatg tcttttgttg 2280 atcaccctcc agattggttg gaagaagttg gtgaaggtct tcgcgagttt ttgggccttg 2340 aagcgggccc accgaaacca aaacccaatc agcagcatca agatcaagcc cgtggtcttg 2400 tgctgcctgg ttataactat ctcggacccg gaaacggtct cgatcgagga gagcctgtca 2460 2520 gagacaaccc ctacctcaag tacaaccag cggacgccga gtttcaggag aagctcgccg 2580 acgacacatc cttcggggga aacctcggaa aggcagtctt tcaggccaag aaaagggttc 2640 tcgaaccttt tggcctggtt gaagagggtg ctaagacggc ccctaccgga aagcggatag 2700 acgaccactt tccaaaaaga aagaaggccc ggaccgaaga ggactccaag ccttccacct 2760 cgtcagacgc cgaagctgga cccagcggat cccagcagct gcaaatccca gcccaaccag 2820 cctcaagttt gggagctgat acaatgtctg cgggaggtgg cggcccattg ggcgacaata 2880 accaaggtgc cgatggagtg ggcaatgcct cgggagattg gcattgc...
Claims
1. A method for generating an AAV vector library encoding variant AAV capsid polypeptides, the method comprising: a) providing a first nucleic acid comprising a P40 promoter and a cell type specific promoter that drives capsid mRNA expression in the absence of helper virus co-transfection, wherein the cell type specific promoter is a synapsin promoter or a GFAP promoter, and a second nucleic acid encoding a plurality of capsid polypeptides having a randomized sequence region of 2, 3, 4, 5, 6, 7, 8 or 9 consecutive amino acids, wherein the randomized sequence is inserted into loop IV or loop VIII of a parent AAV capsid polypeptide or replaces a portion of loop IV or loop VIII of a parent AAV capsid polypeptide; and b) cloning the first nucleic acid and the second nucleic acid under conditions suitable for generating the AAV vector library.
2. The method of claim 1, wherein the cell type specific promoter is the synapsin promoter.
3. The method of claim 1, wherein the cell type specific promoter is the GFAP promoter.
4. The method of claim 1, wherein: i) the P40 promoter and the cell type-specific promoter are located upstream of a transgene encoding the variant AAV capsid polypeptide; or ii) the P40 promoter is located upstream of the transgene encoding the variant AAV capsid polypeptide and the cell type specific promoter is located downstream of the transgene encoding the variant AAV capsid polypeptide.
5. The method of claim 1, wherein the randomized sequence region comprises a peptide insert having 4, 5, 6, 7, 8 or 9 consecutive amino acids.
6. The method of claim 5, wherein the insert is present in loop VIII of the variant AAV capsid polypeptide.
7. The method of claim 5, wherein the insert is present in loop IV of the variant AAV capsid polypeptide.
8. The method of claim 5, wherein the insert is present in: i) any amino acid position between amino acids 452-458 of a variant AAV capsid polypeptide sequence; and / or ii) any amino acid position between the amino acid at positions 586-592 of the variant AAV capsid polypeptide sequence.
9. The method of claim 1, wherein the parent AAV capsid polypeptide comprises an AAV9 capsid polypeptide or an AAV5 capsid polypeptide.
10. The method of claim 1, further comprising c) producing a plurality of AAV particles comprising the AAV vector library.
11. The method of claim 10, further comprising d) administering the AAV particles to an animal.
12. The method of claim 11, wherein: i) the animal is a mouse or a non-human primate; and / or ii) administering the AAV particles intravenously.
13. The method of claim 11, further comprising e) collecting and / or isolating target cells or target tissues from the animal.
14. The method of claim 13, wherein the target cells or target tissues are collected four weeks after administration of the AAV particles.
15. The method of claim 13, further comprising f) recovering RNA and / or antisense RNA encoding the variant AAV capsid polypeptide from the target cell or target tissue.
16. The method of claim 15, wherein the RNA encoding the variant AAV capsid polypeptide is enriched and / or reverse transcribed into cDNA.
17. The method of claim 16, wherein the cDNA is amplified.
18. The method of claim 15, further comprising g) determining the sequence of the variant AAV capsid polypeptide.
19. The method of claim 18, further comprising h) measuring the amount of DNA encoding the variant AAV capsid polypeptide or the amount of RNA encoding the variant AAV capsid polypeptide in the target cell or target tissue.
20. The method of claim 19, wherein the method further comprises repeating steps a)-h).
21. The method of claim 1, wherein the encoded variant AAV capsid polypeptide demonstrates one, two, three, four, or all of the following properties: i) increased target cell transduction or target cell specificity for cells of the central nervous system compared to the parent capsid polypeptide; ii) increased brain transduction compared to the parental capsid polypeptide; iii) increased spinal cord transduction compared to the parental capsid polypeptide; iv) increased delivery of the viral genome to the brain compared to the parent capsid polypeptide; and / or v) Increased levels of viral genome delivery to the spinal cord compared to the parental capsid polypeptide.
22. The method of claim 13, wherein: i) the target cell is a neuron, a neural stem cell, an astrocyte, an oligodendrocyte, a microglia, a retinal cell, a tumor cell, a hematopoietic stem cell, an insulin-producing β cell, a lung epithelial cell, an endothelial cell, a hepatocyte, a skeletal muscle cell, a muscle stem cell, a muscle satellite cell or a cardiomyocyte; and / or ii) the target tissue is: a) tissue of the central nervous system, tissue of the peripheral nervous system and / or peripheral tissue; and / or b) brain tissue, spinal cord tissue, dorsal root ganglion, muscle tissue, liver tissue, heart tissue, gastrocnemius muscle tissue, soleus muscle tissue, pancreatic tissue, kidney tissue, spleen tissue, lung tissue, adrenal tissue, stomach tissue, sciatic nerve tissue, saphenous nerve tissue, thyroid tissue, eye tissue, pituitary tissue, skeletal muscle tissue, colon tissue, duodenum tissue, ileum tissue, jejunum tissue, leg skin tissue, superior cervical ganglion tissue, bladder tissue, ovarian tissue, uterine tissue, prostate tissue and / or testicular tissue.
23. The method of claim 22, wherein the brain tissue is frontal cortex tissue, parietal cortex tissue, occipital cortex tissue, temporal cortex tissue, thalamus tissue, hypothalamus tissue, striatum tissue, putamen tissue, caudate nucleus tissue, hippocampus tissue, entorhinal cortex tissue, basal ganglia tissue and / or deep cerebellar nucleus tissue.
24. The method of claim 1, wherein the vectors of the AAV vector library sequentially comprise: i) the first inverted terminal repeat region; ii) cell-specific promoter; iii) P40 promoter; iv) a transgene encoding a variant AAV capsid polypeptide comprising a randomized sequence region; v) a poly-A sequence region; and vi) a second inverted terminal repeat region.
25. An AAV vector library prepared by the method of any one of claims 1-24.
26. An AAV vector library comprising: a) a first nucleic acid comprising a P40 promoter and a cell type specific promoter, which drives capsid mRNA expression in the absence of helper virus co-transfection, wherein the cell type specific promoter is a synapsin promoter or a GFAP promoter; and b) a second nucleic acid encoding a plurality of capsid polypeptides having a randomized sequence region of 2, 3, 4, 5, 6, 7, 8 or 9 consecutive amino acids, wherein the randomized sequence is inserted into loop IV or loop VIII of a parent AAV capsid polypeptide or replaces a portion of loop IV or loop VIII of a parent AAV capsid polypeptide.
27. The AAV vector library of claim 26, wherein the cell type specific promoter is the synapsin promoter.
28. An AAV vector library as described in claim 26, wherein the cell type specific promoter is the GFAP promoter.
29. The AAV vector library of claim 26, wherein the vectors of the AAV vector library sequentially comprise: i) the first inverted terminal repeat region; ii) cell-specific promoter; iii) P40 promoter; iv) a transgene encoding a variant AAV capsid polypeptide comprising a randomized sequence region; v) a poly-A sequence region; and vi) a second inverted terminal repeat region.
30. A method for producing a plurality of variant AAV capsid polypeptides, the method comprising: a) providing a plurality of AAV particles comprising an AAV vector library, wherein the AAV vector library comprises nucleic acids comprising a P40 promoter and a cell type-specific promoter that drives capsid mRNA expression in the absence of helper virus co-transfection, wherein the cell type-specific promoter is a synapsin promoter or a GFAP promoter, and wherein the nucleic acids encode a plurality of capsid polypeptides having a randomized sequence region of 2, 3, 4, 5, 6, 7, 8, or 9 consecutive amino acids, wherein the randomized sequence is inserted into loop IV or loop VIII of a parent AAV capsid polypeptide or replaces a portion of loop IV or loop VIII of a parent AAV capsid polypeptide; b) administering the AAV particles to an animal, wherein the AAV particles are administered intravenously; c) recovering RNA and / or antisense RNA encoding the variant AAV capsid polypeptide from the target cell or target tissue; d) determining the sequence of said variant AAV capsid polypeptide; and e) measuring the amount of DNA encoding the variant AAV capsid polypeptide or the amount of RNA encoding the variant AAV capsid polypeptide in the target cell or target tissue; and wherein the method is performed in the absence of a helper virus; Thereby generating the plurality of variant AAV capsid polypeptides.
31. The method of claim 30, wherein the cell type specific promoter is the synapsin promoter.
32. The method of claim 30, wherein the cell type specific promoter is the GFAP promoter.
33. The method of claim 30, wherein the vectors of the AAV vector library sequentially comprise: i) the first inverted terminal repeat region; ii) cell-specific promoter; iii) P40 promoter; iv) a transgene encoding a variant AAV capsid polypeptide comprising a randomized sequence region; v) a poly-A sequence region; and vi) a second inverted terminal repeat region.
